<SEC-DOCUMENT>0001104659-22-046052.txt : 20220414
<SEC-HEADER>0001104659-22-046052.hdr.sgml : 20220414
<ACCEPTANCE-DATETIME>20220414163026
ACCESSION NUMBER:		0001104659-22-046052
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20220414
FILED AS OF DATE:		20220414
DATE AS OF CHANGE:		20220414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		22827652

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>tm2212755d1_pre14a.htm
<DESCRIPTION>PRE 14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES&nbsp;</B></P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section&nbsp;14(a)&nbsp;of
the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Filed by the Registrant&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by a Party other than the Registrant&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary Proxy Statement </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 4%"><FONT STYLE="font-family: Wingdings; font-size: 10pt; "><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2)) </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Proxy Statement </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Additional Materials </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting Material Pursuant to &sect;240.14a-12</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protalix BioTherapeutics,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Registrant as Specified In Its Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Person(s)&nbsp;Filing Proxy Statement,
if other than the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Payment of Filing Fee (Check the appropriate
box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No fee required. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee paid previously with preliminary materials. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD>Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2212755d1_pre14asp1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Dear Stockholder,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We cordially invite you to attend the 2022 Annual
Meeting of Stockholders of Protalix BioTherapeutics,&nbsp;Inc. to be held at 6:00 p.m.&nbsp;Israel Daylight Time on June&nbsp;30, 2022
at the offices of our Israeli counsel, Horn&nbsp;&amp; Co., Law Offices, Amot Investments Tower, 2 Weizmann Street, 24th Floor, Tel Aviv
6423902,&nbsp;Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The attached notice of annual meeting and proxy
statement describe the business we will conduct at the meeting and provide information about us that you should consider when you vote
your shares. As set forth in the attached proxy statement, the meeting will be held to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>consider the election of directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>approve an advisory vote on executive compensation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to adopt amendments to the Protalix BioTherapeutics,&nbsp;Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares
of common stock available under the plan from 5,725,171 shares to 8,475,171 shares and to amend certain other terms of said plan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>approve an amendment to our Certificate of Incorporation, as amended, to increase the number of shares of our common stock, par value
$0.001 per share, authorized for issuance from 120,000,000 to 144,000,000; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>ratify the appointment of our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Please take the time to carefully read each of
the proposals stockholders are being asked to consider and vote on.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Please promptly vote your shares either via the
Internet, by telephone or by marking, signing, dating and returning the proxy card in the enclosed envelope. Your vote is important, whether
or not you attend the meeting in person. We encourage you to vote by proxy so that your shares will be represented and voted at the meeting.
If you decide to attend the meeting and vote in person, your proxy may be revoked at your request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We appreciate your support and look forward to
your attending the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2212755d1_pre14asp1img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eyal Rubin&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sr. Vice President and Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2 University Plaza, Suite&nbsp;100, Hackensack, NJ 07601&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel: 1-201-696-9435 | Web: www.protalix.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>









<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF 2022 ANNUAL MEETING OF STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO BE HELD ON JUNE&nbsp;30, 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Stockholders of Protalix BioTherapeutics,&nbsp;Inc.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The 2022 Annual Meeting of Stockholders of Protalix
BioTherapeutics,&nbsp;Inc. (the &ldquo;Company&rdquo;) will be held at the following time, date and place for the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIME:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 93%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6:00 p.m.,&nbsp;Israel Daylight Time</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATE:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;30, 2022</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLACE:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Horn&nbsp;&amp; Co., Law Offices, Amot Investments Tower, 2&nbsp;Weizmann Street, 24th Floor, <BR>
Tel Aviv 6423902,&nbsp;Israel</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PURPOSES:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; color: #231f20">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
elect six members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; color: #231f20">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
approve, on a non-binding advisory basis, the compensation of the Company&rsquo;s named executive officers as disclosed in the proxy statement
that accompanies this notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>To
adopt amendments to the Protalix BioTherapeutics,&nbsp;Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of
common stock available under the plan from 5,725,171 shares to 8,475,171 shares and to amend certain other terms of said plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
approve an amendment to our Certificate of Incorporation, as amended, to increase the number of shares of our common stock, par value
$0.001 per share, authorized for issuance from 120,000,000 to 144,000,000; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; color: #231f20">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
ratify the appointment of Kesselman&nbsp;&amp; Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International
Limited, as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; color: #231f20">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
transact such other business that is properly presented at the meeting or any adjournment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All of these proposals are more fully described
in the proxy statement that follows. You may vote at the meeting and any adjournments if you were the record owner of the Company&rsquo;s
common stock at the close of business on May&nbsp;2, 2022. A list of stockholders of record will be available at the meeting and, during
the 10 days prior to the meeting, at the office of the Company&rsquo;s Corporate Secretary at 2&nbsp;University Plaza, Suite&nbsp;100,
Hackensack, NJ 07601.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Please sign, date and promptly return the enclosed
proxy card in the enclosed envelope, or vote by telephone or Internet (instructions are on your proxy card), so that your shares will
be represented whether or not you attend the annual meeting.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BY ORDER OF THE BOARD OF DIRECTORS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><B><IMG SRC="tm2212755d1_pre14asp1img003.jpg" ALT=""></B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eyal Rubin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carmiel,&nbsp;Israel <BR>
 &nbsp;&nbsp;&nbsp;&nbsp;, 2022</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sr. Vice President and Chief Financial Officer and<BR>
Corporate Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protalix BioTherapeutics,&nbsp;Inc.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2 University Plaza, Suite&nbsp;100&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Hackensack, NJ 07601&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>201-696-9345</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROXY STATEMENT FOR PROTALIX BIOTHERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2022 ANNUAL MEETING OF STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO BE HELD ON JUNE&nbsp;30, 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GENERAL INFORMATION ABOUT THE ANNUAL MEETING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Why Did You Send Me This Proxy Statement?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We sent you this proxy statement and the enclosed
proxy card because the Board of Directors of Protalix BioTherapeutics,&nbsp;Inc. is soliciting your proxy to vote at the 2022 Annual Meeting
of Stockholders (the &ldquo;Annual Meeting&rdquo;) and any adjournments of the meeting to be held at 6:00 p.m.,&nbsp;Israel Daylight Time,
on June&nbsp;30, 2022 at the offices of our Israeli counsel, Horn&nbsp;&amp; Co., Law Offices, Amot Investments Tower, 2 Weizmann Street,
24th Floor, Tel Aviv 6423902,&nbsp;Israel. This proxy statement, along with the accompanying Notice of Annual Meeting of Stockholders,
summarizes the purposes of the meeting and the information you need to know to vote at the annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We anticipate that on or about May&nbsp;13, 2022,
we will begin sending this proxy statement, the attached Notice of Annual Meeting and the form of proxy enclosed to all stockholders entitled
to vote at the meeting. Although not part of this proxy statement, we are also sending along with this proxy statement our Annual Report
on Form&nbsp;10-K which includes financial statements for the fiscal year ended December&nbsp;31, 2021. You can also find a copy of our
Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2021 on the Internet through the electronic data system called
EDGAR provided by the Securities and Exchange Commission, or the SEC, at http://www.sec.gov or through the Investor Relations section
of our website at http://www.protalix.com. In addition, since we are also listed on the Tel Aviv Stock Exchange (the &ldquo;TASE&rdquo;),
we submit copies of all our filings with the SEC to the Israeli Securities Authority and the TASE. Such copies can be retrieved electronically
through the TASE&rsquo;s Internet messaging system (www.maya.tase.co.il) and through the MAGNA distribution site of the Israeli Securities
Authority (www.magna.isc.gov.il). Our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2021 and information
on the website other than the proxy statement are not part of our proxy soliciting materials. Additional copies of the Annual Report on
Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2021 are available upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Who Can Vote?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Only holders of record of our common stock, par
value $0.001 per share, on May&nbsp;2, 2022 (the &ldquo;Record Date&rdquo;), are entitled to vote at the annual meeting. On the Record
Date, there were 46,365,832 shares of common stock outstanding and entitled to vote. The common stock is currently our only outstanding
class of voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You do not need to attend the annual meeting to
vote your shares. Shares represented by valid proxies, received in time for the meeting and not revoked prior to the meeting, will be
voted at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How Many Votes Do I Have?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each share of common stock that you own entitles
you to one vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How Do I Vote?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Whether you plan to attend the annual meeting or
not, we urge you to vote by proxy. Voting by proxy will not affect your right to attend the annual meeting. If your shares are registered
directly in your name through our stock transfer agent, American Stock Transfer&nbsp;&amp; Trust Company, or you have stock certificates,
you may vote:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><B>By mail.</B> Complete, date, sign and mail the enclosed proxy
card in the enclosed postage prepaid envelope. Your proxy will be voted in accordance with your instructions. If you sign the proxy card
but do not specify how you want your shares voted, they will be voted as recommended by our Board of Directors.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><B>By Internet or by telephone.</B> Follow the instructions
attached to the proxy card to vote by Internet or telephone.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><B>In person at the meeting.</B> If you attend the meeting,
you may deliver your completed proxy card in person or you may vote by completing a ballot, which will be available at the meeting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If your shares are held in &ldquo;street name&rdquo;
(held in the name of a bank, broker or other nominee), but not including shares held through a Tel Aviv Stock Exchange Clearing House
Ltd. (the &ldquo;TASE Clearing House&rdquo;) member, you must provide the bank, broker or other nominee with instructions on how to vote
your shares and can generally do so as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>By mail.</B> You will receive instructions from your broker
or other nominee explaining how <B>to vote your shares.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><B>By Internet or by telephone. </B>Follow the instructions
you receive from your broker to vote by Internet or telephone.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><B>In person at the meeting. </B>Contact the broker or other
nominee who holds your shares to obtain a broker&rsquo;s proxy card and bring it with you to the meeting. You will not be able to vote
at the meeting unless you have a proxy card from your broker.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you own shares that are traded through the TASE,
you may vote your shares in one of the following two ways:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><B>By mail. </B>Complete, sign and date the proxy card and attach
to it an ownership certificate from the TASE Clearing House member through which your shares are registered (i.e., your broker, bank
or other nominee) indicating that you were the beneficial owner of the shares on May&nbsp;2, 2022, the Record Date, and return the proxy
card or voting instruction form, along with the ownership certificate, to our designated address for that purpose in Israel, 2&nbsp;Snunit
Street, Science Park, P.O.&nbsp;Box&nbsp;455, Carmiel 2161401,&nbsp;Israel. If the TASE member holding your shares is not a TASE Clearing
House member, please make sure to include an ownership certificate from the TASE Clearing House member in which name your shares are
registered.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><B>In person at the meeting. </B>Attend the meeting, where ballots
will be provided. If you choose to vote in person at the meeting, you need to bring an ownership certificate from the TASE Clearing House
member through which your shares are registered (i.e., your broker, bank or other nominee) indicating that you were the beneficial owner
of the shares on May&nbsp;2, 2022, the Record Date for voting. If the TASE member holding your shares is not a TASE Clearing House member,
please make sure to include an ownership certificate from the TASE Clearing House member in which name your shares are registered.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you need assistance in voting by telephone or
over the Internet or completing your proxy card or have questions regarding the meeting, please contact our proxy advisor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Alliance Advisors, LLC<BR>
200&nbsp;Broadacres Drive, 3rd Floor<BR>
Bloomfield, NJ 07003<BR>
+1 (833) 757-0740 (toll free in the United States)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What Am I Voting On?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You are voting on:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">The election of six members to our Board of Directors to serve
for the ensuing year or until their respective successors have been duly elected (Zeev Bronfeld, Dror Bashan, Amos Bar Shalev, Pol F.
Boudes, M.D., Gwen A. Melincoff and Aharon Schwartz, Ph.D.).</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">To approve, on a non-binding advisory basis, the compensation
of our named executive officers as disclosed in this proxy statement.</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">To adopt amendments to the Protalix BioTherapeutics,&nbsp;Inc.
2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 5,725,171 shares
to 8,475,171 shares and to amend certain other terms of said plan.</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">To approve an amendment to our Certificate of Incorporation,
as amended, to increase the number of shares of our common stock, par value $0.001 per share, authorized for issuance from 120,000,000
to 144,000,000.</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">The ratification of the appointment of Kesselman and Kesselman,
Certified Public Accountant (Isr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting
firm for the fiscal year ending December&nbsp;31, 2022.</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How Does The Board Of Directors Recommend That I Vote At The Meeting?</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board of Directors recommends that you vote
as follows:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">&ldquo;<B>FOR</B>&rdquo; the re-election of all director nominees
named in &ldquo;Proposal&nbsp;1: Election of Directors&rdquo; of this proxy statement.</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">&ldquo;<B>FOR</B>&rdquo; the approval, on a non-binding advisory
basis, of our executive compensation as disclosed in the proxy statement that accompanies this notice and as described in &ldquo;Proposal&nbsp;2:
Advisory Vote on Executive Compensation&rdquo; of this proxy statement.</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">&ldquo;<B>FOR</B>&rdquo; the adoption of amendments to the Protalix
BioTherapeutics,&nbsp;Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the
plan from 5,725,171 shares to 8,475,171 shares and to amend certain other terms of said plan as disclosed in the proxy statement that
accompanies this notice and as described in &ldquo;Proposal&nbsp;3: Advisory Vote on Executive Compensation&rdquo; of this proxy statement.</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">&ldquo;<B>FOR</B>&rdquo; the approval of an amendment to our
Certificate of Incorporation, as amended, to increase the number of shares of our common stock, par value $0.001 per share, authorized
for issuance from 120,000,000 to 144,000,000, as disclosed in the proxy statement that accompanies this notice and as described in &ldquo;Proposal&nbsp;4:
Advisory Vote on Executive Compensation&rdquo; of this proxy statement; and</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">&ldquo;<B>FOR</B>&rdquo; the ratification of Kesselman and Kesselman
as our independent registered public accounting firm for the 2022 fiscal year, as named in &ldquo;Proposal 5: Ratification of Independent
Registered Public Accounting Firm&rdquo; of this proxy statement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any other matter is properly presented at the
meeting or any adjournment, the proxy card provides that your shares will be voted by the proxy holder listed on the proxy card in accordance
with his or her best judgment. At the time this proxy statement was printed, we knew of no matters that needed to be acted on at the annual
meeting, other than those discussed in this proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What Constitutes A Quorum For The Meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Of the 46,365,832 shares of common stock outstanding
as of the Record Date, the holders of at least one-third (1/3) of those shares, or at least 15,455,278 shares, must be present at the
meeting in person or represented by proxy to hold the meeting and conduct business. Once a quorum is established at a meeting, it shall
not be broken by the withdrawal of enough votes to leave less than a quorum. Shares held by stockholders of record who are present at
the meeting in person or by proxy are counted for purposes of determining whether a quorum exists. Abstentions and &ldquo;broker non-votes&rdquo;
are also counted as present and entitled to vote for purposes of determining whether a quorum exists. If a quorum is not present, the
meeting will be adjourned until a quorum is obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What Are The Voting Requirements To Approve A Proposal?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Election of directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Director nominees will be elected by a plurality
of votes cast, which means that the director nominees receiving the highest number of votes will be elected. In voting to elect nominees
to the Board of Directors, stockholders may vote in favor of all the nominees or any individual nominee or withhold their votes as to
all the nominees or any individual nominee. Only &ldquo;FOR&rdquo; and &ldquo;WITHHOLD&rdquo; votes will affect the outcome. Abstentions
and broker non-votes will have no effect on Proposal&nbsp;1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Approval of non-binding advisory resolution on executive
compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You may vote &ldquo;FOR,&rdquo; &ldquo;AGAINST&rdquo;
or &ldquo;ABSTAIN&rdquo; on the advisory vote to approve executive compensation. Approval requires the affirmative vote of the majority
of shares present in person or represented by proxy at the meeting and entitled to vote on the resolution. The outcome of this vote is
not binding; however, the Board of Directors and the Compensation Committee will consider the outcome of the vote when developing and
reviewing the future executive compensation plans. Abstentions and broker non-votes will have no effect on Proposal&nbsp;2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Adoption of amendments to the Protalix BioTherapeutics,&nbsp;Inc.
2006 Stock Incentive Plan, as amended, to increase the number of authorized shares of common stock reserved for issuance under the plan
and to amend certain other terms of the plan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You may vote &ldquo;FOR,&rdquo; &ldquo;AGAINST&rdquo;
or &ldquo;ABSTAIN&rdquo; on the adoption of an amendment to the Protalix BioTherapeutics,&nbsp;Inc. 2006 Stock Incentive Plan, as amended,
to increase the number of authorized shares of common stock reserved for issuance under the plan. If a quorum is present, adoption of
the amendment requires that the number of votes cast at the annual meeting in favor of adoption exceeds the number of votes cast opposing
adoption. Abstentions and broker non-votes will have no effect on Proposal&nbsp;3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Amendment to Certificate of Incorporation, as
amended, to increase the number of authorized shares of common stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may vote &ldquo;FOR,&rdquo; &ldquo;AGAINST&rdquo; or &ldquo;ABSTAIN&rdquo; on the proposal to amend our Certificate of Incorporation,
as amended, to increase the number of shares of our common stock authorized for issuance from 120,000,000 to 144,000,000. The affirmative
vote of a majority of the shares of our common stock outstanding and entitled to vote at the annual meeting is required to approve the
amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 120,000,000
to </FONT>144,000,000. Abstentions will have the same effect as an &ldquo;against&rdquo; vote on Proposal&nbsp;4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Ratification of the selection of Kesselman&nbsp;&amp;
Kesselman as our independent auditor</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You may vote &ldquo;FOR,&rdquo; &ldquo;AGAINST&rdquo;
or &ldquo;ABSTAIN&rdquo; on the ratification of the selection of Kesselman&nbsp;&amp; Kesselman to serve as our principal independent
registered public accounting firm for the fiscal year ending December&nbsp;31, 2022. Ratification of the appointment of our independent
registered public accounting firm requires the affirmative vote of the majority of shares present in person or represented by proxy at
the meeting and entitled to vote on the. Abstentions will have no effect on Proposal&nbsp;5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How Are My Votes Cast When I Sign And Return A Proxy Card?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When you sign the proxy card or submit your proxy
by telephone or over the Internet, you appoint Dror Bashan, our President and Chief Executive Officer, and Eyal Rubin, our Sr. Vice President
and Chief Financial Officer, as your representatives at the meeting. Either Dror Bashan or Eyal Rubin will vote your shares at the meeting
as you have instructed them on the proxy card. Each such person may appoint a substitute for himself.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Even if you plan to attend the meeting, it is a
good idea to complete, sign and return your proxy card or submit your proxy by telephone or over the Internet in advance of the meeting
in case your plans change. This way, your shares will be voted by you whether or not you actually attend the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>May&nbsp;I Revoke My Proxy?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you give us your proxy, you may revoke it at
any time before it is voted at the meeting. There will be no double counting of votes. You may revoke your proxy in any one of the following
ways:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>entering a new vote or by granting a new proxy card or new voting instruction bearing a later date (which automatically revokes the
earlier instructions);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if your shares are held in street name, re-voting by Internet or by telephone as instructed above (only your latest Internet or telephone
vote will be counted);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>notifying our Corporate Secretary, Eyal Rubin, in writing before the annual meeting that you have revoked your proxy; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>attending the meeting in person and voting in person. Attending the meeting in person will not in and of itself revoke a previously
submitted proxy unless you specifically request it.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Can My Broker Vote My Shares For Me?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
broker &ldquo;non-vote&rdquo; occurs when a broker or nominee holding shares for a beneficial owner does not vote on a particular matter
because the matter is not routine and such broker or nominee does not have the discretionary voting authority to vote the shares for which
it is the holder of record with respect to a particular matter at the annual meeting and such broker or nominee has not received instructions
from the beneficial owner. Broker &ldquo;non-votes,&rdquo; and shares as to which proxy authority has been withheld with respect to any
matter, are generally not deemed to be entitled to vote for purposes of determining whether stockholders&rsquo; approval of that matter
has been obtained. Pursuant to New York Stock Exchange (&ldquo;NYSE&rdquo;) Rule&nbsp;452, the uncontested election of directors (Proposal&nbsp;No.&nbsp;1),
the a</FONT>pproval of a non-binding advisory resolution on executive compensation (Proposal No.&nbsp;2), the adoption of amendments to
the Protalix BioTherapeutics,&nbsp;Inc. 2006 Stock Incentive Plan which increase the number of shares of common stock authorized for issuance
under the plan and amend certain other terms of the plan (Proposal No.&nbsp;3) and the amendment to Certificate of Incorporation, as amended,
to increase the number of authorized shares of common stock (Proposal No.&nbsp;4) are non-routine matters and, therefore, may not be voted
upon by brokers without instructions from beneficial owners. Consequently, proxies submitted by brokers for shares beneficially owned
by other persons may not, in the absence of specific instructions from such beneficial owners, vote the shares in favor of or withhold
votes from such proposals at the brokers&rsquo; discretion. The ratification of the selection of Kesselman&nbsp;&amp; Kesselman to serve
as our principal independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2022 (Proposal No.&nbsp;5)
is a routine matter. <B>Please complete your proxy and return it as instructed so your vote can be counted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What If I Receive More Than One Proxy Card?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You may receive more than one proxy card or voting
instruction form if you hold shares of our common stock in more than one account, which may be in registered form or held in street name.
Please vote in the manner described under &ldquo;How Do I Vote?&rdquo; for each account to ensure that all of your shares are voted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What If I Do Not Vote For Some Of The Matters Listed On My Proxy
Card?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you return your proxy card without indicating
your vote, your shares will be voted <I>for</I> the nominees listed on the card; <I>for</I> the approval, on an advisory basis, of the
executive compensation; <I>for</I> the adoption of amendments to the Protalix BioTherapeutics,&nbsp;Inc. 2006 Stock Incentive Plan which
increase the number of shares of common stock authorized for issuance under the plan and amend certain other terms of the plan; <I>for</I>
the amendment to Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock; and <I>for</I>
the ratification of the appointment of Kesselman&nbsp;&amp; Kesselman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Will My Shares Be Voted If I Do Not Return My Proxy Card And Do
Not Attend The Annual Meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If your shares are registered in your name or if
you have stock certificates, they will not be voted if you do not return your proxy card by mail or vote at the meeting as described above
under &ldquo;How Do I Vote?&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If your shares are held in street name and you
do not provide voting instructions to the bank, broker or other nominee that holds your shares as described above under &ldquo;How Do
I Vote?,&rdquo; the bank, broker or other nominee has the authority to vote your shares on certain routine matters scheduled to come before
the meeting even if it does not receive instructions from you. We encourage you to provide voting instructions. This ensures your shares
will be voted at the meeting in the manner you desire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Is Voting Confidential?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Yes. Only the inspector of elections and our employees
who have been assigned the responsibility for overseeing the legal aspects of the annual meeting and our proxy solicitors will have access
to your proxy card. The inspector of elections will tabulate and certify the vote. Any comments written on the proxy card will remain
confidential unless you ask that your name be disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What Are The Costs Of Soliciting These Proxies?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will pay all of the costs of soliciting these
proxies. Our officers, directors and employees may solicit proxies in person or by telephone, fax or email. We will pay these officers,
employees and directors no additional compensation for these services. We will ask banks, brokers and other institutions, nominees and
fiduciaries to forward these proxy materials to their principals and to obtain authority to execute proxies. We will then reimburse them
for their expenses. We have engaged Alliance Advisors&nbsp;LLC to assist us in soliciting proxies for the annual meeting. We will pay
Alliance Advisors a base fee of $10,000, plus reasonable out-of-pocket expenses, plus an additional fee based upon the number of contacts
with stockholders made and work performed. We estimate the total amount payable to Alliance Advisors will be approximately $100,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Could Other Matters Be Decided At The Annual Meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not know of any other matters that will be
considered at the annual meeting. If any other matters arise at the annual meeting at or by the direction of the Board of Directors, the
proxies will be voted at the discretion of the proxy holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What Happens If The Annual Meeting Is Postponed Or Adjourned?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Your proxy will still be valid and may be voted
at the postponed or adjourned meeting. You will still be able to change or revoke your proxy until it is voted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Do I Need A Ticket To Attend The Annual Meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Yes, you will need an admission ticket or proof
of ownership of common stock to enter the annual meeting. If you are a stockholder of record, your admission ticket is the bottom half
of the proxy card sent to you. If you plan to attend the Annual Meeting, please so indicate when you vote and bring the ticket with you
to the annual meeting. If your shares are held in the name of a bank, broker or other holder of record, your admission ticket is the left
side of your voting information form. If you do not bring your admission ticket, you will need proof of ownership to be admitted to the
annual meeting. A recent brokerage statement or letter from a bank or broker is an example of proof of ownership. If you arrive at the
annual meeting without an admission ticket, we will admit you only if we are able to verify that you are a stockholder of our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth information, as
of May&nbsp;2, 2022, regarding beneficial ownership of our common stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; color: #231f20"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each
person who is known by us to own beneficially more than 5% of our common stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; color: #231f20"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each
director;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; color: #231f20"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each
of our executive officers; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; color: #231f20"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
of our directors and executive officers collectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless otherwise noted, we believe that all persons
named in the table have sole voting and investment power with respect to all shares of our common stock beneficially owned by each of
them. For purposes of this table, a person is deemed to be the beneficial owner of securities that can be acquired by such person within
60 days from May&nbsp;2, 2022 upon exercise of options, warrants and convertible securities. Each beneficial owner&rsquo;s percentage
ownership is determined by assuming that options, warrants and convertible securities that are held by such person (but not those held
by any other person) and that are exercisable within such 60 days from such date have been exercised. The information set forth below
is based upon information obtained from the beneficial owners, upon information in our possession regarding their respective holdings
and upon information filed by the holders with the SEC. The percentages of beneficial ownership are based on 46,365,832 shares of our
common stock outstanding as of April&nbsp;15, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The address for all directors and officers is c/o
Protalix BioTherapeutics,&nbsp;Inc., 2 Snunit Street, Science Park, P.O.&nbsp;Box&nbsp;455, Carmiel 2161401,&nbsp;Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount&nbsp;and&nbsp;Nature&nbsp;of</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percentage&nbsp;of</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Name and Address of Beneficial Owner</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Beneficial&nbsp;Ownership</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Class&nbsp;(%)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Board of Directors and Executive Officers</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Zeev Bronfeld<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">567,283</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">1.21</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Dror Bashan<SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">1,273,458</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">2.74</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Amos Bar Shalev<SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">22,668</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Pol F. Boudes, M.D.<SUP>(4)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">22,540</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">David Granot<SUP>(5)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">22,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Gwen A. Melincoff<SUP>(6)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">22,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Aharon Schwartz, Ph.D.<SUP>(7)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">86,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Einat Brill Almon, Ph.D.<SUP>(8)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">207,622</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Yaron Naos<SUP>(9)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">134,867</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Eyal Rubin<SUP>(10)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">423,097</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Yael Hayon<SUP>(11)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">56,774</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">All executive officers and directors as a group (11 persons)<SUP>(12)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">2,839,809</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">6.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20">5% Holders</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Alfred Akirov<SUP>(13)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">4,525,687</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">9.35</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Angels Investments in Hi-Tech&nbsp;Ltd.<SUP>(14)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">2,816,901</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">5.73</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Highbridge Capital Management LLC<SUP>(16)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">5,146,036</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">9.99</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">HIR Investments&nbsp;Ltd.<SUP>(17)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">4,411,305</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">9.12</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Psagot Provident Funds and Pension&nbsp;Ltd.<SUP>(18)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,816,901</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">5.73</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">UBS O&rsquo;Connor<SUP>(19)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">3,057,715</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">6.19</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Whitebox Advisors LP<SUP>(20)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">2,816,108</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">5.73</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>Consists of 216,247 outstanding shares of our common stock held by EBC Holdings Ltd., an investment company wholly-owned by Mr.&nbsp;Bronfeld,
216,036 shares of our common stock issuable upon exercise of an outstanding warrant held by Mr.&nbsp;Bronfeld and 135,000 shares of our
common stock issuable upon exercise of outstanding options within 60 days of May&nbsp;2, 2022. Does not include 105,000 shares of our
common stock underlying options that will not vest within 60 days of May&nbsp;2, 2022.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: split002 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>Consists of 1,085,458 outstanding restricted shares of our common stock that are subject to forfeiture, 68,000 outstanding shares
of our common stock and 120,000 shares of our common stock issuable upon exercise of outstanding options within 60 days of May&nbsp;2,
2022. Does not include 40,000 shares of our common stock underlying options that will not vest within 60 days of May&nbsp;2, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD>Consists of 168 outstanding shares of our common stock and 22,500 shares of our common stock issuable upon exercise of outstanding
options within 60 days of May&nbsp;2, 2022. Does not include 17,500 shares of our common stock underlying options that will not vest within
60 days of May&nbsp;2, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD>Consists of 40 outstanding shares of our common stock and 22,500 shares of our common stock issuable upon exercise of outstanding
options within 60 days of May&nbsp;2, 2022. Does not include 17,500 shares of our common stock underlying options that will not vest within
60 days of May&nbsp;2, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(5)</TD><TD>Consists of 22,500 shares of our common stock issuable upon exercise of outstanding options within 60 days of May&nbsp;2, 2022. Does
not include 17,500 shares of our common stock underlying options that will not vest within 60&nbsp;days of May&nbsp;2, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(6)</TD><TD>Consists of 22,500 shares of our common stock issuable upon exercise of outstanding options within 60 days of May&nbsp;2, 2022. Does
not include 17,500 shares of our common stock underlying options that will not vest within 60&nbsp;days of May&nbsp;2, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(7)</TD><TD>Consists of 64,000 outstanding shares of our common stock and 22,500 shares of our common stock issuable upon exercise of outstanding
options within 60 days of May&nbsp;2, 2022. Does not include 17,500 shares of our common stock underlying options that will not vest within
60 days of May&nbsp;2, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(8)</TD><TD>Consists of 18,500 outstanding shares of our common stock and 189,122 shares of our common stock issuable upon exercise of outstanding
options within 60 days of May&nbsp;2, 2022. Does not include 102,873 shares of our common stock underlying options that will not vest
within 60 days of May&nbsp;2, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(9)</TD><TD>Consists of 19,955 outstanding shares of our common stock and 114,912 shares of our common stock issuable upon exercise of outstanding
options within 60 days of May&nbsp;2, 2022. Does not include 72,744 shares of our common stock underlying options that will not vest within
60 days of May&nbsp;2, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(10)</TD><TD>Consists of 368,097 outstanding restricted shares of our common stock that are subject to forfeiture and 55,000 shares of our common
stock issuable upon exercise of outstanding options within 60 days of May&nbsp;2, 2022. Does not include 25,000 shares of our common stock
underlying options that will not vest within 60 days of May&nbsp;2, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(11)</TD><TD>Consists of 56,774 shares of our common stock issuable upon exercise of outstanding options within 60&nbsp;days of May&nbsp;2, 2022.
Does not include 72,997 shares of our common stock underlying options that will not vest within 60&nbsp;days of May&nbsp;2, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(12)</TD><TD>Consists of 1,840,465 outstanding shares of our common stock, 216,036 shares of our common stock issuable upon exercise of an outstanding
warrant and 783,308 shares of our common stock issuable upon exercise of outstanding options within 60 days of May&nbsp;2, 2022. Does
not include 506,114 shares of our common stock underlying options that will not vest within 60 days of May&nbsp;2, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(13)</TD><TD>Based on a Schedule 13G filed by Alfred Akirov on March&nbsp;30, 2020 for March&nbsp;12, 2020. Consists of 2,513,615 outstanding shares
of our common stock and 2,012,072 shares of our common stock issuable upon exercise of outstanding warrants within 60 days of May&nbsp;2,
2022, in the aggregate, held by Alrov Properties&nbsp;&amp; Lodgings Ltd., or Alrov Properties, Technorov Holdings (1993) Ltd., or Technorov,
and Alrov Holdings Technologies Ltd., or Alrov Technologies. Mr.&nbsp;Akirov is the majority shareholder, and Chairman of the Board of
each of Alrov Properties, which is listed on the Tel Aviv Stock Exchange, and the subsidiaries of Alrov Properties, Technorov and Alrov
Technologies, and, accordingly, in the normal course of business has the power to direct the voting and disposition decisions of such
entities, all subject to the Israeli law provision in regards to a public company. Mr.&nbsp;Akirov&rsquo;s principal business office is
at The Alrov Tower, 46&nbsp;Rothschild Boulevard, Tel Aviv 66883,&nbsp;Israel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Options: NewSection; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(14)</TD><TD>Based on a Schedule 13G filed by Angels Investments on January&nbsp;31, 2022 for December&nbsp;31, 2021. Consists of 2,816,901 shares
of our common stock issuable upon exercise of outstanding warrants within 60 days of May&nbsp;2, 2022 held by Angels Investments. Marius
Nacht is the sole shareholder and director of Angel Investments, and, accordingly, may be deemed to have beneficial ownership (as determined
under Section&nbsp;13(d)&nbsp;of the Securities Exchange Act of 1934, as amended, or the Exchange Act) of such shares held by Angels Investments.
The principal business office of Angels Investments is 42 Brendeis Street, Tel Aviv 6200157,&nbsp;Israel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(16)</TD><TD>Based on a Schedule 13F-HR filed on February&nbsp;11, 2022 for December&nbsp;31, 2021 and a Schedule 13G\A filed on February&nbsp;14,
2022 for December&nbsp;31, 2021, both by Highbridge Capital Management LLC, or Highbridge. Consists of 5,146,036 shares of our common
stock issuable upon conversion of convertible notes and exercise of outstanding warrants within 60 days of May&nbsp;2, 2022, held by Highbridge
Tactical Credit Master Fund, L.P. (the &ldquo;Highbridge Fund&rdquo;). Highbridge, as the trading manager of the Highbridge Fund, and
the Highbridge Fund may each be deemed to be the beneficial owner of such shares. The convertible notes and the warrants are subject to
blocker provisions pursuant to which the holders thereof cannot convert the notes or exercise the warrants to the extent that the reporting
persons would beneficially own, after any such exercise, more than 9.99% of the outstanding shares of our common stock. The disclosed
holdings do not include all of the shares issuable upon exercise of all of the notes and the warrants held due to the blocker provision.
The principal business office of Highbridge is 40 West 57<SUP>th</SUP> Street, 32nd Floor, New York, New York 10019.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(17)</TD><TD>Consists of 2,362,783 outstanding shares of our common stock and 2,012,072 shares of our common stock issuable upon exercise of outstanding
warrants within 60 days of May&nbsp;2, 2022, in the aggregate, held by <FONT STYLE="color: #231f20">HIR Investments&nbsp;Ltd., or </FONT>HIR,
and 36,450 outstanding shares of our common stock held directly or indirectly by Chinar Shah. Mr.&nbsp;Shah has the power to direct the
voting and disposition decisions of, and thus may be deemed to have beneficial ownership (as determined under Section&nbsp;13(d)&nbsp;of
the Exchange Act) of, all such shares and warrants. The principal business office of HIR is Flat No.&nbsp;303, Al-Shamal Building, Al-Khor
Street, Goldsuq, Deira, Dubai, UAE.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(18)</TD><TD>Consists of 2,816,901 shares of our common stock issuable upon exercise of outstanding warrants within 60 days of May&nbsp;2, 2022,
in the aggregate, held collectively by a number of funds managed by Psagot Provident Funds and Pension Ltd., or Psagot. The principal
business office of Psagot is Ehad Ha&rsquo;Am Street 14, Tel Aviv-Yafo,&nbsp;Israel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on a Schedule 13F-HR for December&nbsp;31, 2021 filed
by UBS O&rsquo;Connor LLC (&ldquo;UBS O&rsquo;Connor&rdquo;), on February&nbsp;14, 2022. UBS O&rsquo;Connor serves as the investment manager
to Nineteen77 Global Multi-Strategy Alpha Master Limited (&ldquo;GLEA&rdquo;). In such capacity, UBS O&rsquo;Connor exercises voting and
investment power over the shares of common stock held for the account of GLEA. Consists of shares of our common stock issuable upon conversion
of convertible notes and the exercise of outstanding warrants held by GLEA within 60 days of May&nbsp;2, 2022. The principal business
office of UBS O&rsquo;Connor is One North Wacker Drive, 32</FONT><FONT STYLE="font-size: 10pt">nd</FONT>&nbsp;Floor, Chicago,&nbsp;Illinois
60606.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(20)</TD><TD>Based on a Schedule 13F-HR for December&nbsp;31, 2021 filed by <FONT STYLE="color: #231f20">Whitebox Advisors LLC</FONT> (&ldquo;<FONT STYLE="color: #231f20">Whitebox&rdquo;),
on February&nbsp;14, 2022</FONT>. Consists of shares of our common stock issuable upon conversion of convertible notes held by certain
funds managed by Whitebox. The principal business office of Whitebox is 3033 Excelsior Boulevard, Suite&nbsp;500, Minneapolis, MN 55416.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section&nbsp;16(a)&nbsp;Beneficial Ownership Reporting Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;16(a)&nbsp;of the Exchange Act requires
our directors, executive officers and holders of more than 10% of our common stock to file with the SEC reports regarding their ownership
and changes in ownership of our equity securities. We believe that all Section&nbsp;16 filings requirements were met by our officers and
directors during 2021. In making this statement, we have relied solely upon examination of the copies of Forms 3, 4 and 5, and written
representations of our former and current officers and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROPOSAL 1: ELECTION OF DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the annual meeting, our stockholders will be
asked to elect six directors for a one-year term expiring at the next annual meeting of stockholders. Each director will hold office until
his or her successor has been elected and qualified or until the director&rsquo;s earlier resignation or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors recommends that the persons
named below be elected as directors of our Company and it is intended that the accompanying proxy will be voted for their election as
directors, unless the proxy contains contrary instructions. Shares of common stock represented by all proxies received by the Board of
Directors and not so marked as to withhold authority to vote for any individual nominee or for all nominees will be voted (unless one
or more nominees are unable to serve) for the election of the nominees named below. The Board of Directors knows of no reason why any
such nominee should be unable or unwilling to serve, but if such should be the case, proxies will be voted for the election of some other
person or the size of the Board of Directors will be fixed at a lower number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of the nominees currently serves as a member
of our Board of Directors. The directors are elected by a plurality of the votes cast by the stockholders present or represented by proxy
and entitled to vote at the annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nominees for Election to the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The names of the nominees for election to the Board
of Directors and certain information about such nominees are set forth below. For information concerning the number of shares of common
stock beneficially owned by each nominee, see &ldquo;Security Ownership of Certain Beneficial Owners and Management&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20">Name</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center">Age</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center">Position</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Zeev Bronfeld</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #231f20; text-align: center">70</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="width: 54%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-left: 0.05pt">Chairman of the Board</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Dror Bashan</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center">55</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-left: 0.05pt">President and Chief Executive Officer, Director</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Amos Bar Shalev</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center">69</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-left: 0.05pt">Director</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Pol F. Boudes, M.D.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center">65</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-left: 0.05pt">Director</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Gwen A. Melincoff</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center">70</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-left: 0.05pt">Director</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Aharon Schwartz, Ph.D.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center">79</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-left: 0.05pt">Director</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Zeev
Bronfeld. </B></FONT>Mr.&nbsp;Bronfeld has served as the Chairman of our Board of Directors since August&nbsp;2019. He has served as a
director of Protalix&nbsp;Ltd., our wholly-owned subsidiary and sole operating unit, since 1996 and as our director since December&nbsp;2006.
Mr.&nbsp;Bronfeld brings to us vast experience in management and value building of biotechnology companies. He is an experienced businessman
who is involved in a number of biotechnology companies. He was a co-founder of Bio-cell&nbsp;Ltd., a former Israeli publicly-traded holding
company that specialized in biotechnology companies and served as its Chief Executive Officer from 1986 through 2015. Mr.&nbsp;Bronfeld
currently serves as a director of The Trendlines Group (SGX:42T) and Electreon Wireless&nbsp;Ltd. (TASE:ELWS) (formerly, Biomedix Incubator&nbsp;Ltd.),
both of which are public companies. Mr.&nbsp;Bronfeld is also a director of a number of privately-held companies, most of which are involved
in the life sciences industry, such as Contipi Medical Ltd. From August&nbsp;2010 through April&nbsp;2021, Mr.&nbsp;Bronfeld served as
a director of Entera Bio&nbsp;Ltd. (NASDAQ: ENTX), from November&nbsp;2009 through February&nbsp;2021, he served as a director of D.N.A.
Biomedical Solutions&nbsp;Ltd. (TASE:DNA) and from January&nbsp;2008 through January&nbsp;2017, he served as a director of Macrocure&nbsp;Ltd.,
a Nasdaq-listed company that merged into Leap Therapeutics,&nbsp;Inc. (NASDAQ:LPTX). Mr.&nbsp;Bronfeld received a B.A. in Economics from
the Hebrew University in 1975. We believe Mr.&nbsp;Bronfeld&rsquo;s qualifications to serve on our Board of Directors include his&nbsp;years
of experience in the management of private and public Israeli companies, including life science companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dror
Bashan. </B></FONT>Mr.&nbsp;Bashan has served as our President and Chief Executive Officer and as our director since June&nbsp;2019. He
has over 20&nbsp;years of experience in the pharmaceutical industry with roles ranging from business development, marketing, sales and
finance providing him with both cross regional and cross discipline experience and a deep knowledge of the global pharmaceutical and health
industries. From 1998 through 2018, he served in a number of senior positions at Teva Pharmaceutical Industries Ltd (&ldquo;Teva&rdquo;).
(NYSE:TEVA; TASE:TEVA). Most recently, he served as Teva&rsquo;s Senior Vice President, Global Business Development, and was involved
in strategic alliances, cross-company strategic projects and the acquisition and divestiture of assets. Mr.&nbsp;Bashan holds a BA in
Economics and Business Management from the Tel Aviv University and an MBA from the Tel Aviv University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amos
Bar Shalev. </B></FONT>Mr.&nbsp;Bar Shalev has served as our director since July&nbsp;2008. Previously, Mr.&nbsp;Bar Shalev served as
a director of Protalix&nbsp;Ltd. from 2005 through January&nbsp;2008, and as our director from 2006 through January&nbsp;2008. Mr.&nbsp;Bar
Shalev brings to us extensive experience in managing technology companies. Currently, Mr.&nbsp;Bar Shalev serves on the Board of Directors
of the following privately-held Israeli companies: Aposense&nbsp;Ltd., Steam CC&nbsp;Ltd. and Sirvir&nbsp;Ltd. From 2004 through 2012,
Mr.&nbsp;Bar Shalev served as a director of Technorov Holdings (1993)&nbsp;Ltd. and managed its portfolio. From 1997 through 2004, he
was a Managing Director of TDA Capital Partners, a management company of the TGF (Templeton Tadiran) Fund. From 2004 through 2007, he
was the President of Win Buyer&nbsp;Ltd. He has served on the Board of Directors of a number of Israeli publicly traded and privately-held
Israeli companies including, among others, Velox&nbsp;Ltd., NESS&nbsp;Ltd. (acquired by BioNess&nbsp;Inc.),&nbsp;Idanit (acquired by Scitex
Corporation&nbsp;Ltd.), Objet Geometrix (merged with Stratasys,&nbsp;Inc. (NASDAQ:SSYS)), Verisity, Scitex Vision (acquired by Hewlett
Packard), Golden Wings Investment Company&nbsp;Ltd., the venture capital fund of the Israeli Air Force Veterans Business Club, Win Buyer&nbsp;Ltd.
and Sun Light&nbsp;Ltd. He received his B.Sc. in Electrical Engineering from the Technion,&nbsp;Israel in 1978 and M.B.A. from the Tel
Aviv University in 1981. He holds the highest award from the Israeli Air Force for technological achievements. We believe Mr.&nbsp;Bar
Shalev&rsquo;s qualifications to serve on our Board of Directors include his years of experience in the management of Israeli businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pol
F. Boudes, M.D. </B></FONT>Dr.&nbsp;Boudes joined our Board of Directors in January&nbsp;2020. He is a senior physician and chief medical
officer with more than 25&nbsp;years of experience in research and development, with a special emphasis on orphan drugs and translational
medicine. In March&nbsp;2020, Dr.&nbsp;Boudes was appointed Chief Medical Officer of Galectin Therapeutics&nbsp;Inc. (NASDAQ:GALT). He
also serves as a research and development consultant. From April&nbsp;2014 through October&nbsp;2019, he served as the Chief Medical Officer
of CymaBay Therapeutics,&nbsp;Inc. (Nasdaq:CBAY) where he led the development of treatments for rare liver diseases. Dr.&nbsp;Boudes was
also Chief Medical Officer at Amicus Therapeutics Inc. (Nasdaq:FOLD) from 2009 to 2013 where he was instrumental in the development of
migalastat (Galafold<SUP>&reg;</SUP>) for the treatment of Fabry disease, as well as treatments for Pompe disease and Gaucher disease.
He has served in various roles at Berlex Laboratories (acquired by Bayer HealthCare Pharmaceuticals), Wyeth-Ayerst Research, Hoffmann-La
Roche and Pasteur-Merieux Serums&nbsp;&amp; Vaccines. Dr.&nbsp;Boudes holds an M.D. from the University of Aix-Marseilles, France and
has specialized in Endocrinology and Metabolic Diseases,&nbsp;Internal Medicine, and Geriatric diseases. We believe Dr.&nbsp;Boudes&rsquo;
qualifications to serve on our Board of Directors include his vast experience and knowledge of the research and development of pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gwen
A. Melincoff. </B></FONT>Ms.&nbsp;Melincoff joined our Board of Directors in January&nbsp;2020. She is a seasoned business development
and venture professional with over 25&nbsp;years of deal-making and management experience in the biotechnology and pharmaceutical industries.
Her experience has spanned public and private company boards, venture financing, business development, licensing, mergers and acquisitions,
research operations, marketing, product management and project management. Ms.&nbsp;Melincoff currently serves on the Board of Directors
of Gain Therapeutics,&nbsp;Inc. ((NASDAQ:GANX), Soleno Therapeutics,&nbsp;Inc. (NASDAQ:SOLN) and Collegium Pharmaceutical,&nbsp;Inc. (NASDAQ:COLL)
and. She also serves in an advisory capacity at a number of pharmaceutical companies. From April&nbsp;2017 through June&nbsp;2020, she
served on the Board of Directors of Photocure ASA, from January&nbsp;2017 through January&nbsp;2019, she served on the Board of Directors
of Kamada&nbsp;Ltd. (NASDAQ:KMDA, TASE:KMDA), and from June&nbsp;2014 through November&nbsp;2016, she served on the Board of Directors
of Tobira Therapeutics&nbsp;Inc. (acquired by Allergan plc). From August&nbsp;2014 through September&nbsp;2016, Ms.&nbsp;Melincoff served
as Vice President of Business Development at BTG International&nbsp;Inc. Prior to that, she was Senior Vice President of Corporate Development
at Shire Plc. Additionally, she led the Shire Strategic Investment Group, the venture capital arm of Shire Plc. Ms.&nbsp;Melincoff was
Vice President of Business Development at Adolor Corporation and held executive positions at Eastman Kodak for over ten&nbsp;years in
a number of their health care companies. She holds a B.S. in Biology from The George Washington University and an M.S. in Management and
Health Care Administration from Pennsylvania State University. Ms.&nbsp;Melincoff has also attained the designation of Certified Licensing
Professional (CLP&trade;). Ms.&nbsp;Melincoff was named to the &ldquo;Top Women in Biotech 2013&rdquo; by Fierce Biotech and to the Powerlist
100 of Corporate Venture Capital in 2012 and 2013. We believe Ms.&nbsp;Melincoff&rsquo;s qualifications to serve on our Board of Directors
include her&nbsp;years of experience at pharmaceutical companies, particularly with respect to business development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aharon
Schwartz, Ph.D. </B></FONT>Dr.&nbsp;Schwartz has served as our director since November&nbsp;2014. He retired from Teva in 2011 where he
served in a number of positions from 1975 through 2011, the most recent being Vice President, Head of Teva Innovative Ventures from 2008.
Dr.&nbsp;Schwartz is currently chairman of the Board of Directors of BiolineRx Ltd. (NASDAQ:BLRX, TASE:BLRX) and a member of the Board
of Directors of Barcode Ltd. He also serves as the Head of the Advisory Board of Oncohost Ltd. and works as an independent consultant.
From May&nbsp;2015 through March&nbsp;2020, he served as a member of the Board of Directors of Foamix Pharmaceuticals Ltd., (Nasdaq: FOMX)
which was acquired by Menlo Therapeutics Inc. (Nasdaq: MNLO), and from January&nbsp;2013 through November&nbsp;2017, he served as a member
of the Board of Directors of Alcobra Ltd., which is now called Arcturus Therapeutics Ltd. Dr.&nbsp;Schwartz received his Ph.D. in organic
chemistry in 1978 from the Weizmann Institute of Science, his M.Sc. in organic chemistry from the Technion and a B.Sc. in chemistry and
physics from the Hebrew University of Jerusalem. Dr.&nbsp;Schwartz received a second Ph.D. in 2014 from the Hebrew University of Jerusalem
in the history and philosophy of science. We believe Dr.&nbsp;Schwartz&rsquo;s qualifications to serve on our Board of Directors include
his years of experience at life science companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Our Board of Directors recommends that stockholders
vote &ldquo;FOR&rdquo; the election or re-election of all director nominees named in this &ldquo;Proposal 1: Election of Directors.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Governance and Independent Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In compliance with the listing requirements of
the NYSE American, we have a comprehensive plan of corporate governance for the purpose of defining responsibilities, setting high standards
of professional and personal conduct and assuring compliance with such responsibilities and standards. We currently regularly monitor
developments in the area of corporate governance to ensure we are in compliance with the standards and regulations required by the NYSE
American. A summary of our corporate governance measures follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Independent Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe a majority of the members of our Board
of Directors are independent from management. When making determinations from time to time regarding independence, the Board of Directors
will reference the listing standards adopted by the NYSE American as well as the independence standards set forth in the Sarbanes-Oxley
Act of 2002, or the SOX, and the rules&nbsp;and regulations promulgated by the SEC under that Act, as well as other factors which could
assist our Board of Directors and its committees in determining that a director will have no material relationship with us that could
compromise that director&rsquo;s independence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors has determined that Mr.&nbsp;Bronfeld,
Mr.&nbsp;Bar Shalev, Mr.&nbsp;Granot, Ms.&nbsp;Melincoff, Dr.&nbsp;Boudes and Dr.&nbsp;Schwartz are &ldquo;independent&rdquo; pursuant
to the rules&nbsp;of the NYSE American.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The position of Chairman of the Board is not held
by our chief executive officer at this time. The Board of Directors does not have a policy mandating the separation of these functions.
We believe it is in our best interest that Mr.&nbsp;Bronfeld serve as the chairman of our Board of Directors. This decision was based
on Mr.&nbsp;Bronfeld&rsquo;s experience in the healthcare industry in Israel and globally and his years of experience serving on the Board
of Directors of public and private companies. Our non-management directors hold formal meetings, separate from management, at least twice
per&nbsp;year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Board&rsquo;s Role in Risk Oversight</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors oversees an enterprise-wide
approach to risk management, designed to support the achievement of business objectives, including organizational and strategic objectives,
to improve long-term organizational performance and enhance stockholder value. The involvement of our Board of Directors in setting our
business strategy is a key part of its assessment of management&rsquo;s plans for risk management and its determination of what constitutes
an appropriate level of risk for the Company. The participation of our Board of Directors in our risk oversight process includes receiving
regular reports from members of senior management on areas of material risk to the Company, including operational, financial, legal and
regulatory, and strategic and reputational risks. While the full Board of Directors has the ultimate oversight responsibility for the
risk management process, various committees of the Board of Directors also have responsibility for risk management. For example, financial
risks, including internal controls, are overseen by the Audit and Finance Committee and risks that may be implicated by our executive
compensation programs are overseen by the Compensation Committee. Upon identification of a risk, the assigned committee or our full Board
of Directors discuss or review risk management and risk mitigation strategies. Additional review or reporting on enterprise risks is conducted
as needed or as requested by our Board of Directors or a committee thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board and Committee Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors has an Audit and Finance
Committee, Compensation Committee and Nominating Committee. The membership of each committee is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 33%; font: bold 10pt Times New Roman, Times, Serif; color: #231f20">Committee</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="width: 12%; font: bold 10pt Times New Roman, Times, Serif; color: #231f20; padding-left: 19.95pt">Chairman</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 53%; color: #231f20; text-align: center">Membership</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Audit and Finance Committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">David Granot</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center; padding-left: 0.05pt">David Granot, Amos Bar Shalev and Aharon Schwartz, Ph.D.</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Compensation Committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Amos Bar Shalev</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center; padding-left: 0.05pt">Amos Bar Shalev, David Granot and Aharon Schwartz, Ph.D.</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Nominating Committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Amos Bar Shalev</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center; padding-left: 0.05pt">Amos Bar Shalev, Zeev Bronfeld and Aharon Schwartz, Ph.D.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The primary functions of each committee are as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Audit and Finance Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors has determined that Mr.&nbsp;Granot,
Mr.&nbsp;Bar Shalev and Dr.&nbsp;Schwartz are &ldquo;independent&rdquo; for purposes of membership on the Audit and Finance Committee
pursuant to Section&nbsp;803B(2)&nbsp;of the NYSE American Company Guide and Section&nbsp;10A(m)(3)&nbsp;of the Exchange Act. We require
that all Audit and Finance Committee members possess the required level of financial literacy and at least one member of the Audit and
Finance Committee meet the current standard of requisite financial management expertise as required by the NYSE American and applicable
rules&nbsp;and regulations of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Audit and Finance Committee operates under
a formal charter that governs its duties and conduct. A current copy of the Audit and Finance Committee Charter is available on our website
at http://www.protalix.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All members of the Audit and Finance Committee
are independent from our executive officers and management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our independent registered public accounting firm
reports directly to the Audit and Finance Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Audit and Finance Committee meets with management
and representatives of our registered public accounting firm prior to the filing of officers&rsquo; certifications with the SEC to receive
information concerning, among other things, effectiveness of the design or operation of our internal controls over financial reporting,
as required by Section&nbsp;404 of SOX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Audit and Finance Committee has adopted a Policy
for Reporting Questionable Accounting and Auditing Practices and Policy Prohibiting Retaliation against Reporting employees to enable
confidential and anonymous reporting of improper activities to the Audit and Finance Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr.&nbsp;Granot, Mr.&nbsp;Bar Shalev and Dr.&nbsp;Schwartz
each qualify as &ldquo;audit committee financial experts&rdquo; under the applicable rules&nbsp;of the SEC. In making the determination
as to these individuals&rsquo; status as audit committee financial experts, our Board of Directors determined they have accounting and
related financial management expertise within the meaning of the aforementioned rules, as well as the listing standards of the NYSE American.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Compensation Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors has determined that Mr.&nbsp;Bar
Shalev, Mr.&nbsp;Granot, and Dr.&nbsp;Schwartz are &ldquo;independent&rdquo; for purposes of membership on the Compensation Committee
pursuant to Section&nbsp;805(c)&nbsp;of the NYSE American Company Guide. The Compensation Committee reviews and approves the compensation
of executive officers and key employees and administers our stock incentive plan. A current copy of the Compensation Committee Charter
is available on our website at http://www.protalix.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Nominating Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Nominating Committee is responsible for assisting
our Board of Directors in selecting nominees for election to the Board of Directors and monitoring the composition of the Board of Directors.
A current copy of the Nominating Committee Charter is available on our website at http://www.protalix.com. Although our Board of Directors
does not have a formal policy requiring the Nominating Committee to consider the diversity of directors in its nomination process, in
considering potential new directors, the Nominating Committee will review individuals from various disciplines and backgrounds, and consider
the following qualifications: broad experience in business, finance or administration; familiarity with national business matters; familiarity
with our industry; independence; and prominence and reputation. The committee seeks nominees with a broad diversity of experience, professions,
education, skills and backgrounds with a view to having a Board of Directors that represents a diversity of views, experiences, and backgrounds.
After making such a review, the Nominating Committee submits the nomination to the full Board of Directors for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Nominating Committee will consider any nominees
submitted by stockholders of record at the time of any such nomination in compliance with applicable rules&nbsp;of the SEC and our By-Laws.
The Nominating Committee will determine whether any stockholder nominee meets the qualifications for candidacy described above and in
the Nominating Committee Charter. Stockholders&rsquo; nominations for election at the 2023 Annual Meeting of Stockholders must be submitted
in writing to Eyal Rubin, Corporate Secretary, not less than 45&nbsp;days nor more than 75&nbsp;days prior to the date on which we first
mailed this proxy statement. Such written notice must include the following information: (i)&nbsp;name, age, business address and residence
address of the nominee; (ii)&nbsp;the principal occupation or employment of the nominee; (iii)&nbsp;the class and number of shares of
our Company beneficially owned by the nominee; and (iv)&nbsp;any other information relating to the nominee that would be required to be
disclosed in solicitations for proxies for elections of directors pursuant to Regulation 14A of the Exchange Act. The written notice must
also include the following information with respect to each stockholder delivering such notice: (i)&nbsp;the name and record address of
such stockholder; and (ii)&nbsp;the class and number of shares of our Company beneficially owned by the stockholder. Lastly, the written
notice must include certain information relating to any derivative or hedging transactions by the stockholder delivering such notice and
its Stockholder Associated Persons, as defined in our By-Laws, and other arrangements with other parties regarding our securities, as
presented in detail in our By-Laws. Stockholders can mail any such recommendations, including the criteria outlined above, to Eyal Rubin,
Corporate Secretary, Protalix BioTherapeutics,&nbsp;Inc., 2 University Plaza, Suite&nbsp;100, Hackensack, NJ 07601.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the rules&nbsp;of the NYSE American, a director
of our Company will only qualify as an &ldquo;independent director&rdquo; if, among other things, in the opinion of our Board of Directors,
that person does not have a material relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities
of a director. The Board of Directors has determined that none of the non-employee directors has a relationship that would interfere with
the exercise of independent judgment in carrying out the responsibilities of a director and that each of the non-employee directors is
an &ldquo;independent director&rdquo; as defined under rules&nbsp;of the NYSE American. In addition, the Board of Directors has determined
that all members of the Audit and Finance Committee meet the independence requirements set forth in Section&nbsp;803B(2)&nbsp;of the NYSE
American Company Guide and Section&nbsp;10A(m)(3)&nbsp;of the Exchange Act, and that all members of the Compensation Committee meet the
independence requirements set forth in Rule&nbsp;805(c)&nbsp;of the NYSE American Listed Company Guide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacting the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stockholders who wish to communicate with the Board
of Directors may do so by mailing any such communications to Eyal Rubin, Corporate Secretary, Protalix BioTherapeutics,&nbsp;Inc., 2&nbsp;University
Plaza, Suite&nbsp;100, Hackensack, NJ 07601. All communications are distributed to the Board of Directors, as appropriate, depending upon
the facts and circumstances outlined in the communications received. For example, if any complaints regarding accounting and/or auditing
matters are received, they may be forwarded by our Corporate Secretary to the Audit and Finance Committee for review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Policy Governing Director Attendance at Annual Meetings of Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have no formal policy regarding attendance by
our directors at annual stockholders meetings, although we encourage such attendance and anticipate most of our directors will attend
these meetings. Our directors did not attend our 2021 annual meeting of stockholders due to the COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the&nbsp;year ended December&nbsp;31, 2021,
there were 13 meetings of our Board of Directors, four meetings of the Audit and Finance Committee, one meeting of the Compensation Committee
and one meeting of the Nominating Committee. Our non-management directors hold meetings separate from management at least twice per year.
All of our current directors that served on our Board of Directors during the&nbsp;year ended December&nbsp;31, 2021 attended at least
75% of the aggregate number of meetings of the Board of Directors and the committees of the Board of Directors on which they served.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compensation of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth information with
respect to compensation of our non-employee directors during fiscal&nbsp;year 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fees&nbsp;Earned&nbsp;or</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Option</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Name</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Paid&nbsp;in&nbsp;Cash&nbsp;($)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Award(s)&nbsp;($)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total&nbsp;($)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left">Zeev Bronfeld</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">152,543</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">152,543</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Amos Bar Shalev</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24,436</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">64,436</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">David Granot</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24,436</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">64,436</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Aharon Schwartz, Ph.D.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24,436</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">64,436</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Pol F. Boudes, M.D.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24,436</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">64,436</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Gwen A. Melincoff</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24,436</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">64,436</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 0pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 0pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board of Directors approved a new compensation
program for our non-employee directors, commencing as of January&nbsp;1, 2020. Directors are entitled to a cash payment equal to $40,000
per year, payable quarterly, and were granted options to purchase 40,000 shares of our common stock. The options vest quarterly in 16
equal increments over a four-year period. We granted to the Chairman of the Board an option to purchase 240,000 shares of our common stock,
which option vests quarterly in 16 equal increments over a four-year period. As part of the compensation program, the Chairman of the
Board of Directors is not entitled to cash compensation. His compensation is limited to equity compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compensation Committee Interlocks and Insider Participation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No member of our Compensation Committee or any
executive officer of the Company or of Protalix&nbsp;Ltd. has a relationship that would constitute an interlocking relationship with executive
officers or directors of another entity. No Compensation Committee member is or was an officer or employee of ours or of Protalix&nbsp;Ltd.
or had any relationship that constituted a related party transaction. Further, none of our executive officers serves on the Board of Directors
or compensation committee of any entity that has one or more executive officers serving as a member of our Board of Directors or Compensation
Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Code of Business Conduct and Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Code of Business Conduct and Ethics includes
provisions ranging from restrictions on gifts to conflicts of interest. All of our employees and directors are bound by this Code of Business
Conduct and Ethics. Violations of our Code of Business Conduct and Ethics may be reported to the Audit and Finance Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Code of Business Conduct and Ethics includes
provisions applicable to all of our employees, including senior financial officers and members of our Board of Directors and is posted
on our website (www.protalix.com). We intend to post amendments to or waivers from any such Code of Business Conduct and Ethics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Insider Trading, Prohibition on Short-term, Speculative Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Insider Trading and Blackout Policy includes
restrictions regarding the timing and types of transactions in our securities by our directors, officers, including our Named Executive
officers, and other employees. Our directors, officers and certain other designated other employees are prohibited from trading during
blackout periods (during the period from and including the close of business on the seventh day prior to the end of the third month of
each quarter and ends on the opening of the second business day following our filing with the SEC of the Company&rsquo;s quarterly or
annual financial reports or earlier public release of quarterly or annual financial information) and without the clearance of our Compliance
Officer. In addition, the policy provides that none of our directors, officers or other employees may engage in the following transactions:
(i)&nbsp;purchasing our securities on margin; (ii)&nbsp;pledging our securities; (iii)&nbsp;short sales; (d)&nbsp;buying or selling puts
or calls in connection with our securities; and (v)&nbsp;engaging in derivative transactions relating to our securities (e.g., exchange
traded options,&nbsp;etc.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our 2021 Named Executive Officers consist of the
following individuals:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20">Name</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center">Age</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center">Position</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: left">Dror Bashan</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center">55</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="width: 54%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">President and Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Einat Brill Almon, Ph.D. (1)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center">63</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Senior Vice President, Chief Development Officer</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Eyal Rubin</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center">46</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Sr. Vice President, Chief Financial Officer, Treasurer and Secretary</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Einat
Brill Almon, Ph.D. </B></FONT>Dr.&nbsp;Almon joined Protalix&nbsp;Ltd. in December&nbsp;2004, originally as a Senior Director and later
as a Vice President and became our Senior Vice President, Product Development in 2006 and our Chief Development Officer in 2020. Dr.&nbsp;Almon
has many&nbsp;years of experience in the management of life science projects and companies, including biotechnology and agrobiotech, with
direct experience in clinical, device and scientific software development, as well as a strong background and work experience in intellectual
property. Prior to joining Protalix&nbsp;Ltd., from 2001 to 2004, she served as Director of R&amp;D and IP of Medgenics Medical (Israel)&nbsp;Ltd.
(formerly, Biogenics&nbsp;Ltd.), a company that developed an autologous platform for tissue-based protein drug delivery. Medgenics Medical,
based in Israel, is a wholly-owned subsidiary of Aevi Genomic Medicine,&nbsp;Inc. (NASDAQ:GNMX) (formerly, Medgenics&nbsp;Inc.). Dr.&nbsp;Almon
has trained as a biotechnology patent agent at leading IP firms in Israel. Dr.&nbsp;Almon holds a Ph.D. and an M.Sc. in molecular biology
of cancer research from the Weizmann Institute of Science, a B.Sc. from the Hebrew University and has carried out Post- Doctoral research
at the Hebrew University in molecular biology of plant genetic engineering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Eyal
Rubin. </B></FONT>Mr.&nbsp;Rubin has served as our Senior Vice President and Chief Financial Officer since September&nbsp;2019. He brings
more than 20&nbsp;years of finance and capital markets experience, an extensive background in financial planning and operations, management
and strategy and a deep knowledge of the biotechnology and pharmaceutical industries. Prior to joining Protalix, he served as Executive
Vice President and Chief Financial Officer of BrainStorm Cell Therapeutics&nbsp;Inc. (NASDAQ:BCLI), a publicly traded biotechnology company,
where he was responsible for all corporate finance, accounting and investor relations activities. Prior to his role at BrainStorm, Mr.&nbsp;Rubin
served at Teva (NYSE:TEVA; TASE:TEVA) in several roles, most recently as Vice President, Head of Corporate Treasury. In this role, Mr.&nbsp;Rubin
was responsible for Teva&rsquo;s cash operations and cash management, as well as Teva&rsquo;s equity and debt capital markets transactions.
Mr.&nbsp;Rubin holds a BA in Financing and IT Systems from the College of Management,&nbsp;Israel, where he graduated Summa Cum Laude
with a specialization in Financing and IT Systems, and an MBA from Bar-Ilan University,&nbsp;Israel, where he graduated Summa Cum Laude
with a specialization in Finance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
March&nbsp;31, 2022, Einat Brill Almon, Ph.D., having reached retirement age, retired from her position as our Sr. Vice President&nbsp;&amp;
Chief Development Officer. Dr.&nbsp;Almon will continue her service to our company on a consultancy basis, taking a facilitating role
in the continued progress of our clinical development program, as well as assisting in the identification of her replacement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The biographical information for Mr.&nbsp;Bashan
is set forth above under &ldquo;Proposal&nbsp;1: Election of Directors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no family relationships among directors
or executive officers of our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The primary goals of the Compensation Committee
of our Board of Directors with respect to executive compensation are to attract and retain the most talented and dedicated executives
possible, to tie annual and long-term cash and stock incentives to achievement of specified performance objectives, and to align executives&rsquo;
incentives with stockholder value creation. To achieve these goals, the Compensation Committee implements and maintains compensation plans
that tie a portion of executives&rsquo; overall compensation to key strategic goals such as developments in our clinical path, the establishment
of key strategic collaborations, the build-up of our pipeline and the strengthening of our financial position. The Compensation Committee
evaluates individual executive performance with a goal of setting compensation at levels the committee believes are comparable with executives
in other companies of similar size and stage of development operating in the biotechnology industry while taking into account our relative
performance and our own strategic goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Elements of Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Executive compensation consists of following elements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Base
Salary.</I></B></FONT> Base salaries for our executive officers are established based on the scope of their responsibilities taking into
account competitive market compensation paid by other companies for similar positions. Generally, we believe that executive base salaries
should be targeted near the median of the range of salaries for executives in similar positions with similar responsibilities at comparable
companies. The Compensation Committee convenes from time to time to evaluate present and future executive compensation, which evaluation
generally includes an evaluation of the peer group considered in analyzing executive compensation. The Compensation Committee intends
to continue reviewing and revising the peer group periodically to ensure that it continues to reflect companies similar to the Company
in size and development stage. The Compensation Committee also reviews executive compensation reports and an analysis of publicly-traded
biotechnology companies prepared by third party experts from a well-known consulting firm for additional data and other information regarding
executive compensation for comparative purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Base salaries are usually reviewed annually, and
adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and
experience. The base salaries of each of our President and Chief Executive Officer, our Senior Vice President, Chief Development Officer,
and our Senior Vice President and Chief Financial Officer, who we refer to collectively as the &ldquo;Named Executive Officers,&rdquo;
are discussed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Annual
Bonus</I></B></FONT><B>. </B>The Compensation Committee has the authority to award discretionary annual bonuses to our executive officers.
The discretionary annual bonus awards were intended to compensate officers for achieving financial, clinical, regulatory and operational
goals and for achieving individual annual performance objectives. For any given&nbsp;year, the compensation objectives vary, but relate
generally to strategic factors such as developments in our clinical path, the execution of a license agreement for the commercialization
of product candidates, the establishment of key strategic collaborations, the build-up of our pipeline and financial factors such as capital
raising. Bonuses are awarded generally based on corporate performance, with adjustments made within a range for individual performance,
at the discretion of the Compensation Committee. The Compensation Committee determines, on a discretionary basis, the size of the entire
bonus pool and the amount of the actual award to each Named Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Compensation Committee selects, in its discretion,
the executive officers of the Company or our subsidiary who are eligible to receive bonuses for any given year. Any bonus granted by the
Compensation Committee will generally be paid upon the achievement of a specific milestone, subject to certain terms and conditions. The
Compensation Committee has not fixed a minimum or maximum award for any executive officer&rsquo;s annual discretionary bonus. Each of
our executive officers is eligible for a discretionary annual bonus under his or her employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Options
and Share-Based Compensation. </I></B></FONT>Our Amended and Restated 2006 Stock Incentive Plan authorizes us to grant options to purchase
shares of common stock, restricted stock and other securities to our employees, directors and consultants. Our Compensation Committee
is the administrator of the stock incentive plan. Stock option or other grants are generally made at the commencement of employment and
following a significant change in job responsibilities or to meet other special retention or performance objectives. The Compensation
Committee reviews and approves stock option and other awards to executive officers based upon a review of competitive compensation data,
its assessment of individual performance, a review of each executive&rsquo;s existing long-term incentives, and retention considerations.
The exercise price of stock options granted under our Amended and Restated 2006 Stock Incentive Plan, as amended, must be equal to at
least 100% of the fair market value of our common stock on the date of grant; however, in certain circumstances, grants may be made at
a lower price to Israeli grantees who are residents of the State of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Severance
and Change in Control Benefits. </I></B></FONT>The Compensation Committee granted the following payments that would be payable in connection
with a change of control: $1.0 million to the President and Chief Executive Officer and $400,000 to each of the other executive Vice Presidents.
Such payments are subject to certain terms and conditions. In addition to the foregoing, pursuant to the employment agreements entered
into with each of our executive officers, the executive officer is entitled to be insured by Protalix&nbsp;Ltd. under a Manager&rsquo;s
Policy in lieu of severance. The intention of such Manager&rsquo;s Policies is to provide the Israel-based officers with severance protection
of one&nbsp;month&rsquo;s salary for each year of employment. In addition, the stock options and restricted stock granted to each of our
Named Executive Officers provide that all of such instruments are subject to accelerated vesting immediately upon a change in control
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Compensation. </I></B></FONT>Consistent with our compensation philosophy, we intend to continue to maintain our current benefits for our
executive officers; however, the Compensation Committee in its discretion may revise, amend, or add to the officer&rsquo;s executive benefits
if it deems it advisable. As an additional benefit to all of our Israel-based Named Executive Officers and for most of our employees,
we generally contribute to certain funds amounts equaling a total of approximately 15% of their gross salaries for certain pension and
other savings plans for the benefit of the Named Executive Officers. In addition, in accordance with customary practice in Israel, our
Israel-based executives&rsquo; agreements require us to contribute towards their vocational studies, and to provide annual recreational
allowances, a company car and a company phone. We believe these benefits are currently equivalent with median competitive levels for comparable
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Executive
Compensation. </I></B></FONT>We refer to the &ldquo;Summary Compensation Table&rdquo; set forth below for information regarding the compensation
earned during the fiscal&nbsp;year ended December&nbsp;31, 2021 by our Named Executive Officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth a summary for the
fiscal&nbsp;years ended December&nbsp;31, 2021 and 2020, respectively, of the cash and non-cash compensation awarded, paid or accrued
by us or Protalix&nbsp;Ltd. to our President and Chief Executive Officer, our Senior Vice President, Chief Development Officer, and our
Senior Vice President and Chief Financial Officer, who we refer to collectively as the &ldquo;Named Executive Officers.&rdquo; There were
no restricted stock awards, long-term incentive plan payouts or other compensation paid during fiscal&nbsp;years December&nbsp;31, 2021
and 2020 by us or Protalix&nbsp;Ltd. to the Named Executive Officers, except as set forth below. All of the Named Executive Officers are
employees of our subsidiary, Protalix&nbsp;Ltd. All currency amounts are expressed in U.S.&nbsp;dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">Option</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">All&nbsp;Other</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: bottom">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">Salary</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">Bonus</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">Stock</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">Awards</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">Compensation</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">Total</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: bottom">
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">Name and Principal Position</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">Year</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">($)</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">($)</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">Awards&nbsp;($)</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">($)(1)</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">($)(2)</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">($)</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 37%; text-align: left"><FONT STYLE="font-size: 8pt">Dror Bashan</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: center"><FONT STYLE="font-size: 8pt">2021</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">373,817</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">585,224</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">82,371</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">116,287</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">1,157,699</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 8pt">President
    and Chief</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">2020</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">351,569</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">137,522</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">579,047</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">163,518</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">110,296</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">1,341,952</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: italic 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 8pt">Executive
    Officer</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Einat Brill Almon, Ph.D. (3)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: center"><FONT STYLE="font-size: 8pt">2021</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">339,937</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">196,784</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">91,044</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">627,765</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 8pt">Senior
    Vice President, Chief</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: center"><FONT STYLE="font-size: 8pt">2020</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">293,190</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">200,000</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">218,963</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">172,513</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">884,666</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: italic 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 8pt">Development
    Officer</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">Eyal Rubin</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: center"><FONT STYLE="font-size: 8pt">2021</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">325,101</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">385,201</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">21,062</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">105,460</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">836,824</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 8pt">Senior
    Vice President, Chief</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: center"><FONT STYLE="font-size: 8pt">2020</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">303,540</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">92,646</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">382,191</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">43,023</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 8pt">98,699</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">920,099</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: italic 8pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-left: 6pt"><FONT STYLE="font-size: 8pt">Financial
    Officer</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  </TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 0pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 0pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">(1)</FONT></TD><TD>Amounts in this column represent the grant date fair value of the option awards as computed in accordance with ASC 718, not including
any estimates of forfeitures related to service-based vesting conditions. See Note 9(c)&nbsp;&ldquo;Stock based compensation,&rdquo; of
<I>Notes to Consolidated Financial Statements</I> in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2021 for
a discussion of assumptions we made in determining the grant date fair value of our option awards for the fiscal year ended December&nbsp;31,
2021.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Includes employer contributions to pension and/or insurance plans and other miscellaneous payments.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">On March&nbsp;31, 2022, Einat Brill Almon,
Ph.D., having reached retirement age, retired from her position as our Sr. Vice President&nbsp;&amp; Chief Development Officer. Dr.&nbsp;Almon
will continue her service to our company on a consultancy</FONT> basis, taking a facilitating role in the continued progress of our clinical
development program, as well as assisting in the identification of her replacement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Options: NewSection; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #231f20">On June&nbsp;7, 2020, we granted
10-year options to purchase 196,995 shares of our common stock to Einat Brill Almon, Ph.D., our Sr. Vice President and Chief Development
Officer under the Plan. The options have an exercise price equal to $3.59 per share and vest over a four-year period in 16 equal quarterly
increments. Vesting of the options granted to Dr.&nbsp;Almon are subject to automatic acceleration in full upon a Corporate Transaction
or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. Our President and
Chief Executive Officer may, in his discretion, grant options to Dr.&nbsp;Almon to purchase additional shares if the Company effects certain
transactions in which it issues additional shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #231f20">On August&nbsp;11, 2020, we granted
447,927 restricted shares of our common stock to Dror Bashan, our President and Chief Executive Officer, and 246,146 restricted shares
of our common stock to Eyal Rubin, our Sr. Vice President and Chief Financial Officer, under the Plan. The restricted shares vest over
a four-year period in 16 equal quarterly increments and are subject to automatic acceleration in full upon a Corporate Transaction or
a Change in Control, and are subject to certain other terms and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Outstanding Equity Awards at Fiscal&nbsp;Year-End</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth information with
respect to the Named Executive Officers concerning outstanding equity awards as of December&nbsp;31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; background-color: White; font-size: 7pt; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White; color: #231f20; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; background-color: White; padding-bottom: 1pt; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White; color: #231f20; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; font-size: 7pt; background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #231f20"><B>Option&nbsp;Awards</B></FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; background-color: White; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White; color: #231f20; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; background-color: White; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White; color: #231f20; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 7pt">Stock&nbsp;Awards</FONT></TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>Number</B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>Number</B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; font-size: 7pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="background-color: White; font-size: 7pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="background-color: White; font-size: 7pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">Number</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">Market
    value</FONT></TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>of&nbsp;Securities</B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>of&nbsp;Securities</B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; font-size: 7pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="background-color: White; font-size: 7pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="background-color: White; font-size: 7pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">of
    shares</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">of
    shares</FONT></TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>Underlying</B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>Underlying</B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; font-size: 7pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="background-color: White; font-size: 7pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="background-color: White; font-size: 7pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">or
    units</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">or
    units</FONT></TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>Unexercised</B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>Unexercised</B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; font-size: 7pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="background-color: White; font-size: 7pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="background-color: White; font-size: 7pt; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">of
    stock</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">of
    stock</FONT></TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; background-color: White; font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #231f20"><B>Options</B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #231f20"><B>Options</B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #231f20"><B>Option&nbsp;Exercise</B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">Option&nbsp;Expiration</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">that
    have</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">that
    have</FONT></TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: left; background-color: White; color: #231f20"><FONT STYLE="font-size: 7pt">Name</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #231f20"><B>Exercisable&nbsp;(#)</B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #231f20"><B>Unexercisable&nbsp;(#)</B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: #231f20"><B>Price&nbsp;($)</B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; background-color: White; color: #231f20; text-align: center"><FONT STYLE="font-size: 7pt">Date</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">not
    vested (#)</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-size: 7pt">not
    vested ($)</FONT></TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 46%; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">Dror
    Bashan</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 7%; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">100,000</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 7%; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">60,000</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 7%; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">4.69</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 7%; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">6/30/2029</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 7%; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">307,950</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 7%; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">255,598</FONT></TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">Einat Brill Almon</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">25,000</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">&mdash;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">17.20</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">3/23/2025</FONT></TD><TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">56,875</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">13,125</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">5.60</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">9/13/2028</FONT></TD><TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">73,873</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">123,122</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">3.59</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">6/07/2030</FONT></TD><TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font-size: 7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 7pt; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">Eyal Rubin</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">45,000</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">35,000</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">2.00</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">9/22/2029</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">150,075</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; color: #231f20; text-align: right"><FONT STYLE="font-size: 7pt">124,562</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Potential Payments upon Termination or Change-in-Control/Corporate
Transaction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of our Named Executive Officers (while they
remain employed by the Company) is entitled to be insured by Protalix&nbsp;Ltd. under a Manager&rsquo;s Policy in lieu of severance upon
termination. The intention of such Manager&rsquo;s Policies is to provide our officers with severance protection of one&nbsp;month&rsquo;s
salary for each&nbsp;year of employment. The following payments would be payable in connection with a change of control of the Company:
$1.0&nbsp;million to the President and Chief Executive Officer and $400,000 to each of the other Named Executive Officers, subject to
certain terms and conditions. In addition to the foregoing, the vesting periods of outstanding options held by our Named Executive Officers
are accelerated upon a change of control. Had we experienced a change of control on December&nbsp;31, 2021, the value of the acceleration
of the vesting period of the options held by Mr.&nbsp;Bashan, Dr.&nbsp;Almon and Mr.&nbsp;Rubin would be $0 as the options held by each
of them that had not been fully vested on such date had an exercise price that was higher than the closing price of our common stock on
that date. In addition, had we experienced a change of control on December&nbsp;31, 2021, the value of the acceleration of the vesting
of the shares of restricted stock held by each of Mr.&nbsp;Bashan and Mr.&nbsp;Rubin as of such date would be $255,598 and $124,562, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employment Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dror
Bashan. </B></FONT>Pursuant to Mr.&nbsp;Bashan&rsquo;s employment agreement, his current&nbsp;monthly base salary is NIS 95,000 (approximately
$30,500 and Mr.&nbsp;Bashan is entitled to an annual discretionary bonus subject to the sole discretion of our Board of Directors, to
be determined on the basis of agreed-upon annual objectives which shall include both measurable and strategic parameters. He is also entitled
to a one-time bonus of $1.0 million upon the occurrence of certain change of control transactions. The monthly salary is subject to cost
of living adjustments from time to time as may be required by law. The Board of Directors also granted to Mr.&nbsp;Bashan options to purchase
160,000 shares of our common stock at an exercise price equal to $4.69 per share, the closing sales price of the common stock on the NYSE
American on the date of grant. The options vest over four&nbsp;years on a quarterly basis in 16 equal increments, subject to certain conditions.
Vesting of the options will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in
our Plan. Mr.&nbsp;Bashan&rsquo;s employment agreement is terminable by the Company on 180&nbsp;days&rsquo; written notice for any reason.
Mr.&nbsp;Bashan may terminate the agreement on 90&nbsp;days&rsquo; written notice for any reason during its term. We may terminate the
Agreement for cause without notice. Mr.&nbsp;Bashan is entitled to be insured by the Company under a Manager&rsquo;s Policy in lieu of
severance, Company contributions towards vocational studies, annual recreational allowances, a company car, a company laptop and a company
phone. Mr.&nbsp;Bashan is entitled to 24 working&nbsp;days of vacation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Einat
Brill Almon, Ph.D. (1)&nbsp;</B></FONT>Pursuant to Dr.&nbsp;Almon&rsquo;s employment agreement, her current&nbsp;monthly base salary is
NIS 80,000 (approximately $25,700) per&nbsp;month. She is also entitled to certain specified bonuses in the event that Protalix achieves
certain specified clinical development milestones within specified timelines. In addition, vesting of all of Dr.&nbsp;Almon&rsquo;s options
and restricted shares will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in our
Plan. The employment agreement is terminable by either party on 60&nbsp;days&rsquo; written notice for any reason and we may terminate
the agreement for cause without notice. Dr.&nbsp;Almon is entitled to be insured by Protalix&nbsp;Ltd. under a Manager&rsquo;s Policy
in lieu of severance, Company contributions towards vocational studies, annual recreational allowances, a company car, a company laptop
and a company phone at up to NIS 1,000 per&nbsp;month. Dr.&nbsp;Almon is entitled to 29 working&nbsp;days of vacation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Eyal
Rubin. </B></FONT>Pursuant to Mr.&nbsp;Rubin&rsquo;s employment agreement, his current&nbsp;monthly base salary is NIS 80,000 (approximately
$25,700) and Mr.&nbsp;Rubin is entitled to an annual discretionary bonus subject to the sole discretion of our Board of Directors, to
be determined on the basis of agreed-upon annual objectives which shall include both measurable and strategic parameters. He is also entitled
to a one-time bonus of $400,000 upon the occurrence of certain change of control transactions. The monthly salary is subject to cost of
living adjustments from time to time as may be required by law. The Board of Directors also granted to Mr.&nbsp;Rubin options to purchase
80,000 shares of our common stock at an exercise price equal to $2.00 per share, the closing sales price of the common stock on the NYSE
American on the date of grant. The options vest over four&nbsp;years on a quarterly basis in 16 equal increments, subject to certain conditions.
Vesting of the options will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in
our Plan. In addition, contingent upon certain conditions, Mr.&nbsp;Rubin is entitled to a grant of restricted stock units with an aggregate
value of $100,000, on an annual basis. Mr.&nbsp;Rubin&rsquo;s employment agreement is terminable by the Company on 180&nbsp;days&rsquo;
written notice for any reason. Mr.&nbsp;Rubin may terminate the agreement on 90&nbsp;days&rsquo; written notice for any reason during
its term. We may terminate the Agreement for cause without notice. Mr.&nbsp;Rubin is entitled to be insured by the Company under a Manager&rsquo;s
Policy in lieu of severance, Company contributions towards vocational studies, annual recreational allowances, a company car, a company
laptop and a company phone. Mr.&nbsp;Rubin is entitled to 24 working&nbsp;days of vacation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
March&nbsp;31, 2022, Einat Brill Almon, Ph.D., having reached retirement age, retired from her position as our Sr. Vice President&nbsp;&amp;
Chief Development Officer. Dr.&nbsp;Almon will continue her service to our company on a consultancy basis, taking a facilitating role
in the continued progress of our clinical development program, as well as assisting in the identification of her replacement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amended and Restated 2006 Stock Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors and our stockholders approved
our Plan on December&nbsp;14, 2006. Since its initial approval, our stockholders have approved amendments to the plan on four times, the
last time being on June&nbsp;7, 2020. Of the 5,725,171 shares reserved for issuance under the Plan, as amended, as of December&nbsp;31,
2021, there are outstanding options to purchase 2,259,020 shares of our common stock in the aggregate, subject to adjustment for a stock
split or any future stock dividend or other similar change in our common stock or our capital structure. As of December&nbsp;31, 2021,
options to acquire 1,786,256 shares of common stock remain available for grant under the amended Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our amended Plan provides for the grant of stock
options, restricted stock, restricted stock units, stock appreciation rights and dividend equivalent rights, collectively referred to
as &ldquo;awards.&rdquo; Stock options granted under the amended Plan may be either incentive stock options under the provisions of Section&nbsp;422
of the IRC, or non-qualified stock options. Incentive stock options may be granted only to employees. Awards other than incentive stock
options may be granted to employees, directors and consultants. Shares issued in connection with awards other than options or stock appreciation
rights shall count as one and one-half&nbsp;(1.5) shares for each share issued for purposes of the number of shares authorized for issuance
under the plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The amended Plan is also designed to comply with
the provisions of the Israeli Income Tax Ordinance New Version, 1961 (including as amended pursuant to Amendment 132 thereto), or the
Tax Ordinance, and is intended to enable us to grant awards to grantees who are Israeli residents as follows: (i)&nbsp;awards to employees
pursuant to Section&nbsp;102 of the Tax Ordinance; and (ii)&nbsp;awards to non-employees pursuant to Section&nbsp;3(I)&nbsp;of the Tax
Ordinance. For this purpose, &ldquo;employee&rdquo; refers only to employees, office holders and directors of the Company or a related
entity excluding those who are considered &ldquo;Controlling Stockholders&rdquo; pursuant to, or otherwise excluded by, the Tax Ordinance.
In accordance with the terms and conditions imposed by the Tax Ordinance, grantees who receive awards under the amended Plan may be afforded
certain tax benefits in Israel as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors or the Compensation Committee,
referred to as the &ldquo;plan administrator,&rdquo; will administer our amended Plan, including selecting the grantees, determining the
number of shares to be subject to each award, determining the exercise or purchase price of each award, and determining the vesting and
exercise periods of each award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The exercise price of stock options granted under
the Plan must be equal to at least 100% of the fair market value of our common stock on the date of grant; however, in certain circumstances,
grants may be made at a lower price to Israeli grantees who are residents of the State of Israel. If, however, incentive stock options
are granted to an employee who owns stock possessing more than 10% of the voting power of all classes of our stock or the stock of any
parent or subsidiary of the Company, the exercise price of any incentive stock option granted must equal at least 110% of the fair market
value on the grant date and the maximum term of these incentive stock options must not exceed five&nbsp;years. The maximum term of all
other awards must not exceed 10&nbsp;years (or five&nbsp;years in the case of an incentive stock option granted to any participant who
owns stock representing more than 10% of the voting power of all classes of our stock or the stock of any parent or subsidiary of the
Company). The plan administrator will determine the exercise or purchase price (if any) of all other awards granted under the amended
Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the amended Plan, incentive stock options
and options to Israeli grantees may not be sold, pledged, assigned, hypothecated, transferred or disposed of in any manner other than
by will or by the laws of descent or distribution and may be exercised during the lifetime of the participant only by the participant.
Other awards shall be transferable by will or by the laws of descent or distribution and to the extent and in the manner authorized by
the plan administrator by gift or pursuant to a domestic relations order to members of the participant&rsquo;s immediate family. The amended
Plan permits the designation of beneficiaries by holders of awards, including incentive stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the service of a participant in the amended
Plan is terminated for any reason other than cause, the participant may exercise awards that were vested as of the termination date for
a period ending upon the earlier of 12&nbsp;months from the date of termination (or such shorter or longer period set forth in the award
agreement) or the expiration date of the awards unless otherwise determined by the plan administrator. If the service of a participant
in the amended Plan is terminated for cause, the participant may exercise awards that were vested as of the termination date for a period
ending upon the earlier of 14&nbsp;days from the date of termination (or such shorter or longer period set forth in the award agreement)
or the expiration date of the awards unless otherwise determined by the plan administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Split-Segment; Name: split003 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the event of a corporate transaction, all awards
will terminate unless assumed by the successor corporation. Unless otherwise provided in a participant&rsquo;s award agreement, in the
event of a corporate transaction and with respect to the portion of each award that is assumed or replaced, then such portion will automatically
become fully vested and exercisable immediately upon termination of a participant&rsquo;s service if the participant is terminated by
the successor company or us without cause within 12&nbsp;months after the corporate transaction. With respect to the portion of each award
that is not assumed or replaced, such portion will automatically become fully vested and exercisable immediately prior to the effective
date of the corporate transaction so long as the participant&rsquo;s service has not been terminated prior to such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the event of a change in control, except as
otherwise provided in a participant&rsquo;s award agreement, following a change in control (other than a change in control that also is
a corporate transaction) and upon the termination of a participant&rsquo;s service without cause within 12&nbsp;months after a change
in control, each award of such participant that is outstanding at such time will automatically become fully vested and exercisable immediately
upon the participant&rsquo;s termination. In addition, the stock options and shares of restricted stock issued to each of our Named Executive
Officers are subject to accelerated vesting immediately upon a corporate transaction or a change in control of the Company, as defined
in our amended Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under our amended Plan, a corporate transaction
is generally defined as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>a merger or consolidation in which we are not the surviving entity, except for the principal purpose of changing the Company&rsquo;s
state of incorporation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the sale, transfer or other disposition of all or substantially all of our assets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the complete liquidation or dissolution of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>any reverse merger in which we are the surviving entity but our shares of common stock outstanding immediately prior to such merger
are converted or exchanged by virtue of the merger into other property, whether in the form of securities, cash or otherwise, or in which
securities possessing more than forty&nbsp;percent (40%) of the total combined voting power of our outstanding securities are transferred
to a person or persons different from those who held such securities immediately prior to such merger; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>acquisition in a single or series of related transactions by any person or related group of persons of beneficial ownership of securities
possessing more than fifty&nbsp;percent (50%) of the total combined voting power of our outstanding securities but excluding any such
transaction or series of related transactions that the plan administrator determines not to be a corporate transaction (provided however
that the plan administrator shall have no discretion in connection with a corporate transaction for the purchase of all or substantially
all of our shares unless the principal purpose of such transaction is changing the Company&rsquo;s state of incorporation).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under our amended Plan, a change of control is
defined as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="color: #231f20">the direct or indirect acquisition by any person or related group of persons of beneficial ownership
of securities possessing more than fifty&nbsp;percent (50%) of the total combined voting power of our outstanding securities pursuant
to a tender or exchange offer made directly to our stockholders </FONT>and which a majority of the members of our Board of Directors (who
have generally been on our board for at least 12&nbsp;months) who are not affiliates or associates of the offeror do not recommend stockholders
accept the offer; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="color: #231f20">a change in the composition of our </FONT>Board of Directors <FONT STYLE="color: #231f20">over a period
of 12&nbsp;months or less, such that a majority of our </FONT>Board of Directors <FONT STYLE="color: #231f20">members ceases, by reason
of one or more contested elections for board membership, to be comprised of individuals who were previously directors of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Options: NewSection; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless terminated sooner, the amended Plan will
automatically terminate on December&nbsp;31, 2028. Our Board of Directors has the authority to amend, suspend or terminate our amended
Plan. No amendment, suspension or termination of the amended Plan shall adversely affect any rights under awards already granted to a
participant. To the extent necessary to comply with applicable provisions of federal securities laws, state corporate and securities laws,
the IRC, the rules&nbsp;of any applicable stock exchange or national market system, and the rules&nbsp;of any non-U.S. jurisdiction applicable
to awards granted to residents therein (including the Tax Ordinance), we shall obtain stockholder approval of any such amendment to the
Plan in such a manner and to such a degree as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Impact of Israeli Tax Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The awards granted to employees pursuant to Section&nbsp;102
of the Tax Ordinance under the amended Plan may be designated by us as approved options under the capital gains alternative, or as approved
options under the ordinary income tax alternative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To qualify for these benefits, certain requirements
must be met, including registration of the options in the name of a trustee. Each option, and any shares of common stock acquired upon
the exercise of the option, must be held by the trustee for a period commencing on the date of grant and deposit into trust with the trustee
and ending 24&nbsp;months thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the terms of the capital gains alternative,
we may not deduct expenses pertaining to the options for tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the amended Plan, we may also grant to employees
options pursuant to Section&nbsp;102(c)&nbsp;of the Tax Ordinance that are not required to be held in trust by a trustee. This alternative,
while facilitating immediate exercise of vested options and sale of the underlying shares, will subject the optionee to the marginal income
tax rate of up to 50% as well as payments to the National Insurance Institute and health tax on the date of the sale of the shares or
options. Under the Plan, we may also grant to non-employees options pursuant to Section&nbsp;3(I)&nbsp;of the Tax Ordinance. Under that
section, the income tax on the benefit arising to the optionee upon the exercise of options and the issuance of common stock is generally
due at the time of exercise of the options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These options shall be further subject to the terms
of the tax ruling that has been obtained by Protalix&nbsp;Ltd. from the Israeli tax authorities in connection with the merger. Under the
tax ruling, the options issued by us in connection with the assumption of Section&nbsp;102 options previously issued by Protalix&nbsp;Ltd.
under the capital gains alternative shall be issued to a trustee, shall be designated under the capital gains alternative and the issuance
date of the original options shall be deemed the issuance date for the assumed options for the calculation of the respective holding period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All related party transactions are reviewed and
approved by the Audit and Finance Committee, as required by the Audit and Finance Committee Charter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There were no transactions during the last two
fiscal years, or any currently proposed transaction, in which we were or are to be a participant and in which the amount involved exceeded
or exceeds the lesser of $120,000 or one percent of the average of our total assets at year end for the last two completed fiscal years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AUDIT COMMITTEE REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>The information contained in this report shall
not be deemed to be &ldquo;soliciting material&rdquo; or to be &ldquo;filed&rdquo; with the SEC, nor shall such information be incorporated
by reference into any future filings with the SEC, or subject to the liabilities of Section&nbsp;18 of the Exchange Act, except to the
extent that we specifically incorporate it by reference into a document filed under the Securities Act or the Exchange Act.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Audit and Finance Committee of our Board of
Directors operates under a written charter adopted by our Board of Directors, and currently consists of Mr.&nbsp;Granot, Chairman of the
Committee, Mr.&nbsp;Bar Shalev and Dr.&nbsp;Schwartz. As described more fully in its charter, the Audit Committee provides oversight of
the quality and integrity of our consolidated financial statements, internal controls and financial reporting process, and our process
to manage business and financial risks and compliance with legal, ethical and regulatory requirements. In addition, the Audit and Finance
Committee interacts directly with and evaluates the qualifications, independence and performance of the independent auditors, Kesselman&nbsp;&amp;
Kesselman, and is responsible for the appointment, compensation, retention and oversight of the work of the auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Management is responsible for the preparation,
presentation and integrity of the consolidated financial statements, and evaluation of and assessment of the effectiveness of our internal
control over financial reporting. The independent auditors are responsible for performing an independent audit of the consolidated financial
statements in accordance with the standards of the Public Company Accounting Oversight Board (the &ldquo;PCAOB&rdquo;). The Audit and
Finance Committee&rsquo;s responsibility is to monitor and oversee these processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Audit and Finance Committee has reviewed and
discussed the audited consolidated financial statements with our Board of Directors and management. The Audit and Finance Committee has
discussed with Kesselman&nbsp;&amp; Kesselman the matters required to be discussed by the applicable requirements of the PCAOB and the
SEC. The Audit and Finance Committee has received the written disclosures and the letter from Kesselman&nbsp;&amp; Kesselman required
by applicable requirements of the PCAOB regarding the independent accountant&rsquo;s communications with the Audit and Finance Committee
concerning independence, and has discussed with Kesselman&nbsp;&amp; Kesselman that firm&rsquo;s independence from our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on the review and discussions of the audited
consolidated financial statements and discussions with management and Kesselman&nbsp;&amp; Kesselman, the Audit Committee recommended
to Board of Directors that the audited consolidated financial statements be included in our Annual Report on Form&nbsp;10-K for the fiscal&nbsp;year
ended December&nbsp;31, 2021 for filing with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Respectfully submitted on April&nbsp;12, 2022,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>David Granot, Chairman</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Amos Bar Shalev</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Aharon Schwartz, Ph.D.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROPOSAL 2: ADVISORY VOTE TO APPROVE EXECUTIVE
COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As required by Section&nbsp;14A of the Exchange
Act, we are providing our stockholders with the opportunity to vote to approve, on a non-binding, advisory basis, the compensation of
the our Named Executive Officers as disclosed in this proxy statement in accordance with the compensation disclosure rules&nbsp;of the
SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that the executive compensation program
for the Named Executive Officers, as described in the &ldquo;Management&rdquo; section of this proxy statement, is based on a pay-for-performance
culture and seeks to align the interests of our Named Executive Officers with the interests of our stockholders. We believe that our compensation
programs are designed to reward our Named Executive Officers for the achievement of short-term and long-term strategic and operational
goals and the achievement of increased total stockholder return, while at the same time creating a culture that focuses executives on
prudent risk management and appropriately rewards them for performance. Our executive compensation program is also designed to be competitive
with our peer companies, and seeks to enable us to attract and retain the best possible executive talent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also believe that the extensive disclosure of
compensation information provided in this proxy statement provides our stockholders the information they need to make an informed decision
as they weigh the pay of the Named Executive Officers in relation to our performance. This &ldquo;Say-on-Pay&rdquo; proposal gives you
the stockholder the opportunity to endorse or not endorse the compensation we paid to the Named Executive Officers through the resolution
set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&ldquo;RESOLVED, that the compensation
paid to the Named Executive Officers of Protalix BioTherapeutics,&nbsp;Inc., as disclosed pursuant to Item&nbsp;402 of Regulation S-K,
including the compensation tables and narrative discussion included in this proxy statement, is hereby APPROVED.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because your vote is advisory, it will not be binding
upon our Company, our Board of Directors or the Compensation Committee. The vote on this resolution is not intended to address any specific
element of compensation, but rather relates to the overall compensation of our named executive officers, as described in this proxy statement
in accordance with the compensation disclosure rules&nbsp;of the SEC. Our Company, our Board of Directors, and the Compensation Committee
will consider the outcome of the vote when evaluating future executive compensation arrangements for our named executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This proposal is provided as required pursuant
to Rule&nbsp;14a-21(a)&nbsp;promulgated under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Our Board of Directors recommends that stockholders
vote &ldquo;FOR&rdquo; the approval of the executive compensation as disclosed in this proxy statement and as described in this &ldquo;Proposal&nbsp;2:
Advisory Vote to Approve Executive Compensation.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROPOSAL&nbsp;3: AMENDMENTS TO THE PROTALIX
BIOTHERAPEUTICS,&nbsp;INC.<BR>
2006 STOCK INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF<BR>
AUTHORIZED SHARES OF COMMON STOCK RESERVED FOR ISSUANCE UNDER THE PLAN<BR>
AND TO AMEND CERTAIN OTHER TERMS OF THE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are asking our stockholders to approve an amendment
to our amended 2006 Stock Incentive Plan, or the Existing Plan and, as amended, the Plan, so that we can continue to use the Plan in order
to attract and retain key talent, encourage stock ownership by our employees, non-employee directors and consultants, better align with
governance best practices. Our Board of Directors unanimously approved the proposed amendment to the Plan, subject to approval of our
stockholders at the Annual Meeting. Approval of the Plan requires the affirmative vote of the record holders of a majority of the outstanding
shares of our common stock that are present in person or by proxy at the Annual Meeting and entitled to vote on this matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Primary</B></FONT><B>
Changes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As part of the proposed amendments to the Existing
Plan, we propose to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left">Increase the number of shares of common stock reserved for issuance
under the Existing Plan by 2,750,000 shares to 8,475,171 shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left">Increase the annual per person limits on the number of shares
covered by awards of stock options and stock appreciation rights by 2,750,000 shares to 8,475,171 shares; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Increase the per person limits on the number of shares covered
by awards of restricted stock and restricted stock units intended to be &ldquo;performance based compensation&rdquo; by 2,750,000 shares
to 8,475,171 shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Background on Code Section&nbsp;162(m)&nbsp;Approval</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are also asking our stockholders to approve
this amendment to the material terms of the Existing Plan so that we may grant awards under the Plan that are designed to qualify for
the exception from the limits on corporate income tax deductions pursuant to Code Section&nbsp;162(m). To the extent we grant such awards
and they qualify for the exception, we may deduct for federal income tax purposes compensation in excess of&thinsp; $1.0&nbsp;million
that may be paid to certain executive officers in any single year. Compensation includes cash compensation and income arising from the
exercise of nonstatutory stock options, as a result of the grant, vesting or settlement of other types of equity awards, and from disqualifying
dispositions of incentive stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under Code Section&nbsp;162(m), no deduction is
allowed in any taxable year of our Company for compensation in excess of&thinsp; $1.0&nbsp;million paid to our &ldquo;covered employees.&rdquo;
A &ldquo;covered employee&rdquo; is our chief executive officer and our three other most highly compensated officers, other than our chief
financial officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An exception to the $1.0&nbsp;million limit under
Code Section&nbsp;162(m)&nbsp;applies to compensation that is paid to a covered employee pursuant to a stock incentive plan approved by
stockholders and that specifies, among other things, the maximum number of shares with respect to which options and stock appreciation
rights may be granted to eligible participants under such plan during a specified period. Compensation paid pursuant to options granted
under such a plan and with an exercise price equal to the fair market value of common stock on the date of grant is deemed to be inherently
performance-based, since such awards provide value to participants only if the stock price appreciates. To the extent required by Section&nbsp;162(m)&nbsp;of
the Code or the regulations thereunder, in applying the foregoing limitation, if any option or stock appreciation right is canceled, the
canceled award shall continue to count against the maximum number of shares with respect to which an award may be granted to a participant.
The Plan provides that the maximum number of shares with respect to which options and stock appreciation rights may be granted to a participant
during a calendar year is 5,725,171 shares. The foregoing limitation shall be adjusted proportionately by the plan administrator in the
event of a stock split, reverse stock split, stock dividend, combination or reclassification of shares or other similar change in our
shares of common stock or our capital structure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For awards of restricted stock and restricted stock&nbsp;units
that are intended to be performance-based compensation under Section&nbsp;162(m)&nbsp;of the Code, the maximum number of shares of common
stock subject to such awards that may be granted to a participant during a calendar year is 5,725,171 shares. The foregoing limitation
shall be adjusted proportionately by the plan administrator in the event of a stock split, reverse stock split, stock dividend, combination
or reclassification of shares or other similar change in our shares or our capital structure. In order for restricted stock and restricted
stock&nbsp;units to qualify as performance-based compensation, the plan administrator must establish a performance goal with respect to
such award in writing not later than 90&nbsp;days after the commencement of the services to which it relates (or, if earlier, the date
after which 25% of the period of service to which the performance goal relates has elapsed) and while the outcome is substantially uncertain.
In addition, the performance goal must be stated in terms of an objective formula or standard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Plan includes the following performance criteria
that may be considered by the plan administrator when granting performance-based awards: (i)&nbsp;increase in share price, (ii)&nbsp;earnings
per share; (iii)&nbsp;total stockholder return; (iv)&nbsp;operating margin; (v)&nbsp;gross margin; (vi)&nbsp;return on equity; (vii)&nbsp;return
on assets; (viii)&nbsp;return on investment; (ix)&nbsp;operating income; (x)&nbsp;net operating income; (xi)&nbsp;pre-tax profit; (xii)&nbsp;cash
flow; (xiii)&nbsp;revenue: (xiv)&nbsp;expenses; (xv)&nbsp;earnings before interest, taxes and depreciation; (xvi)&nbsp;economic value
added; and (xvii)&nbsp;market share. The performance criteria may be applicable to our Company, any parent or subsidiary of our Company,
and/or any individual business&nbsp;units of our Company or any parent or subsidiary of our Company. In addition, the performance criteria
will be calculated in accordance with generally accepted accounting principles, excluding the effect (whether positive or negative) of
any change in accounting standards and any extraordinary, unusual or nonrecurring item occurring after the establishment of the performance
criteria applicable to the award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stockholder approval of the Plan pursuant to this
proposal will constitute stockholder approval of the material terms of the Plan, including the per person limitations on stock awards
and the performance criteria described above, for Code Section&nbsp;162(m)&nbsp;purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe strongly that approval of this amendment
to the Existing Plan is essential to our success. Our employees are our most valuable asset. Stock options and the other awards permitted
under the Plan are vital to our ability to attract and retain outstanding and highly skilled employees, especially in the competitive
labor markets in which we operate. These awards also are crucial to our ability to motivate employees to achieve our goals. Our Board
of Directors after reviewing the allocation of awards under the Plan has determined that it is in the best interest of our Company to
increase the equity compensation granted to our current and future employees. The proposed terms of the Plan are designed to allow us
to continue to attract, retain and motivate people whose skills and performance are critical to our success. We will continue to monitor
the environment in which we operate and make changes to our equity compensation program to help us meet our goals, including achieving
long-term stockholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Our Board of Directors recommends that stockholders
vote &ldquo;FOR&rdquo; the adoption of the amendments to the Protalix BioTherapeutics,&nbsp;Inc. Amended and Restated 2006 Stock Incentive
Plan described in this Proposal&nbsp;3: Amendments to the Protalix BioTherapeutics,&nbsp;Inc. Amended and Restated 2006 Stock Incentive
Plan to Increase the Number of Authorized Shares of Common Stock Reserved for Issuance under the Plan and to Amend Certain other Terms
of the Plan.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A general description of the principal terms of
the Plan is set forth below. This description is qualified in its entirety by the terms of the Plan, a copy of which is attached hereto
as <U>Appendix A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At December&nbsp;31, 2021, there were outstanding
under the Existing Plan options to purchase common stock issued covering 2,259,020 shares of our common stock with a weighted average
exercise price of $4.42 per share and a weighted average remaining contractual life of 7.52 years. The outstanding options represent approximately
4.65% of our outstanding shares on an &ldquo;as exercised&rdquo; basis. As of December&nbsp;31, 2021, we had 1,786,256 shares of common
stock available for future issuance under the Existing Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of April&nbsp;1, 2022, the fair market value
of a share of our common stock was $1.05.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table provides information as of December&nbsp;31, 2021
with respect to the shares of our common stock that may be issued under our existing equity compensation plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">A</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">B</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">C</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><B>Plan Category</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Number&nbsp;of&nbsp;Securities<BR> to be
    Issued<BR> Upon Exercise of<BR> Outstanding Options</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Weighted&nbsp;Average<BR> Exercise Price
    of<BR> Outstanding&nbsp;Options</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Number&nbsp;of&nbsp;Securities&nbsp;Remaining<BR>
    Available for Future Issuance<BR> Under&nbsp;Equity&nbsp;Compensation&nbsp;Plans<BR> (Excluding Securities Reflected in<BR> Column
    A)</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left">Equity Compensation Plans Approved by Stockholders</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,259,020</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">4.42</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,786,256</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity Compensation Plans Not Approved by Stockholders</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,259,020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.42</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,786,256</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Description</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Purpose</I></B></FONT>.
The purposes of the Plan are to attract and retain the best available personnel, to provide additional incentives to our officers, directors,
employees and consultants through ownership of our common stock, and to promote the success of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shares
Reserved for Issuance under the Plan</I></B></FONT><B>. </B>We currently have 5,725,171 shares of common stock reserved for issuance under
the Existing Plan. If approved by our stockholders, the total number of shares of common stock reserved for issuance under the Plan will
be increased by 2,750,000 shares for a total of 8,475,171 shares. Shares issued in connection with awards other than options or stock
appreciation rights shall count as one and one-half (1.5) shares for each share issued. The number of shares of common stock available
under the Plan will be subject to adjustment in the event of a stock split, reverse stock split, stock dividend, combination or reclassification
of shares or other similar change in our shares or our capital structure. Any shares of common stock covered by an award (or portion of
an award) which is forfeited, canceled or expires (whether voluntarily or involuntarily) are deemed not to have been issued for purposes
of determining the maximum aggregate number of shares of common stock which may be issued under the Plan. Shares that actually have been
issued under the Plan pursuant to an award will not be returned to the Plan and will not be available for future issuance under the Plan,
except that if unvested shares of common stock are forfeited, or repurchased by us at the lower of their original purchase price or their
fair market value (as defined in the Plan) at the time of repurchase, such shares of common stock shall become available for future grant
under the Plan. Any shares covered by an award which are surrendered (i)&nbsp;in payment of the award exercise or purchase price (including
pursuant to the &lsquo;&lsquo;net exercise&rsquo;&rsquo; of an option pursuant to Section&nbsp;7(b)(v)&nbsp;of the Plan) or (ii)&nbsp;in
satisfaction of tax withholding obligations incident to the exercise of an award will not be returned to the Plan and will not be available
for future issuance under the Plan. Shares that are covered by the portion of a SAR that is exercised (whether or not shares are actually
issued) will be considered issued. Shares that are counted as one and one-half (1.5) shares upon issuance will be counted as one and one-half
(1.5) shares upon return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
any calendar year, the maximum number of shares with respect to which options and stock appreciation rights may be granted to a participant
is currently </FONT>5,725,171 shares. If approved by our stockholders, the maximum number of shares with respect to which options and
stock appreciation rights may be granted to a participant in any calendar year will be 8,475,171 shares. The maximum number of shares
of restricted stock and restricted stock units that are intended to be performance-based compensation under Section&nbsp;162(m)&nbsp;of
the Code that may be awarded to a participant in any calendar year is 8,475,171 shares. The foregoing limitations shall be adjusted proportionately
by the plan administrator in the event of a stock split, reverse stock split, stock dividend, combination or reclassification of shares
or other similar change in our shares or our capital structure, and its determination shall be final, binding and conclusive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Administration</I></B></FONT>.
Our Board of Directors or the Compensation Committee, referred to as the &ldquo;plan administrator,&rdquo; administers the Plan, including
selecting the grantees, determining the number of shares to be subject to each award, determining the exercise or purchase price of each
award, and determining the vesting and exercise periods of each award. The Plan is currently being administered by the Compensation Committee.
With respect to grants to officers and directors, the Compensation Committee shall be constituted in such a manner as to satisfy applicable
laws, including Rule&nbsp;16b-3 promulgated under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Terms
and Conditions of Awards. </I></B></FONT>The Amendment provides for the grant of stock options, restricted stock, restricted stock units,
stock appreciation rights and dividend equivalent rights, collectively referred to as &ldquo;awards.&rdquo; Stock options granted under
the Plan may be either incentive stock options under the provisions of Section&nbsp;422 of the Internal Revenue Code, or non-qualified
stock options. Incentive stock options may be granted only to our employees or to employees of our related entities. Awards other than
incentive stock options may be granted to our employees, directors and consultants or to employees, consultants and directors of our related
entities. Because the Plan provides for broad discretion in selecting which eligible persons will participate and in granting awards,
the total number of persons who will actually participate in the Amended Plan and the benefits that will be provided to the participants
cannot be determined at this time. As of December&nbsp;31, 2021, approximately 200 employees (five of whom are current executive officers
of the Company) and six directors were eligible for awards under the Plan. In addition, we engage certain of consultants that also may
be eligible for awards under the Plan. To the extent that the aggregate fair market value of the shares subject to options designated
as incentive stock options which become exercisable for the first time by a participant during any calendar year exceeds $100,000, such
excess options shall be treated as nonqualified stock options. Each award granted under the Plan shall be designated in an award agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Plan is also designed to comply with the provisions of the Israeli
Income Tax Ordinance New Version, 1961 (including as amended pursuant to Amendment 132 thereto), or the tax ordinance, and is intended
to enable us to grant awards to grantees who are Israeli residents as follows: (i)&nbsp;awards to employees pursuant to Section&nbsp;102
of the tax ordinance; and (ii)&nbsp;awards to non-employees pursuant to Section&nbsp;3(I)&nbsp;of the tax ordinance. For this purpose,
 &ldquo;employee&rdquo; refers only to employees, office holders and directors of our Company or a related entity excluding those who are
considered &ldquo;Controlling Stockholders&rdquo; pursuant to, or otherwise excluded by, the tax ordinance. In accordance with the terms
and conditions imposed by the tax ordinance, grantees who receive awards under the Amendment may be afforded certain tax benefits in Israel
as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The exercise price of stock options granted under the Plan must be
equal to at least 100% of the fair market value of our common stock on the date of grant. If, however, incentive stock options are granted
to an employee who owns stock possessing more than 10% of the voting power of all classes of our stock or the stock of any parent or subsidiary
of our Company, the exercise price of any incentive stock option granted must equal at least 110% of the fair market value on the grant
date and the maximum term of these incentive stock options must not exceed five years. The maximum term of all other awards must not exceed
10 years (or 5&nbsp;years in the case of an incentive stock option granted to any participant who owns stock representing more than 10%
of the voting power of all classes of our stock or the stock of any parent or subsidiary of our Company). The plan administrator will
determine the exercise or purchase price (if any) of all other awards granted under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Plan, incentive stock options and options to Israeli grantees
may not be sold, pledged, assigned, hypothecated, transferred or disposed of in any manner other than by will or by the laws of descent
or distribution and may be exercised during the lifetime of the participant only by the participant. Other awards shall be transferable
by will or by the laws of descent or distribution and, during the lifetime of the participant, to the extent and in the manner authorized
by the plan administrator by gift or pursuant to a domestic relations order to members of the participant&rsquo;s immediate family. The
Plan permits the designation of beneficiaries by holders of awards, including incentive stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the service of a participant in the Plan is terminated for any reason
other than cause, the participant may exercise awards that were vested as of the termination date for a period ending upon the earlier
of 12 months from the date of termination (or such shorter or longer period set forth in the award agreement) or the expiration date of
the awards unless otherwise determined by the plan administrator. If the service of a participant in the Plan is terminated for cause,
the participant may exercise awards that were vested as of the termination date for a period ending upon the earlier of 14&nbsp;days from
the date of termination (or such shorter or longer period set forth in the award agreement) or the expiration date of the awards unless
otherwise determined by the plan administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Performance Criteria.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Amendment,
Suspension and Termination. </I></B></FONT>The Board may at any time amend, suspend, or terminate the Plan; provided, however, that no
such amendment shall be made without the approval of the Company&rsquo;s stockholders if such amendment would require stockholder approval
under any other applicable law or regulation. Any amendment, suspension or termination of the Plan may not adversely affect the rights
of any participant under an outstanding award (unless such participant&rsquo;s consent is obtained). Notwithstanding the foregoing, the
reduction or increase of the exercise price of any stock option or the base appreciation amount of a SAR and the canceling of any stock
option or SAR at a time when its exercise price or base appreciation amount exceeds the fair market value of the underlying shares in
exchange for another award shall be subject to stockholder approval unless such exchange occurs in connection with a corporate transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Corporate
Transaction and Change in Control</I></B></FONT><B>. </B>In the event of a corporate transaction, all outstanding awards will terminate
unless assumed by the successor corporation. Unless otherwise provided in a participant&rsquo;s award agreement, in the event of a corporate
transaction and with respect to the portion of each award that is assumed or replaced, then such portion will automatically become fully
vested and exercisable immediately upon termination of a participant&rsquo;s service if the participant is terminated by the successor
company or us without cause within 12 months after the corporate transaction. With respect to the portion of each award that is not assumed
or replaced, such portion of the award will automatically become fully vested and exercisable immediately prior to the effective date
of the corporate transaction so long as the participant&rsquo;s service has not been terminated prior to such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event of a change in control, except as otherwise provided in
a participant&rsquo;s award agreement, following a change in control (other than a change in control that also is a corporate transaction)
and upon the termination of a participant&rsquo;s service without cause within 12 months after a change in control, each award of such
participant that is outstanding at such time will automatically become fully vested and exercisable immediately upon the participant&rsquo;s
termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Under the Plan, a corporate transaction
is generally defined as:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">a
                                            merger or consolidation in which we are not the surviving entity, except for the principal
                                            purpose of changing our Company&rsquo;s state of incorporation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">the
                                            sale, transfer or other disposition of all or substantially all of our assets;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">the
                                            complete liquidation or dissolution of our Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">any
                                            reverse merger in which we are the surviving entity but our shares of common stock outstanding
                                            immediately prior to such merger are converted or exchanged by virtue of the merger into
                                            other property, whether in the form of securities, cash or otherwise, or in which securities
                                            possessing more than forty percent (40%) of the total combined voting power of our outstanding
                                            securities are transferred to a person or persons different from those who held such securities
                                            immediately prior to such merger; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">acquisition
                                            in a single or series of related transactions by any person or related group of persons (other
                                            than by us or by an employee benefit plan sponsored by us) of beneficial ownership of securities
                                            possessing more than fifty percent (50%) of the total combined voting power of our outstanding
                                            securities but excluding any such transaction or series of related transactions that the
                                            plan administrator determines not to be a corporate transaction (provided however that the
                                            plan administrator shall have no discretion in connection with a corporate transaction for
                                            the purchase of all or substantially all of our shares unless the principal purpose of such
                                            transaction is changing our Company&rsquo;s state of incorporation).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Under the Plan, a change of control
is defined as:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">the
                                            direct or indirect acquisition by any person or related group of persons of beneficial ownership
                                            of securities possessing more than fifty percent (50%) of the total combined voting power
                                            of our outstanding securities pursuant to a tender or exchange offer made directly to our
                                            stockholders and which a majority of the members of our Board of Directors (who have generally
                                            been on our Board of Directors for at least 12 months) who are not affiliates or associates
                                            of the offeror do not recommend stockholders accept the offer; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">a
                                            change in the composition of our Board of Directors over a period of 12 months or less, such
                                            that a majority of the members of our Board of Directors ceases, by reason of one or more
                                            contested elections for board membership, to be comprised of individuals who were previously
                                            directors of our Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Amendment,
Suspension or Termination of the Plan</I></B></FONT><B><FONT STYLE="font-size: 10pt">. </FONT></B><FONT STYLE="font-size: 10pt">Unless
terminated sooner, the Plan will automatically terminate on December&nbsp;31, 2028. Our Board of Directors has the authority to amend,
suspend or terminate the Plan. No amendment, suspension or termination of the Plan shall adversely affect any rights under awards already
granted to a participant. To the extent necessary to comply with applicable provisions of federal securities laws, state corporate and
securities laws, the Internal Revenue Code, the rules&nbsp;of any applicable stock exchange or national market system, and the rules&nbsp;of
any non-U.S. jurisdiction applicable to awards granted to residents therein (including the tax ordinance), we shall obtain stockholder
approval of any such amendment to the Plan in such a manner and to such a degree as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amended Plan Benefits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The grant of awards under the Plan, including grants to our executive
officers, is subject to the discretion of the plan administrator. Except with respect to options issued to the Chairman of our Board of
Directors and our new President and Chief Executive Officer, as set forth below, the allocation of the new shares is not determinable
at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="7" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">New Plan Benefits</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="7" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Protalix BioTherapeutics,&nbsp;Inc. 2006 Stock Incentive Plan, amended</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 33%; text-align: center">Name and Position</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dollar Value ($) <BR>
(1)</B></FONT></TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center">Number of Units</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Eyal Rubin,&nbsp;Sr. VP&nbsp;&amp; CFO</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Annual Grant of Restricted Stock for $100,000</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
dollar values of the options listed in this table are based on the grant date (i.e., the date of board approval) of each option grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain Federal Tax Consequences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following summary of the U.S. federal income tax consequences of
the Plan transactions is based upon federal income tax laws in effect on the date of this Proxy Statement. This summary does not purport
to be complete, and does not discuss state, local or non-U.S. tax consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nonqualified
Stock Options</I></FONT>. The grant of a nonqualified stock option under the Plan will not result in any U.S. federal income tax consequences
to us or the participant, if a U.S. taxpayer. Upon exercise of a nonqualified stock option, the participant is subject to income taxes
at the rate applicable to ordinary compensation income on the difference between the option exercise price and the fair market value of
the shares at the time of exercise. This income is subject to withholding for U.S. federal income and employment tax purposes. We are
entitled to an income tax deduction in the amount of the income recognized by the participant, subject to possible limitations imposed
by Section&nbsp;162(m)&nbsp;of the Code and so long as we withhold the appropriate taxes with respect to such income (if required) and
the participant&rsquo;s total compensation is deemed reasonable in amount. Any gain or loss on the participant&rsquo;s subsequent disposition
of the shares will receive long or short-term capital gain or loss treatment, depending on whether the shares are held for more than one
year following exercise. We do not receive a tax deduction for any such gain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A nonqualified stock option can be considered deferred compensation
and be subject to Section&nbsp;409A of the Code. A nonqualified stock option that does not meet the requirements of Code Section&nbsp;409A
can result in the acceleration of income recognition, an additional 20% tax obligation, plus penalties and interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Incentive
Stock Options</I></FONT>. The grant of an incentive stock option under the Plan will not result in any U.S. federal income tax consequences
to us or the participant, if a U.S. taxpayer. A participant recognizes no federal taxable income upon exercising an incentive stock option
(subject to the alternative minimum tax rules&nbsp;discussed below), and we receive no deduction at the time of exercise. In the event
of a disposition of stock acquired upon exercise of an incentive stock option, the tax consequences depend upon how long the participant
has held the shares. If the participant does not dispose of the shares within two years after the incentive stock option was granted,
nor within one year after the incentive stock option was exercised, the participant will recognize a long-term capital gain (or loss)
equal to the difference between the sale price of the shares and the exercise price. We are not entitled to any deduction under these
circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: split004 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the participant is a U.S. taxpayer and fails to satisfy either
of the foregoing holding periods (referred to as a &ldquo;disqualifying disposition&rdquo;), he or she must recognize ordinary income
in the year of the disposition. The amount of ordinary income generally is the lesser of (i)&nbsp;the difference between the amount realized
on the disposition and the exercise price or (ii)&nbsp;the difference between the fair market value of the stock at the time of exercise
and the exercise price. Any gain in excess of the amount taxed as ordinary income will be treated as a long or short-term capital gain,
depending on whether the stock was held for more than one year. We are entitled, in the year of the disqualifying disposition, to a deduction
equal to the amount of ordinary income recognized by the participant, subject to possible limitations imposed by Section&nbsp;162(m)&nbsp;of
the Code and so long as the participant&rsquo;s total compensation is deemed reasonable in amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The &ldquo;spread&rdquo; under an incentive stock option&mdash;i.e.,
the difference between the fair market value of the shares at exercise and the exercise price&mdash;is classified as an item of adjustment
in the year of exercise for purposes of the alternative minimum tax. If a participant&rsquo;s alternative minimum tax liability exceeds
such participant&rsquo;s regular income tax liability, the participant will owe the larger amount of taxes. In order to avoid the application
of alternative minimum tax with respect to incentive stock options, the participant must sell the shares within the calendar year in which
the incentive stock options are exercised. However, such a sale of shares within the year of exercise will constitute a disqualifying
disposition, as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock
Appreciation Rights</I></FONT>. Recipients of stock appreciation rights, or SARs, if U.S. taxpayers, generally should not recognize income
until the SAR is exercised (assuming there is no ceiling on the value of the right). Upon exercise, the recipient will normally recognize
taxable ordinary income for U.S. federal income tax purposes equal to the amount of cash and fair market value of the shares, if any,
received upon such exercise. Recipients who are employees will be subject to withholding for federal income and employment tax purposes
with respect to income recognized upon exercise of a SAR. Recipients will recognize gain upon the disposition of any shares received on
exercise of a SAR equal to the excess of (i)&nbsp;the amount realized on such disposition over (ii)&nbsp;the ordinary income recognized
with respect to such shares under the principles set forth above. That gain will be taxable as long or short-term capital gain depending
on whether the shares were held for more than one year. We will be entitled to a tax deduction to the extent and in the year that ordinary
income is recognized by the recipient, subject to possible limitations imposed by Section&nbsp;162(m)&nbsp;of the Code and so long as
we withhold the appropriate taxes with respect to such income (if required) and the recipient&rsquo;s total compensation is deemed reasonable
in amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A SAR can be considered non-qualified deferred compensation and be
subject to Section&nbsp;409A of the Code. A SAR that does not meet the requirements of Code Section&nbsp;409A can result in the acceleration
of income recognition, an additional 20% tax obligation, plus penalties and interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Restricted
Stock</I></FONT>. The grant of restricted stock will subject the recipient to ordinary compensation income on the difference between the
amount paid for such stock and the fair market value of the shares on the date that the restrictions lapse. This income is subject to
withholding for federal income and employment tax purposes. We are entitled to an income tax deduction in the amount of the ordinary income
recognized by the recipient, subject to possible limitations imposed by Section&nbsp;162(m)&nbsp;of the Code and so long as we withhold
the appropriate taxes with respect to such income (if required) and the participant&rsquo;s total compensation is deemed reasonable in
amount. Any gain or loss on the recipient&rsquo;s subsequent disposition of the shares will receive long or short-term capital gain or
loss treatment depending on how long the stock has been held since the restrictions lapsed. We do not receive a tax deduction for any
such gain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recipients of restricted stock may make an election under Section&nbsp;83(b)&nbsp;of
the Code, or a Section&nbsp;83(b)&nbsp;Election, to recognize as ordinary compensation income in the year that such restricted stock is
granted, the amount equal to the spread between the amount paid for such stock and the fair market value on the date of the issuance of
the stock. If such an election is made, the recipient recognizes no further amounts of compensation income upon the lapse of any restrictions
and any gain or loss on subsequent disposition will be long or short-term capital gain to the recipient. The Section&nbsp;83(b)&nbsp;Election
must be made within 30 days from the time the restricted stock is issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Restricted
Stock Units</I></FONT>. Recipients of restricted stock units generally should not recognize income until such units are converted into
cash or shares. Upon conversion, the recipient will normally recognize taxable ordinary income for federal income tax purposes equal to
the amount of cash and fair market value of the shares, if any, received upon such conversion. Recipients who are employees will be subject
to withholding for federal income and employment tax purposes with respect to income recognized upon conversion of the restricted stock
units. Participants will recognize gain upon the disposition of any shares received upon conversion of the restricted stock units equal
to the excess of (i)&nbsp;the amount realized on such disposition over (ii)&nbsp;the ordinary income recognized with respect to such shares
under the principles set forth above. That gain will be taxable as long or short-term capital gain depending on whether the shares were
held for more than one year. We will be entitled to a tax deduction to the extent and in the year that ordinary income is recognized by
the recipient, subject to possible limitations imposed by Section&nbsp;162(m)&nbsp;of the Code and so long as we withhold the appropriate
taxes with respect to such income (if required) and the recipient&rsquo;s total compensation is deemed reasonable in amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Restricted stock units also can be considered non-qualified deferred
compensation and be subject to Section&nbsp;409A of the Code. A grant of restricted stock units that is non-qualified deferred compensation
but does not meet the requirements of Code Section&nbsp;409A will result in an additional 20% tax obligation, plus penalties and interest
to such recipient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends
and Dividend Equivalents</I></FONT>. Recipients of stock-based awards that earn dividends or dividend equivalents will recognize taxable
ordinary income on any dividend payments received with respect to unvested and/or unexercised shares subject to such awards, which income
is subject to withholding for federal income and employment tax purposes. We are entitled to an income tax deduction in the amount of
the income recognized by a participant, subject to possible limitations imposed by Section&nbsp;162(m)&nbsp;of the Code and so long as
we withhold the appropriate taxes with respect to such income (if required) and the individual&rsquo;s total compensation is deemed reasonable
in amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Impact of Israeli Tax Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The awards granted to employees pursuant to Section&nbsp;102 of the
tax ordinance under the Plan may be designated by us as approved options under the capital gains alternative, or as approved options under
the ordinary income tax alternative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To qualify for these benefits, certain requirements must be met, including
registration of the options in the name of a trustee. Each option, and any shares of common stock acquired upon the exercise of the option,
must be held by the trustee for a period commencing on the date of grant and deposit into trust with the trustee and ending 24 months
thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the capital gains alternative, we may not deduct
expenses pertaining to the options for tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Plan, we may also grant to employees options pursuant to
Section&nbsp;102(c)&nbsp;of the tax ordinance that are not required to be held in trust by a trustee. This alternative, while facilitating
immediate exercise of vested options and sale of the underlying shares, will subject the optionee to the marginal income tax rate of up
to 50% as well as payments to the National Insurance Institute and health tax on the date of the sale of the shares or options. Under
the 2006 Stock Incentive Plan, we may also grant to non-employees options pursuant to Section&nbsp;3(I)&nbsp;of the tax ordinance. Under
that section, the income tax on the benefit arising to the optionee upon the exercise of options and the issuance of common stock is generally
due at the time of exercise of the options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>These options shall be further subject to the terms of the tax ruling
that has been obtained by Protalix Ltd. from the Israeli tax authorities in connection with our merger in 2006. Under the tax ruling,
the options issued by us in connection with the assumption of Section&nbsp;102 options previously issued by Protalix Ltd. under the capital
gains alternative shall be issued to a trustee, shall be designated under the capital gains alternative and the issuance date of the original
options shall be deemed the issuance date for the assumed options for the calculation of the respective holding period.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROPOSAL 4: AMENDMENT TO INCREASE THE NUMBER
OF<BR>
AUTHORIZED SHARES OF COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On March&nbsp;23, 2022, our Board of Directors
authorized and approved an amendment to our Certificate of Incorporation, as amended (&ldquo;Certificate&rdquo;), to increase the number
of authorized shares of our common stock from 120,000,000 to 144,000,000 (the &ldquo;Amendment&rdquo;). We are not proposing any change
to the authorized number of shares of preferred stock. Under the Delaware General Corporation Law, we are required to obtain the affirmative
vote of the holders of a majority of our outstanding shares of common stock to amend the Certificate to increase the number of authorized
shares of common stock. Our Board of Directors determined that the Amendment is advisable and in the best interest of our Company and
our stockholders, and recommends that our stockholders approve the Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of April&nbsp;15, 2022, 46,365,832 shares of
our common stock were outstanding. As discussed in more detail in this Proposal&nbsp;4, we have reserved approximately 4.0&nbsp;million
shares of common stock for issuances in connection with outstanding share-based incentives under our Existing Plan, approximately 14.6&nbsp;million
shares of common stock for issuances in connection with the exercise of our outstanding warrants (the &ldquo;2020 Warrants&rdquo;) and
approximately 21.4&nbsp;million shares for issuance in connection with conversion of our outstanding 7.50% convertible notes (the &ldquo;2024
Notes&rdquo;). The amount of unreserved, authorized shares leaves us with an insufficient number of shares of common stock for corporate
purposes, and impedes and undermines our ability to raise capital in the future. If our stockholders do not approve this Proposal&nbsp;4,
we are left without the authorized shares of common stock necessary for us to pursue a variety of business and financial objectives without
further action of our stockholders (except when required by applicable law or regulation). As a result, we believe that a delay in securing,
or a failure to secure, stockholder approval of this Proposal&nbsp;2 will impair the financial viability of our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Description of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Certificate currently authorizes the issuance
of 120,000,000 shares of common stock and 100,000,000 shares of preferred stock, par value $0.0001 per share, for a total of 220,000,000
shares of capital stock. As of April&nbsp;15, 2022, there were 46,365,832 shares of common stock issued and outstanding, and no shares
of preferred stock issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have reserved a number of additional shares
of common stock for future issuance under our equity compensation plan. As of December&nbsp;31, 2021, 2,259,020 shares of common stock
are reserved for issuance upon the exercise of outstanding stock options under the Existing Plan and 1,786,256 shares of common stock
are reserved for issuance in connection with future grants of stock options and/or future issuances of shares under the plan. In addition,
approximately 21.4&nbsp;million shares of common stock are reserved for issuance upon conversions of 2024 Notes. A significant amount
of the shares reserved for issuance upon the conversion of our outstanding convertible promissory notes includes shares issuable upon
conversions that are effected in connection with a fundamental change, as described in the indentures governing 2024 Notes. Finally, approximately
14.6&nbsp;million shares of common stock are reserved for issuance upon exercises of the 2020 Warrants. After taking into account the
total number of shares of common stock issued and outstanding, in addition to the aggregate number of shares of common stock reserved
for future issuance as described in this paragraph, we do not have enough unauthorized, unreserved shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Purpose of the Amendment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Board of Directors believes that it is in
our best interest, and in the best interest of our stockholders, to increase the number of authorized shares of common stock available
for future issuance. The lack of authorized shares of common stock impedes and undermines our ability to raise capital in the future to
finance the last steps needed to bring our pegunigalsidase alfa investigational drug candidate to its anticipated approval finance and
the research and development activities to further enhance and strengthen our product development pipeline, among other corporate activities.
Absent an increase in the authorized number of shares of common stock, we are left with limited flexibility with respect to the management
of our capital structure. Consequently, we may elect to cash-settle at least part or all of our obligations upon the conversion of our
2024 Notes. In addition, we are limited in our ability to elect to redeem outstanding convertible notes should we find it in our best
interest to do so based on market conditions or other factors. Accordingly, our Board of Directors has determined that increasing the
number of authorized shares of common stock available for future issuance will provide our Company with the ability to best manage our
obligations under our 2024 Notes and greater flexibility in considering and planning our future business needs. Such plans may involve
the issuance, from time to time, of additional shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As discussed above, if our stockholders do not
approve this Proposal&nbsp;4, we are left without the authorized shares of common stock necessary to pursue a variety of business and
financial objectives without further action of the stockholders (except when required by applicable law or regulation). As a result, we
believe that a delay in securing, or a failure to secure, stockholder approval of this Proposal&nbsp;2 would impair the financial viability
of our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We anticipate that we may issue additional shares
of common stock in the future in connection with one or more of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>issuances in connection with the refinancing or retirement of our outstanding existing convertible notes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>issuances pursuant to the conversion of outstanding or future convertible securities, including the 2020 Warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>issuances in connection with the interest payments and make-whole payments under our outstanding convertible notes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>issuances in connection with any partnerships, strategic alliances, collaborations or other similar transactions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>issuances in connection with strategic investments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>financing transactions, such as public or private offerings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>issuances under current and future stock incentive plans;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>acquisitions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>stock dividends;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>stock splits; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other proper corporate purpose.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors evaluates such opportunities,
from time to time, and considers different capital structuring alternatives designed to advance our business strategy. If additional authorized
shares of common stock are available, transactions dependent upon the issuance of additional shares would be less likely to be impeded
or undermined by delays and uncertainties occasioned by the need to obtain prior stockholder authorization. Our Board of Directors will
have the discretion to issue the shares of common stock without further stockholder action, except as may be required for a particular
transaction by applicable law or regulation, or the NYSE American Company Guide. As of the date of this Proxy Statement, we have no specific
plans, agreements or commitments to issue any shares of common stock for which approval of the proposed Amendment is required, except
as described herein. Our Board of Directors believes the additional authorized shares will provide us with needed flexibility to issue
shares of common stock in the future without the potential expense and delay incident to obtaining stockholder approval for a particular
issuance. Our Board of Directors believes that a failure to approve this proposed Amendment will seriously restrict our ability to manage
our capital needs and will be detrimental to the interests of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Possible Effects of the Amendment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The issuance of additional shares of common stock
may, among other things, have a dilutive effect on earnings per share and on stockholders&rsquo; equity and voting rights. Furthermore,
future sales of substantial amounts of our common stock, or the perception that these sales might occur, could adversely affect the prevailing
market price of our common stock or limit our ability to raise additional capital. Stockholders should recognize that, as a result of
this proposal, they will own a smaller percentage of shares relative to the total authorized shares of our Company than they presently
own.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Neither the Delaware General Corporation Law,
the Certificate, nor our Bylaws provides for appraisal or other similar rights for dissenting stockholders in connection with this proposal.
Accordingly, our stockholders will have no right to dissent and obtain payment for their shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The text of the proposed Amendment is set forth
in Exhibit&nbsp;A attached to this Proxy Statement, and this discussion is qualified in its entirety by reference to Exhibit&nbsp;A. If
this proposed Amendment is approved by the stockholders, it will become effective upon filing of a Certificate of Amendment with the Secretary
of State of the State of Delaware. We expect to file the Certificate of Amendment promptly upon approval by our stockholders. In accordance
with the Delaware General Corporation Law, however, our Board of Directors may elect to abandon the Amendment without further action by
the stockholders at any time prior to the effectiveness of the filing of the Certificate of Amendment with the Secretary of State of the
State of Delaware, notwithstanding stockholder approval of the Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Board of Directors recommends that stockholders vote &ldquo;FOR&rdquo; the </B></FONT><B>approval of the Amendment to the Certificate
of Incorporation, as amended, to Increase the Number of Authorized Shares of Common Stock from 120,000,000 to 144,000,000 as disclosed
in this proxy statement and as described in this &ldquo;Proposal 4: Amendment to Increase the Number of Authorized Shares of Common Stock.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROPOSAL 5: RATIFICATION OF APPOINTMENT OF&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors, upon the recommendation
of its Audit and Finance Committee, has ratified the selection of Kesselman&nbsp;&amp; Kesselman to serve as our independent registered
public accounting firm for the fiscal&nbsp;year ending December&nbsp;31, 2022. The Audit and Finance Committee of our Board of Directors
is solely responsible for selecting our independent public accountants. Although stockholder approval is not required to appoint Kesselman&nbsp;&amp;
Kesselman as our independent public accountant firm, we believe that submitting the appointment of Kesselman&nbsp;&amp; Kesselman to our
stockholders for ratification is a matter of good corporate governance. If our stockholders do not ratify the appointment, then the appointment
may be reconsidered by the Audit and Finance Committee. Even if the appointment is ratified, the Audit and Finance Committee may engage
a different independent registered public accounting firm at any time during the year if it determines that such a change would be in
the best interest of our Company and our stockholders. The proxy will be voted as specified, and if no specification is made, the proxy
will be cast &ldquo;FOR&rdquo; this proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During our fiscal&nbsp;year ended December&nbsp;31,
2021, there were no disagreements with Kesselman&nbsp;&amp; Kesselman on any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedures, which if not resolve to their satisfaction would have caused them to make reference to the
subject matter of the disagreements in connection with their opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Audit and Finance Committee will consider whether
the provision of any other services by Kesselman&nbsp;&amp; Kesselman is compatible with maintaining the independence of Kesselman&nbsp;&amp;
Kesselman. The Audit and Finance Committee has concluded that Kesselman&nbsp;&amp; Kesselman is independent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect representatives of Kesselman&nbsp;&amp;
Kesselman will be present at the annual meeting. They will have the opportunity to make a statement if they desire to do so and are expected
to be available to answer stockholders&rsquo; questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Our Board of Directors recommends that stockholders
vote &ldquo;FOR&rdquo; the ratification of the appointment of Kesselman&nbsp;&amp; Kesselman for the fiscal&nbsp;year ending December&nbsp;31,
2022.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth fees billed to us
by our independent registered public accounting firm during the fiscal&nbsp;years ended December&nbsp;31, 2021 and 2020 for: (i)&nbsp;services
rendered for the audit of our annual financial statements and the review of our quarterly financial statements; (ii)&nbsp;services by
our independent registered public accounting firm that are reasonably related to the performance of the audit or review of our financial
statements and that are not reported as Audit Fees; (iii)&nbsp;services rendered in connection with tax compliance, tax advice and tax
planning; and (iv)&nbsp;all other fees for services rendered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year Ended December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Audit Fees</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">284,500</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">243,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Audit Related Fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Tax Fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">61,768</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">All Other Fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Policy on Audit Committee Pre-Approval of Audit and Permissible
Non-Audit Services of Independent Auditors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Audit and Finance Committee has the sole
authority to approve the scope of the audit and any audit- related services, as well as all audit fees and terms. The Audit and
Finance Committee must pre-approve any audit and non-audit services provided by our independent registered public accounting firm.
The Audit and Finance Committee will not approve the engagement of the independent registered public accounting firm to perform any
services that the independent registered public accounting firm would be prohibited from providing under applicable laws,
rules&nbsp;and regulations, including those of self-regulating organizations. The Audit and Finance Committee will approve permitted
non-audit services by our independent registered public accounting firm only if it determines that using a different firm to perform
such services will be more effective or economical. The Audit and Finance Committee annually reviews and pre-approves the statutory
audit fees that can be provided by the independent registered public accounting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SOLICITATION OF PROXIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have engaged Alliance Advisors LLC to assist
us in soliciting proxies for the annual meeting. We will pay Alliance Advisors a base fee of approximately $10,000, plus reasonable out-of-pocket
expenses, plus an additional fee based upon the number of contacts with stockholders made and work performed. We estimate the total amount
payable to Alliance Advisors will be approximately $100,000. Our officers, directors and employees may solicit proxies in person or by
telephone, fax or email. We will pay these officers, employees and directors no additional compensation for these services. We will ask
banks, brokers and other institutions, nominees and fiduciaries to forward these proxy materials to their principals and to obtain authority
to execute proxies. We will then reimburse them for their expenses. We will pay all of the costs of soliciting these proxies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If you need assistance in voting by telephone
or over the Internet or completing your proxy card or have questions regarding the Annual Meeting, please contact our proxy advisor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Alliance Advisors, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">200 Broadacres Drive, 3rd&nbsp;Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Bloomfield, NJ 07003</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">+1 (833) 757-0740 (toll free in the United States)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STOCKHOLDER PROPOSALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All stockholder proposals intended to be presented
at our 2023 Annual Meeting of Stockholders must be submitted in writing to Eyal Rubin, Corporate Secretary, Protalix BioTherapeutics,&nbsp;Inc.,
2&nbsp;University Plaza, Suite&nbsp;100, Hackensack, NJ 07601,&nbsp;Israel and received by us no later than January&nbsp;13, 2023, and
must comply in all other respects with applicable rules&nbsp;and regulations of the SEC relating to such inclusion. Such notice must include,
with respect to each matter the stockholder proposes to bring before the annual meeting: (i)&nbsp;a brief description of the business
desired to be brought before the annual meeting and the reasons for conducting such business at the annual meeting; (ii)&nbsp;the name
and record address of the stockholder proposing such business; (iii)&nbsp;the class and number of shares of our Company which are beneficially
owned by the stockholder; and (iv)&nbsp;any material interest of the stockholder in such business. In addition, the notice must include
certain information relating to any derivative or hedging transactions by the stockholder delivering such notice and its Stockholder Associated
Persons, as defined in our By-Laws, and other arrangements with other parties regarding our securities, as presented in detail in our
By-Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any such proposal submitted with respect to our
2023 Annual Meeting of Stockholders which is submitted outside the requirements of Rule&nbsp;14a-8 promulgated under the Exchange Act
will be considered timely if we receive written notice of that proposal not less than 45&nbsp;days nor more than 75&nbsp;days prior to
the date in 2023 on which we first mailed this proxy statement in 2022; however, if the date of the annual meeting is changed by more
than 30&nbsp;days from the date of the prior&nbsp;year&rsquo;s annual meeting, the notice will be considered untimely if it is not received
at least 90&nbsp;days prior to the newly announced date that we will mail our proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANNUAL REPORT TO STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Annual Report on Form&nbsp;10-K for the fiscal&nbsp;year
ended December&nbsp;31, 2021 filed with the SEC, which provides additional information about us, will be distributed to all stockholders
entitled to vote along with the proxy materials. Additional copies of our Annual Report on Form&nbsp;10-K for the fiscal&nbsp;year ended
December&nbsp;31, 2021 are available on the Internet at http://www.sec.gov and http://www.protalix.com and are also available in paper
form without charge upon written request to Investor Relations, Protalix BioTherapeutics,&nbsp;Inc., 2&nbsp;University Plaza, Suite&nbsp;100,
Hackensack, NJ 07601.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>HOUSEHOLDING OF PROXY MATERIALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The SEC has adopted rules&nbsp;that permit companies
and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy statements and annual reports with respect to two or
more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. This process, which
is commonly referred to as &ldquo;householding,&rdquo; potentially means extra convenience for stockholders and cost savings for companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This year, a number of brokers with account holders
who are stockholders of our Company will be &ldquo;householding&rdquo; our proxy materials. A single proxy statement may be delivered
to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once a stockholder
has received notice from its broker that it will be &ldquo;householding&rdquo; communications to such stockholder&rsquo;s address, &ldquo;householding&rdquo;
will continue until such stockholder is notified otherwise or until such stockholder notifies its broker or us that it no longer wishes
to participate in &ldquo;householding.&rdquo; If, at any time, a stockholder no longer wishes to participate in &ldquo;householding&rdquo;
and would prefer to receive a separate proxy statement and annual report in the future such stockholder may (1)&nbsp;notify its broker
or (2)&nbsp;<FONT STYLE="color: #231f20">direct its written request to: Eyal Rubin, Corporate Secretary, Protalix BioTherapeutics,&nbsp;</FONT>Inc.,
2&nbsp;University Plaza, Suite&nbsp;100, Hackensack, NJ 07601, +1 (201)&nbsp;696-9345. Stockholders who currently receive multiple copies
of the proxy <FONT STYLE="color: #231f20">statement at their address and would like to request &ldquo;householding&rdquo; of their communications
should contact their broker. In addition, we will promptly deliver, upon written or oral request to the address or telephone number above,
a separate copy of the annual </FONT>report and proxy statement to such stockholders at a shared address to which a single copy of the
documents was delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OTHER MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Board of Directors knows of no other business
to be acted upon at the annual meeting. However, if any other business properly comes before the annual meeting, it is the intention of
the persons named in the enclosed proxy to vote on such matters in accordance with their best judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The prompt return of your proxy is appreciated
and will be helpful in obtaining the necessary vote. Therefore, whether or not you expect to attend the annual meeting please sign the
proxy and return it in the enclosed envelope or vote by internet or telephone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BY ORDER OF THE BOARD OF DIRECTORS,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B><IMG SRC="tm2212755d1_pre14asp4img001.jpg" ALT=""></B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eyal Rubin</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sr. Vice President and Chief Financial Officer and<BR>
Corporate Secretary</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carmiel,&nbsp;Israel </FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Appendix A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOURTH CERTIFICATE OF AMENDMENT TO<BR>
CERTIFICATE OF INCORPORATION OF<BR>
PROTALIX BIOTHERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Pursuant to Section&nbsp;242 of the<BR>
General Corporation Law of the State of Delaware)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Protalix BioTherapeutics,&nbsp;Inc.,
a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
name of the corporation is Protalix BioTherapeutics,&nbsp;Inc. (the &ldquo;Corporation&rdquo;). The Certificate of Incorporation of the
Corporation was filed with the Secretary of the State of Delaware on March&nbsp;30, 2016, as amended by that Certificate of Amendment
dated August&nbsp;15, 2016, that Second Certificate of Amendment dated January&nbsp;10, 2019 and that Third Certificate of Amendment dated
December&nbsp;16, 2019 (the &ldquo;Certificate of Incorporation&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Certificate of Amendment to Certificate of Incorporation of the Corporation was duly adopted by the Board of Directors of the Corporation
pursuant to a resolution setting forth the proposed amendment of the Certificate of Incorporation and declaring said amendment to be advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Article&nbsp;III
of the Certificate of Incorporation, as amended, is hereby amended and restated in its entirety as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
Corporation is authorized to issue the following shares of capital stock: (a)&nbsp;</FONT>144,000,000 shares of common stock, par value
$.001 per share (the &ldquo;Common Stock&rdquo;); and (b)&nbsp;100,000,000 shares of preferred stock, par value $.0001 per share (the
 &ldquo;Preferred Stock&rdquo;). The voting rights, the rights of redemption and other relative rights and preferences of the Preferred
Stock shall be established by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Board of Directors may authorize the
issuance of such stock to such persons upon such terms and for such consideration in cash, property or services as the Board of Directors
may determine and as may be allowed by law. The just valuation of such property or services shall be fixed by the Board of Directors.
All such stock when issued shall be fully paid and exempt from assessment.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aforesaid amendment was duly adopted in accordance with the provisions of Section&nbsp;242 of the General Corporation Law of the State
of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of this page&nbsp;intentionally left
blank.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">IN WITNESS WHEREOF, the Corporation has
caused this Certificate of Amendment to Certificate of Incorporation to be signed by its duly authorized President and Chief
Executive Officer this &nbsp;&nbsp;&nbsp;&nbsp; day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">PROTALIX BIOTHERAPEUTICS,&nbsp;INC.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><U></U></TD></TR>

<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Dror Bashan</TD></TR>

<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>President and Chief Executive Officer</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2212755d1_pre14aimg001.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">PROTALIX BIOTHERAPEUTICS, INC. 2  University Plaza, Suite  100   Hackensack, New Jersey 07601 THIS  PROXY  IS  SOLICITED  ON  BEHALF  OF  THE BOARD  OF DIRECTORS The undersigned hereby appoints Dror Bashan and Eyal Rubin as proxies, each with full power of substitution, to represent and vote as designated on the reverse side, all the shares of Common Stock of Protalix BioTherapeutics, Inc . held of record by the undersigned on May 2 , 2022 , at the Annual Meeting of Stockholders to be held on June 30 , 2022 , or any adjournment or postponement thereof . UNLESS A CONTRARY DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED FOR THE PROPOSALS, AS MORE SPECIFICALLY DESCRIBED IN THE PROXY STATEMENT . IF SPECIFIC INSTRUCTIONS ARE INDICATED, THIS PROXY WILL BE VOTED IN ACCORDANCE THEREWITH . (Continued and to be marked, dated and signed on the other side) PLEASE  DETACH  ALONG PERFORATED LINE AND  MAIL IN  THE ENVELOPE PROVIDED. Important  Notice Regarding  the  Availability  of Proxy  Materials for  the  Annual   Meeting  of  Stockholders  to be  held  on  June 30, 2022. The  Notice  of  Meeting,  Proxy  Statement, and  our  2021  Form  10 - K  Report and   Proxy Card  are  available  at: http://www.web.viewproxy.com/Protalix/2022</P>

<!-- Field: Page; Sequence: 45; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2212755d1_pre14aimg002.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White"> Please  mark  your  votes  in  blue or  black ink  as  shown  here  1. To  elect six members to the Board of Directors to serve for the ensuing year  or  until their   respective successors have been duly elected Zeev Bronfeld 2. To approve, on a non - binding advisory basis, the compensation of the Company&#8217;s named executive officers as disclosed in the proxy statement that accompanies this notice .  FOR   AGAINST   ABSTAIN 3. To adopt amendments to the Protalix BioTherapeutics, Inc . 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 5 , 725 , 171 shares to 8 , 475 , 171 shares and to amend certain other terms of said plan .  FOR   AGAINST   ABSTAIN 4. To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of shares of our common stock, par value $ 0 . 001 per share, authorized for issuance from 120 , 000 , 000 to 144 , 000 , 000 .  FOR   AGAINST   ABSTAIN 5. To ratify the appointment of Kesselman &amp; Kesselman, Certified Public Accountant (lsr . ), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31 , 2022 .  FOR   AGAINST   ABSTAIN I plan  to  attend the meeting  F OR from  all nominees (see instructions below)  all nominees  WITHHOLD AUTHORITY  FOR  ALL  EXCEPT Dror Bashan Amos Bar Shalev Pol  F.  Boudes, M.D. Gwen A. Melincoff Aharon Schwartz, Ph.D. INSTRUCTION:  To  withhold  authority  to vote for any individual nominee(s), mark, &#8220;For All Except&#8221;   and fill in the circle next to each nominee you wish to withhold, as shown here:  Date: Sig na t u r e Address Change/Comments:  (If  you noted any Address Changes and/or Comments   above, please mark box.)  CONTROL NUMBER Signature (if held jointly) NOTE : Please sign exactly as your name or names appear on this Proxy . When shares are held jointly, each holder should sign . When signing as executor, administrator, attorney, trustee or guardian, please give full title as such . If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such . If signer is a partnership, please sign in partnership name by authorized person . PLEASE  DETACH  ALONG PERFORATED LINE AND  MAIL IN  THE ENVELOPE PROVIDED. PROXY VOTING INSTRUCTIONS Please  have your 11 - digit control number ready when voting  by  Internet or Telephone THE  BOARD  OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE ELECTION OF ALL DIRECTOR NOMINEES, AND A  VOTE  &#8220;FOR&#8221; PROPOSALS  2,  3, 4  AND 5. PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. SCAN TO VIEW  MATERIALS  &amp; VOTE  CONTROL NUMBER INTERNET Vote Your Shares on the   Internet: Go  to  www.FCRVote.com/PLX Have your proxy card available   when you access the above   website. Follow the prompts to   vote your shares.  TELEPHONE Vote Your Shares by Phone: Call 1 (866) 402 - 3905 Use any touch - tone telephone to vote your Shares . Have your proxy card available when you call . Follow the voting instructions to vote your shares . MAIL Vote Your Shares by Mail: Mark, sign, and date your  proxy   card, then detach it, and  return   it in the postage - paid envelope   provided.</P>

<!-- Field: Page; Sequence: 46; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2212755d1_pre14aimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2212755d1_pre14aimg001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U(# 2(  A$! Q$!_\0
M'0 !  (" P$!              <(!08!! D# O_$ %P0   & @(! @0#!@,%
M P8!'0 ! @,$!081!Q(A"!,4(C%!%191(S)78:;2"1=")#-6<9484H$E-SAV
MD;0Y0W5WA;.U&31)4U1B<H>AL;+%14=5@H.&EL'#T_#_Q  6 0$! 0
M             0+_Q  6$0$! 0                   1'_V@ , P$  A$#
M$0 _ /5,
M
M
M
M
M
M
M  !QL!R XV.0     !QL!R     XV Y !QL!R           XV.0
M
M
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MW/(T^>J=DV.())I75O\ 1*6D().^Z4D6T[/H1HT7[(]ECTFHJHZ2IAP3F2+
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MD?DQFP
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MCLI:S2DB)2EJ4>SUK90  '&AR
M
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MKR>R;(_^9@)8
M
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MGP 0
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M))F7C:B\[_\ P^!V<3S*'F'XO\&R^S^%V#M:][Z2+LZWKL:=&>T^2T9Z/^1
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MD224>E$:NNQLV*9S4YE35MG626G69\9,MI!.I4LD']=DDS+Y3^4]&9$9&7V
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MM1H)*5'>.IK:SCZCJ:>NB/,UC"6H$2/&9<>)I)%I/8R)1D6B\N+/7W,]F-@
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MF>:TY:AVSME5;B92H/XFM4I3LHD=3@KA]R;3V-!=V$DDE$1%;"_R>NQG\/\
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MC;T?(XG%V0S)F+/8ZHKN54W+LIB+/5/B)BFETW%&U*4TJ8:_)+TVV:_HG=U
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M58[:2:ZN<QN5:V$Z+*4EV!'[NU[,=1(==^+6^2DMH4M1I;2I)I)!"WEYF/Y
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M:G#2V@DEV4HU*/1?<U*,S/[F9F [(
M
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M,6CD=OW'6$ND?R+))I/Z&1%LS,O!'7G+H62<J^E_@''+AJ^J,DJ>1JS';>3
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MYU]=>="+^/O3E,Y2YQYUL9.=<B8$TC)$)8;Q6V57,3$FPD_<41MJ)PR^G8C
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M\AK\3U>\=S^"9O+L>;*>Q"$\4>2I$<SD-.&\ADDJ:^I'V<0?_P!RHC$$\O\
M_GG]4_\ \B97_N[XK=S?62^&/2U7,1&%JQ#E/#L??4E"3Z1+N,4-QQ1_9)/,
M(4H_N:V_Y LFO4KDKD&NXMPVPR:VCSI5?"]OW6JV*J2^?=Q+9=6T^5>5EO7T
M+9B&,/\ 7IQSG&50L>JZ_*EV,F<S7*)VB?2AAYQ9(3[JM?(6S(S,]$1;,_H+
M'%]!6GTJ?^>?U(?^MK?_ +ND$27C'J!Q3+^$I'*U<J4O$68,RQ6ZXP:'O9C&
MX3I]#\[VRO1??Q^HTK+/6]QUA\G'(\AB_G2+^AC9)":K:IR0KX)\S)M2R3^Z
M>TZ,C^AF1?<A4#AWC+E2Q_P^Y]_5<R?@^$IQZ\=7A_Y7B/\ =E"Y?O,_&*43
MA>Z:5GVUM'N>/W2'SE9+(Q;E+AF5'Y9B\.+7P=3-'>S*EFQ2^7O[^&)ITR21
MJUW[_4B:,ON8-8] >'.<*'G"ML9M%"N(3,!U++I7%>Y$4I2D]BZDLMF6ON-#
MY$];/'O&>=7N)6D:_E6](3*I_P"&U+DEIDG6DNH,UI\$1H47_L/]#&2]*F:'
MEV(7"7^78G,<V-/VNXB5#5:49M3:.D<VF_E,R-*U=OJ??7V(0-%QOE/(O6/Z
MC$<9Y93XJ:"QXIZ[6O\ BE.;KS]HV_LDTZ<WLCWV+] 93-D'KAXPH<9PV^:E
MV=U7Y8F4=6517.R'5G&-)/I4WHE)4DUEX,OL9_0MCM<!^H+C+-4WU-BKDRFF
M5JG;2?7WL5Z)()#KBG')2E.[[)-:U;/L?7QLDEUW6O./3[?<:<G^F;"L5SMZ
MER^4_E,Y_+7:QF812W(K+LA28J](Z*+LA*3/Y241[-1;&+5@F;W]YSGC6=WT
MO(.=W<*7!HWHY-1HEK1*<-PRC-M-H^=3J5-K2LOJK1&:>YD635C8_P#B"\,2
M+M$([^4Q7+D'$1?R*]]NL6\1;-!2%((OLKR>D_*9[ZZ4<K77,V.XYR;08)9K
MD0KN_BO2:MQQA7PTLVO+C*'=:]U*?F-)Z\&7G9D0IWEWJAXDO?1L_@5<XJ7E
M,G'4X_%PMFN=7,9L"9)"4&WT^K3J>_8_!FCP9J,B/O>H7&;/..,.'_3U"1%L
M.6DU]?-DV3LMP_P%,1A*'IJG4?,9K5W;3O?8U&>M]3!%A:WU><?VKT%QAVQ_
M")UZO'(]XJ"X4!R:1>$$[K]U1_*E>NIF1^=%L;A.YGQV%RM6\=).3+RB9 <L
MUQXL=3B(D9!Z]U]9%U;2I7RIV>S,TEKYBW!GI]I,.]0/I8E<57%#'HIF/-GC
MM]CZ3[.5LYHS_;(,S,_F67O(7M1&HU%V4:5!_AX8Y^.\+HY3NYTF[S?-GG'+
M6VFF2G5MQ7%Q&&BT1$24H9W]-F:SV9Z3H)IYIY]Q#@6JKIF4RI).V;YQX$"!
M%<DR93A:-1(;01^$D>S,]%]"^ID1Z=6>L_CN[P"TRRO_ !J8Q53&X%A6-U3W
MXA%=7OH2F#3O2B+9*+9?;9&1D6@^N&3A+ESQV65Y%DW&UJP_+71Y_3)3\+ >
M4V1.QY"B5[A$Z@BT1$7;J?S=260^'HJY@O<RSCD3'+#(:?DN%4IB/-Y]50/@
MES>Z5$AA]))(E+0E)ZT:NI$9&I6_ ;MQ[ZY./.3\KB8_1P<E7-D2S@F[(I76
MV67B+:D.+,M(,ON1_3[C;Z[U-X);<U3.*XMBX[EL5M2UMDRHV#6EM+BVB=(N
MIN)0LE*27TT9'HR,A%'I3RJ%A&+^I'(+(U)KJODO))TE:"V9--(96O6]%OJD
M_J9"H$%CE;&,'QWF:QXJ4VB-EJN09N9(MX;CTF!,)"78R(OAU+:VS01>?!;/
MJG>R+)J^/*WK4P'AG+)V/Y'"R-$F&MIMR3%IW78REN-I<0E+I%U49DLB\']?
M Q<_UY\<5E33SY-?E+?XM+EPH<0Z)\I+JX[;#CIDWKL:23(1\Q>/"_\ NF,=
MZZ[)BWX*QJ7%<2]&?RFD=:=2>TK0I\C2HOY&1D8TCU[V[M!SCZ?+!G.V.,W6
M?S#URF3 1.;A;C1T^67/E5WW[?GZ&X1EY(@1*3/KDX\7B629(_!R:OJ:!IAZ
M8[84KK!Z=?0RCH2OWS[K3LB^A>1WLH]:G&6(<1XUR3/L9"L9R%XV()QV?<?4
MHO<[[;(]D23;42C_ -)Z(_)BJO.'(2LH](7,D.9SW7\UR4MU#S3<*B8K%5J"
ML626H_:/]H2S4C][]WV_'[QC6.:\7?0CEG"7TN-TW&<>]N:Y"5.'K\5.,Y'V
MKZ*(D2)Z2\F9&1[T>C!K%T^0_65@/&E]44UE'O9ME:5#5XPS55BY1_"N+4A*
ME=?W?F09>?U+]1B;3UW<;46 N9C9QLBK:9%HU4;F5#C+JGW&7'4Z0K1FGJTO
MS]-Z_45LY7R61BWJ:P.5'Y9B\.+7Q' :.]F5+-DE\OC5G\,33IDDC5KOW^I$
MT9?<QD>1K^-R3Q]Q16VO*T#FW?,-(S*LF:9FO0U'=9=3\*IEO:5?1PS4?DR<
MU]B,#%QLCY]Q3&;K#:MY]^7)RZ),FU"H3?O-OM1HY2'%=B^FVU$:?UV(F_\
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MVA/?QM2R,SWX&K^LBJD4-#B/*U8R;EIQU;)M'B01=UUKNF9[:3,CUME7;_\
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M_%7J<X9YNS!Z+A620;C)6H9[)R ]%D*8)78TH-YI!K(C^8TIWKZF7W%=^?\
M(,CS7AWAPX_(6)YGE:>6:F-'O\>)#T!B1[;QLDM#:U;-!J0I2=[-)_3R0S&!
M5&<2?65BT?F_((#N04M=.E88JEA(8AVC;K9MR>SAF2_=0WHS9-)D1$M1*UY4
M9;_!_P 0GTUUK\I^/G+++\I?N/N-4$]"G5?]Y1E&\G]O(D"-S)Q5D^,YIE)6
M%>_54!+BW\F77.-N-(0A+G5;;K9+<0:5)-'5*B69D2.Q[(4C])W)&9T' .+P
M*GGSBS"J]GXKVJ/)%,E/C;E.J/W>SB3^8S-:?'[JT_\ ,]FYSBK+U#Y?Q75R
M"<K>9)N-V?:*]\J(:%/%.<+H9&I+B8NS,EIV2B+Z*V#6+D5_J#XZ1Q]C.6P[
MYES&,AF,U=-(C17UG*D.+4VVPVRELW.W9"RZFGQU5O1$->S#U<\.4V&-7E]D
MR$8[.G2J8G7:J6ZEV0T1D\T;9,F>B\ELRZG^IBK>-5;K7J;Q/@AU@_P;%<]L
M\RCMH69(C0CBIEP4DA9GVT])<3V2?U(SUOL8G_\ P_\ _P R][_ZVW'_ +P8
M)9C&4_K9],C57;,U>2P&:]+'NSV6,<F-MJ;4M#6UI^&^;9NI3K1^%?36]3WE
M6=8MQ-&QR/<2T5,>YLXV/U3345:DN2W243+)$VDR01D@RVK22UY,O H%_P#4
M9O\ _O\ B$;KZ@,:YGI\EX,?Y%S'',AI3Y-HT,1JBJ7%=1(-;G5:E&9[3T)P
MM?JI)_8"S%TG^-L4ER'I$C&J>1(>6;CCKL!I2EJ,]FHS-/DS/R9_J,C^6J[\
M(_"_@8GX=U]OX/X=/L]/^[TUKKO[:'%!E5/E/XA^#VL&U_#I;E?,^!DH?^&D
MMZ]QASJ9]'$[+L@]&6RV0RH(Q?Y:KOPC\+^!B?AW7V_@_AT^ST_[O36NN_MH
M<Q<=KX<PY;,..U*4VEDWFV4I6;:?W4&HBV9%]B,9, '2F4\.?-B2WXS#LN)W
M^'?6TE3C/<M*Z*,MIV7@]?4AUY6,UDZQCSY$")(FQO\ <27F$K<:_P#N%&6T
M_P#@,J  ,+'Q"GB,PFF*V$PW"4;D5#<5M*8ZC/9J01%\IF9GLRUO9C-  Q?Y
M:K?Q?\4^!B?B/7V_C/AT^]T_[O?6^NOML==&%TC5P=JBIKV[0U&HYJ8C9/[,
MC(S[Z[;,C,C/?T&< !TIU1$LGXK\B,R\_%5[C#CK25J:5_WDF9>#^W@?C\!@
M_B7XC\*Q\?[/P_Q7LI]WV^W;IVUOKOSKZ;\ZV,@ #&IQZO1:.628<9-@MOV5
M2R823IHV1]#7K9I\%XWKP/A5X?34DIV37U<*#(>_WKL:,AM;GG9]C(O/G]1F
M0 8ZTQZMNI,.1.@19<B&OW(SLAA+BF5;(^R#,OE/:4GLON1?H/O95L:VB.19
M;#,F,X75QE]LG$++]#2?@R': !C7\>KY3,1IZ''=;B.)>CH<92HF5I_<4@C+
MY33YT9>2V/S>8S59*VTW:UL2R;:,U(1+82Z23/[D2B/1C*  Z5I3P[IA+$V,
MS+82LG";?:2XGL7[JM&1^2^I&.O*QFLG6,>?(@1)$V-_N)+S"5N-?_<*,MI_
M\!E0 827A=)86C=E*J*^18-*2IN6[$0IU!I/:=+,MEK[?H?T'>MJ>'>PUQ)\
M9B;$7KNQ):2XVK1D9;2HC(]&1'_S(=T '4LJR-;1'(LMAF3&<+JXR^V3B%E^
MAI/P9#KQ<=KX<PY;,..U*4VEDWFV4I6;:?W4&HBV9%]B,9, &!FX-0V;TIV9
M3UTMV422?<?B-K4[U(B3W,R^;1$6M_31#\P>/\;JIK4N!05<"6UOH_&@M-N)
MV1D>E$G9>#,O^1F-@                         8FYQ2GR&96S+*K@SYE
M8Z<B#(E1D.N1'3+1K:4HC-"M>.R='H8YOC3%6L<G8^C&Z=%!.6MR55)KVBBO
MK6KLM3C77JLU'Y,U$>S\GL;. #0['@;C>Z@UT.RP#%K&+6M''@L2J2,XB*UO
M?1I*D&2$[\Z3HMC(0>*</K,3D8M$Q>DC8S([>]3-5K*(;G8R-79DDDA6]%O9
M>3^HVP &M7_&^,992,4UYCU3<U#"4I;@3X#3\=!)(NNFUI-):T6M%XT0_)\9
MXLNBK:1>.U"Z:L<;>@5ZJ]HX\1Q'EM;3?7JA23,S(TD6C/P-G !B<AQ2GRQF
M*S<U4&V9BR$2V&Y\9#Z6GT>4.I)9&25I/R2B\E]C"SQ6GN+JJN)M5!EVU5[O
MX?/?C(<?A^ZDDN^TX9=F^Z2(E=3+L1:/8RP -(R;A'CW-K9=KD>"XSD%FM"6
MU3;2GCR7C2GZ$:W$*5HOL6_ ZJO3YQDND;ICX\Q0ZAN2J6FO51Q3CI>4DDJ<
M)OIU)9I2DC41;,DD6Q(( -1Q[B?$<.J;&MQW&Z;'8-AOXJ/55C$=M\S2:=K0
ME!)7X/7S$?CQ]/ ['&V!0>,<'IL7K%*7!JXJ(S:U))!K,B^9?5.DI[*VKJ@D
MI+>B(B(B&S  P_Y1IOS)^8OPN%^/_"? ?BOPR/BOAN_?V?=UV]OM\W3>M^=#
M]4V*4^/3+*96U<&!,LW2D3I$6,AIR6Z1:);JDD1K5KQV5L]#+  U.+Q5B$'X
M'X;%Z2-\!+<GQ/:K64_#25[[OMZ3\KBMGM9?,?W,=3).$L"S&Z*XO\*QR\N"
M2E*;"RIX\B0DD_ND3BT&KQOQY\?8;N #&S<>K[*GD5,R%&EU<AA49Z$^RE;+
MC*D]5-J0?@T&1F1I/P9&9#[5%1#H:V+75T5B#7Q&D,1XL9LFVF6TEI*$)+PE
M)$1$1%X(B'< !B:#%*?%OQ#\'JH%5^(RW+"9\#%0Q\3)<U[C[G4B[N*T799[
M,]%LQB(?%&'UV,S<<B8O21,?G+6Y+JF*UE$60I>NQN-$GHHSTG9F1[T0VT &
ML8]QGBN(4TJHHL<IZ6KE=O?A5]>TPP[LM'V;0DDGLC/>R\[/8_<?CG&HF*'B
M[%#5LXR;2F#IFX3:89M*,S4V;)%T-)F9F:=:/9[+R8V0 &O2./L;EUM+7/T%
M4_7TCS,BKBNP6U-5[K):9<829::4V1F2#3HTD?@;"  ,##P:@KLDL,AB4M;%
MOK!"&YMHS#;1*DI01$@G'2+NLDDDB(E&>M%KZ#K1>,\5@QKV-'QJFCQ[Y3B[
M9IJO:2FQ4YV]Q4@B+]L:NRNQKWOL>_J-G !I%UPAQ[DT>NCW."XS;1ZR.F)
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M>B\;4?ZCIL\!\;QJ*32-8!BS=)*>2^_6(I(R8SKB2TE:VB1U4HB,]*,MD-^
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M(NQ%]QF+_"J'*;"IGV]+76DVI>.17R9L1#SD-T]?.TI1&;:OE3Y3H_!?H,V
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M@]5!JOQ&6Y83/@8R&/B9+FO<?<ZD7=Q6B[+/9GHMF,J
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MN (
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MM)&>QNN#\;8[QQ^/_EZO^ _'K9^\L?V[COOS7NONN_.I77MU3\J=)+7@B&S
M B7+O2QQIG66NY+>8X4VU>6TX_N;)1'?4T9&V;D=+I-.&1D1_,@_)%L=W(_3
M=QWELS,)=OCC4Z5EQPU7#KDA[;ZXJ#1&6C2_V*D),R)370_/DS,2: "'ZGTE
M<5TE)E51&Q5ERNREJ,U<,3)4B24LH^S9-1N.*,E),S5W3I1J/L9FKR-:S?TI
M5%;Q-F&*<<M-T-CEB685C:6=C+E.%%-:4O\ 5;BW%F?LFXE*-DDS,NW@6% !
MC<=H8N+T<"I@IZ0H+#<9A&B+JVA))27C^1$,D
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M^H(W]H?GWD3^%W]01O[1)@ (S_/O(G\+OZ@C?VA^?>1/X7?U!&_M$F  C/\
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M$F  C/\ /O(G\+OZ@C?V@),
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MO1[1>+5)K>-4";9(1\8M9:ZI02D+ZDGMX?<\)T0ZU9P?S!QY;8I8X=(PEZ3
MX\JL/FNW,N61-2HJG5*>90VQ^U;VXG1*4@U:/9)^HMF "C=SZ&;R-9X@B'28
M/G]51XA#QY:<QE2XZRDM29#SCK:8[*R)*O>(B(U;T6CWK9[G;\,<Q0\ARR9C
M!8'7QLMQZJI9Q2I<U9UJXS#S3JHZ$LZ<27OKZ=U)WT3VUY(6Q !H?$&(VO'V
M,Q,5D+AR**B@0:NHF-N+.3(:9C(;6N0@TDE"C6D]$@U$:=&9D?@M\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M!6:/ZI':/U!<RXQEBJVLP; ZN#8)LF8K[DK3S+*UFYU4HE$2G#T2&R/6OJ L
MR @9OUS\(N6!0RSJ*3BVU.M.*B24LOI3X,FG3:Z.J[?+T0I2C41I(C41D,E$
M]87$DS#9^4HR]ANDK[!NJFO/Q9#3D62X>D(=96T3C9&9'\RDDGY5>?E/03.
MB_CGU+\<\LW\NDQ7)6+.WCL_$'#6R]'6XSO1.M$ZA/NM^2/NCLG1D>]&6\9_
MVN^)?S7^7?SG!_$/C/P[W>COP?Q.M^Q\7T]CW-?Z/<W]OJ F,!#>8^KSBC <
MVF8?>94F)E$23%AN52($IYY3LALG&4H)MI7N$I)I^9.R2:DDHTF9$>B>G[UN
M8SREC/(E_?&UB]9C-F^25O,/I1^'H2V3;KCBD$DWEN*67LI^<OD+J>R,PL^
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M7CR._P 9\\83R^NP:Q6Y*?)KS04N&_&>B2HY*+:36R\A"TD9>2,TZ/[; 2
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MZ>2-/TU9X
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MDK)/J]H0)D/HGXVR63,1*3>-T,V8=A*QB-=2FJAY\U]U+.*E?0MJTK2=%LO
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M7R@U,F5Z:QY3S,=+;^WS22?]U\Q%[A;3Y+SY'J.7T#0Y MT  !
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MIS_S=20N0K_#<<HL;@7D*NKVV/>:?77-.DCW'$*-".[BE+2DB-9D7E.A/?\
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MGE$.2Q8R;2P>6_.6XRMM/N/GV4DB2OJ1I3\OD]&9F9[IPGQTWQ+Q;CF'M/\
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M,RUY+LDME]R$TX'POC?'.;9ME50W)3;Y@^Q)M%O/&M"EM$LD=$_Z2_:*\?\
M(!O@
M
M
M
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ME%X^;>B(B+6BUWU^G[C]>&4N)'BU?^6Z685A75IH4;4:02EJ]Q!;\'MQP_\
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M@RUU))F9DDOE_D)9
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M<!:]*/+/&1\OX,=[EV4JO(,DIDGX5MDWH;G5U7P_<EZC+\)0HO*?/D]>GLZ
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MDB4KPO9EV\B]O^5^'?\ "E'_ --9_M#_ "OP[_A2C_Z:S_:"Z\U<BQWAZ]Y
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MIJ.!C\3X6MA1H$;L:B9BLI:1L_J?5)$6S!+==\  $
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
(       !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2212755d1_pre14aimg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2212755d1_pre14aimg002.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U(# 2(  A$! Q$!_\0
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M.'_G78_K)G[59I\"J]2LIQR!F>:W:_7*WW2T Q5S[\Q+C/K4X-UIBMQ6W&5
M((W4\Y\Y7T@BK\2UDO[%ML5WMFK%PRC,;K=K[ O&&R+A&>3;8+*9Y;E)92@/
M,%L1HR@I2MCU#[E; LFMS?&CA_YUV/ZR9^U3XT,/_.JQ_63/VJ_/6_ZSZG/(
MLUQCY9D\5#.,8@^;LS+C)M4*=/8.[UR:6VI:VG7$^U'%(/91'--6%9=2<BN_
MBIOUIN6?R+=:H68I@Q;4YFD&W\V@EE2&4VYV,IZ0E:E*3NAU'+D4IV*2:%F-
MD?&AA_YU6/ZR9^U3XT,/_.JQ_63/VJRAHQE\K5:79VKKKM>;=F^1Q[@W=\*M
MS<13MJ<96H!#'%DF$IGB!R?Y]7_>=ZX5LS',L6\.%BRBX:IY"RG*<O-BO.0W
M0QWTV* U-FQR\Q\B TISIL(4XOD$J6%)"=J(V9\:.'_G78_K)G[5/C1P_P#.
MNQ_63/VJP7?]8L\NDV)CN+YIEFH./1LKGV^!>\8<BQKG>(K-K\TME#JFRR\6
M7 H%P)W= (0-U( ^[+]:LQ8TMTENDS5-^*Q<K#<IYDV^?$@RI:VGT^76793
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MMVF"(K!9FVQ4A"$J+?#J[N,K+_F>6R0. [\=B-E_&CA_YUV/ZR9^U3XT</\
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MS YO.P'37-<S5:(]^2VT?1MLC15H1Q*PIMDR933P+QY</5).P*01L7XT,/\
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ML5<%[I"04J"0"%S:IZINZ,R<.Q['<+=RBYY"_(B6^U6V1'@I1T6%/K[NE*
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M9Q()3R'<IX@_-%3C*<<Q_*,_?RIR3D<>0[C,S&3';QR:4!J0ZVXIW<L_.!:
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ME)4I*M@/DP#WVV)"?G$"I9BGB Q7.,P7CUB7,N3J8K$L3F(JU12V\PB0TKJ
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M;^\5AW,?#AJ#J);,AF6S3.VZ8K58[58&;';Y\-\3G6KK#DKE;((9+;#4=Q*
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M+0CQ]U$(:"%;;;;]D$DE"2.UC^@F)8J]:E6F*["9M=R:ND..EU1;:=;M8M:
M >Y2(H"=B3W[[^RK&I04+A'A0QW'[C<A+E3YEC3(C>CK.9KHC(99M,:WH+S>
MX2MT!ETA8_SD'YR$D2/#/#5B6"S+5*MSES=?MLMN:PJ9,4[\JW$DQ$'8]@D,
M2G$<$[)[)5MRY*5:]*"E97A(P259[5 X3VA:V(D:'(;E'JM-QXWEFT]]TJW:
M['D#N0%>T U(XV@V-1<QQW)&UW'SF/L>6MS#D]UQAA/0,?LE:E'NV=B.7$J
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M<GMO5KZX^)&R:$77&;;<['>[Y-R!$M<5NSHCG@(_2ZA67GF@/\LG;;??8_\
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M*M@E/'9) 6MJSX8,5U@MECMUTE7"WPK/ DVR.U!#"]X[[;;:T\GVG5(7Q:2
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M#ZRE$'V$#M69V6M:8NF,Z3(DY=)ND/(E2(4-B.VU(F0%06>FTITN.+;2)/7
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MJ5NR1S4WQ!ZMR^.Z9G^=]!>20;0]'N,:W#A'6EIY-PC^4=87\W8Q.N0GH@)
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M/*;#;+O)D[-N*2O=&W'?M05GX;M;M<];UP6GI2V;9=[%(E+R"7AJHT.V2@M
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M!1W4I1 V7N1ON=]R*SOKUIKE]^UMNN0XQ!>!N.+P<25< #LTQ*<NGF' 1_\
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M2"%;@!+FZN)3L97<M5;ODVAM_P EQZTKM^2,^D+9'@R'&G>C/8DNP_6.X2I
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M'FI##K2FYBHLQB(\TES?IAP.2$'AS*DI(ZH:40FOZO?BW9L6<S,5<PB]3KI
M82B6U;E(?6F:J")B8S:1W<W"FFPYV'-P=N(4H6"-!<#3=;C<DXS 3.N)=,M]
M*"%/=1P/.!6Q^:IU(<(]A6.1]8[UZ[GHUAM[R9_(;CCMOFWA]GH/2'F KK)X
M%OUTGU5G@I2-U GB>.^W:@XV*ZYPL@TPO69R+6Y#9L[4AV7#1-CK6CHM]12"
MI:T):7Q(!2^6BD[\N*=EF V_Q@F[V9Z1"P.Z/7!B=,AO0W9*&$I3'A,S2^%N
MA)4VMI]'%03ZQ((W00NK;L^DF*6'&+ICL&S1FK)=>IY^&M)<3+YMI:7U2HDK
MY-I2@[GYH ]@VKR6;0[",?;<;M^/0XC;A=4M+:3ZZG6@TZM6Y[J6VE*5*.Y(
M2G<]AL%?WCQ#S[UDECAX]C\M-F5?+=;)]WDK9V0N3%;E](-<N?\ D7V=UC?U
ME; $ J'MN^NUYQG/,NLKN+^DXT.7:[?9_)R4-N2Y$I'(I<*U;(2GUSR_S4'8
M*) ,R5H9@ZLCA7_X-P/3$(,^7E]+UVBTC@TH=]N24;H"B"KB>._'M7JR#1[$
M<JEW&3=K%#GO7!MEN2MUONX&5\V5$@C92%=TK'K)V&Q[ 4$??UZAQ=(9.=/V
M64P8LMRVOVMZ0PAQN6W-,%QOJ%?!0#Z5 *225)'J)4HA!@EH\8GIR&W)AX!>
M%)0F(B6U(D-1W8TB3=95K984VZ4J"U28BAZP3Q2K=?$@IJWU:48LO"6L0-EA
MIQIH(#=M0WQ:24.!U*NQWY!Q(7R^=R'+??O7EL^B>%8_%7%MV/0H<5;D5TLM
M((1RCR5RV"$[[#A(=<=  ^>M1.^YH*MOWC-M>.1[3YO$KL9DA4_ST1EQ#BHB
M8<Y<-[CQWZRBMIQ2$I'K)3[BI(/OM_BM1*M\J2_A=RC+<;CFU,>;86J>IZX"
MWMI)Y;-!3ZV]BH_,5R(!!35@W30[![VJ(9V-P))BOR9#?-O?UI#Q?D!7?UDN
M.DK4A6Z5'VBONEZ-8;.M3EMD6"$]"<BF$IA;>Z>B7>MP'?M\IZX([A6Q!! H
M(7BVMEQAZ;YOE.2V60U(L=UE1$VF,II3I""A+;25A7!14I>P42.Q!5Q[@<W/
M/%:C3:39H5^PB[QKG+CO3941F0Q(,>.V\&RM!;4KJJ4"5I0-E$#8A*B$FRK9
MI)B=GQ*?B\2Q06\=N'5\W;2SR9D%P?*%843R*O:HGN223W))Y:_#WIZY$MT9
M6*6U3%O6ZMA):_\ EJPX\%G?=Q+BP%+2OD%'NH&@KQ[Q.W96<+:5A[D;#H4#
M)Y,JX.S8Z7GC:934=2VN;B$(05E:=G2CNM*N24(4I7,5XPV9EJ%V^#-UBF#<
M)5ODVHA 7*4B+&?;6VMT(]12)392KL%>T$I*5&YI^C>'71#;<RP0I+;?I$)0
MXV2-IY4J:DC?NEY2U%:3V)(.W8;>*#H%@-MBJC1\9@M1U.JD*;2E6RG5)0E3
MA];NM26VP5'N0A.Y["@Z>F>?.:@6B?(D6EVR3[?/>MLN$Z\E[@ZV1OQ6GLH$
M%)WV'M/T5+ZYUGL$&P^<\C'1'\Y(7+?X#;FZK;DH_P )V%=&@4I2@4I2@4I2
M@4I2@56S_AKTFER7I$G3'#)$AY9<<==QZ(I:U$[DJ46]R23[3W-632@B.):1
MX3I_+?DXKB%@QJ0^@-O.VBUL15NI!W 46TI) /N-5[??#7"S.RS;'.O<ZUVU
M%YF7:$_: R)+9ENJ??25OM.\%A];JDO,\'$A02E2 %<KPI09ZOG@<TXR"Z95
M.ELNJ<R%YR6\/)02IB0Y(3)6ZATQRZYN\CETWUNM;$IZ?#U:G%F\/^.6+2U[
M XBW8]I?<ZSST6/%B.+<ZH<*N##*&4]TI&R&TC8>S?O5FTH*H1X<L?9M*[>U
M<KFAM5J7:0M98=V;5),GD4+:4A9YG;BM*FRGU5(4"=^;AWA9L6%N0S'R3(9S
M4:3'F]&:[&4AQYEQU;:CQ824@!XH#:"EM*$(2E*=CO=-*"D8_A1L+#-P;7DV
M2/I>;;;@\WHR?1?2FIG,*C\&$[J;D)2L%WJ<M@%\AVKKH\/-N5D]JOTK)\@N
M,Z$Q#:>,MUA8G+BO/O,O/'H@A85*D#9LH1Q<VX>JCC:]*"F<9\+6/8U+M#PO
MM_N*;*8C5I8FOLE$"+&6I345'!I)6V.0!4X5N$(2.?8[_=;_  S6*TY/BE[B
M7N\L.XX%ICL),;9Y*U.*4EQWH]8()<W+;;B&U%""I*B"3<%*"IKSX<+'D&77
M6\7"]WN1;;G<47:5CP>:1!<E(AMPT.;I;#PV;:2>(=XE7<@[) BN/>"'3W'[
M JS(\T]"<4L/=.-"AK?95 F0>BZJ-':Z@#4^0>HK=TJ4"7"!M6@Z4%-_@N8W
M/6Q(R"[7;++DBZ1KH[<+SY9;D@L-AMIAQ+;*&RT-DJ(" 5+0E142!7MP30^#
MA4S$X\"05V;%X$IJ*)'>3)F27 IZ2ZI(0G?8.$[)V4I]9V3Q3O:]*!2E*!2E
M*!2E*!7-R'(;?BMGF7:[2V+?:X;*GY,R2X&VV6TC=2E*/8 #WUTJCFH>$L:B
M8;=<>DRY$!N<STQ*B\>HRH$*2M(4"DE*D@[$$';N"*#B8AK-9\OO M(M]XL=
MT=CF7%AW^W.P7); ("EM)< *N!4CFGY[?41S2GFG?HY7J=8L-RO&,=N3SC=S
MR-;R(*$H)2>D$<BH_O1R=:0/I4XD>^HUC>"9==\RM60YM=K0ZY9(SS$&+8(K
MC+;KCP"77W2ZM:OFH 0VD[)Y+Y*<)3PCVHWA^DZD7_(KY)R*;;IZV(T>S(A.
ME+,8QU"0RZ\@@\E"7NYNDC<-M#?=(V"RL8U)L.71YKMOG-%4*3+BR&G'$I<:
M5&DNQG5*3ON$]1ES91[$#>O?'S&SRVX;C%SA/HF%0C*:E-J#_%02K@0?6V40
MD[;[$@>VL_2O"M+D6ZY.,3;-$O=QAY*W+EHMX<2^]<KJQ-9*^23S#2&"UR5N
M4[@I^:!7/L'@Y=CV21:KC=("D+M6106)#4=UYR$[=!"V>:+RE*Y,^7?2#SW4
M%I(X E*0T6<]QX6Y-P-\M@@*44B5YUOI$@@$<]]MP2.W\(^FO/GVH-OT]@P'
MID:;/DW&6(,*!;8RGY$EXH6X4H2/H;;=622 $MJ)-4-&\*,FZ7"3<;VWBD=<
M@2=K79K4IN#'6N F(VZA"R?7[$E6PV3P2-^.YL?,M-+U>-.L8L,!ZR2UVI$=
MN5 O]O\ -09P:0E(((V6TXA:4N-N))V*2"D[A20F6-:B6C*+7:YC#CD)RX]5
M+$&XH,:65M$AU!97LKD@I4%  [;;[[;&OKPO4_'L^QVSWJT7!AZ+=8[,B.VI
MU(=V=9ZR$*1ONE?3W44^T $[=JJ;'/#[?K)F5BOMPN=@RAQIA#$MV^VMV4_!
M#4V7*;%O6IXEL@2PR%+4I03&942HI(J.0O!VJV80S:+=<;?:KDSCECM2)T*(
MIK:5$$YN9)]78\GV)[J H[G=1*N0]4AH^9EUGMT9<B7<X,5A'#DZ_*0A(YC=
M'<G;UA[/IKFWW5'&,9O%LM5TO4*%<+E*,*-'<>'-3P84_P 5?YGR:"=U[ [I
M&^ZT@YZRGP<3+YBBK+&O-L9;<NLA2>M"</E;=Y81(;#*T+2XGHLMMDMH6VA:
MU.=T[]^A,\+EUCH1>+6]C2LNCWF+=&)5UMZGVN#5A1;.BI0"5J2ET+D)'LW
M[ DD!HRQY-:LE;=<M5RB7)MHA*UQ'TNA)/N)23L:@^=Z_6#3N_3[9=8%X<3;
M;<Q=KC.A0E/QX$1UQY"7GE)[I2/+/J.P.R4$U&-"]++]H_"$"1"LDAVY2"_=
MKM!+B7I+B64I2XL*V )* D-H2$)3N$A/L/8RC0&SZAZEWC(LC7+EVN79K?;$
MVJ/<I<9A[H/S75B2TTXAN0VH2D#INI6/56-MEG<)IB>HMDS1$KT9+0X]%ERX
M;T=2@'4+CR78SI*-]PGJ,K /O W%1MK7RP.96Y8UP+Q'2FYFS"ZO05" 9GN:
MZPW *CLD%0 *BE(.Z@#%,.T)E8)F;62VU5H%S4K)%27/+*0J4;E=F)C)<6D;
MJZ33);[GVD;=A7R-'LIE7Z=!DW2SMXC+REK)G$M-/&<M;+[4AEG<D(0 ^PT5
M'97JA2=O6W 7K2N?9/.^23Z0Z'G-O7\MRZ?OVVY=_9_\_>NA0*4I0*4I0*4I
M0*4I0*4I0*4I0*4I00;6?!']2< EV*,[$:D+D1)C8GL%Z,ZJ/*:D!EY (*FG
M"UTUC?YJU>WV512_"%,E2V)4QW&7FYLYF1<X+5L4F,TVB\,7 L1T$J!0M+;B
M%!0 4IQ2MME%(U=2@R5F7@UG9$+:B+>;?$BQW[T@L&.XE,=F;=')K:F2@I(4
MVE824@I!4A!"T<15B2M @[I%F6*,FV(N=_O%QO"YBXF[;JWKB[+92\!LI?%*
MFVR220$^K[ !>-*#).2^#FZY%DN;7,7V!'3?X5Q2SP8="F7I=M5"Z:N*@%-H
M*N0)W]5#:>&Z4K$Y'ACLPS@WGT78O('*&[P88MZ.\-NQB W%^;MLE\!\#YH(
M!'<;U?M*#-FEOAFNFFV8X9<V9]D,:UVF'"N91!6I^:\Q;DP@I!=*PT?DVSU&
MN!+8Z:DJ^?7VWWPTS[SG%WN*YEB%NES+A<!)]'J]).N2K<N%Y9UWELIA/4*_
M9N>DTG8<=SHZE!0>IWA\D9?I=BF/VI5GB77'VD-Q9,R,I;+:@P6UJ2V-VU@^
MTH=;<0H;CB#LH02_>$"^7C.KED*K[9PJ0I026(+D8J0M#6X+2#T@4K9]O%2U
MAS<K3QXJUO2@H##] ;EC.K+&2K>L+ENB7&\7!N2S;UHNDCT@X72V\]R(*6BK
M@GMW0AOYO'8T1JG?\%C:[:F0,LS'%,2D-WYB8AZ?$<-V5OC\5EL(?&X#"E.J
MY)VWV2Z!_E.2-[51VBW[H7Q"?QM9_P#Y$1J#+F+8E@NJ.:76R8WJOBEWOE\L
M=RLD*-"9?;=6'K6II2B@;-GIJ:Y%7$K<3N2M)1Q5LC!-.'=.[QDJK,S;(=FO
M5^1<?(QV"RF+'3:XT;@VE("0HO1@K_-XK/OJ-:TC_P#"%\/?\;7C_P"1$FN5
MXI_$=?-#,AP>TV6!:9"LA;N#CLF[MSG$,B/Y?8!$-AYTE77/[S8<>Y%%M:&I
M65<H\3NH%J;R:79\(LM[MN"6B'<<J?7=G8RW7'8B)3K<%"V=R&VE<^3W$J!X
M\>0V/#LOC5O&0:V)Q6WVK'YMK7?V;0B W+DIO2HSJ&U"=TND6NDCJ[J)6#\F
ML >PT1H[4S6[!=&_1OPUR>#CGI+J>4\ZHIZW3X<^.P/LZB-__>%0;\-W0K])
MMB_\57V::F?NK]$OXHR3_E@4\;O[E#4W^*%_\R:"\:5#M7L^C:7:;9)ELM/.
M/9K>_-+8'^44A!*$#V#=2MDC<@;D=Q5$V7Q97R[Z16VY1L:M\S4"=E2\,%J:
MN!1;VYWKN)<+^RE%H1TI=/JA2M^( W!H-3TK*-X\6%^L.EUTG2(.(7'-&<CC
MXY!:L>1HFVN4X[Q67''$D.Q^+:9&Z'$!6['( I5V_G+?&5)MV'0\BLUFBS8L
MG3YS,T)D.*20\B3&9,<\21L"^O<@GNCL2*#6%*R'^&7?+ACF:RK5AR)%QQQJ
MRM2H;GF'#!E2GI#,T24,MN.<(RXZP0TA2E =AMM7W7/Q2:BC109Y9,?PF:S!
MO!L]R*+\X^P^IR1'8CO1BVV5)25/GFT^&W$!'S5;C<-(Z@ZCXWI9CRK[E5WC
M62T)<2TJ7*40@+5\U/8'N:K/\-W0K])MB_\ %5]FN)K^N]KP#2E61LV^/?#G
M^.&6U:G5NQDK\^C?IJ6E*BGV?.2#[:T90<C$\LM6<8_"OECFM7*T36P[&F,'
M=#R#^^2?H[5UZH[P1?N4-,OXH1_S*JJK)XY)%\T[U4R-FRV]2\:A^F;)'$@J
M$^WJDOL-N/$$\%_(\E)!V <003OV#8U*QO8?&=E=TP7-)QQ:TW*\6-^W!IRW
M&XB,8\IQ2%R'([L5,OILE"BI2&2%;[(W*%5TKGXI-11HH,\LF/X3-9@W@V>Y
M%%^<?8?4Y(CL1WHQ;;*DI*GSS:?#;B CYJMQN&MJ5F"\^*"]X9K+A6 Y!:[,
M7IJ8<>_RK;,<6F)+F>83$1'#@0IQ)6P@+*D@CJHV!)[<NZ>,B?8,TL$"?CT<
M6&5E&06*Y3V75E<&- DL1FY6WO!7(0ISW)2%*]@)H-9TJO?#]J+)U<T<Q7,I
M<-FWR;U"3*<BL**D-DDC8$]R.U6%0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I
M0*4I0*C5ZU(QC'+FBW77(;3;;@L-%,29/:9=(=66V2$J4"0M:5(3_G*! W(J
M2UDOQ*^&:_:UZN1[B(<65BDB+8H4]MV2$+6S'N<A^4 G_P#0NC8CVDD"@T%?
M-8\&QB-(DWG,L>M,>/,5;G7IMV890W*" LL*4I0 <""%<#ZVQ!VVKPS-?]-;
M=>56B7J#BD6[)<2TJ ]?(R'PL[;)Z97RW/(;#;?N/I%8]NWA'U3^#DMZ=$@Y
M7E+61W&6Q=6KLW$=>C/PH+*'G$/1WFE]14/=UM2 =_F*"2:MY'AMN2<HLURD
MV?'7%P].'\>D/0(K3#)NQ5&*'&F@@<$#I.!) 3Q&P 'N"ZK7KIIU?8<R7:\\
MQBYQ81:3*?B7F,ZA@NK#;06I*R$E:R$IWVY$[#<]JZ=UU,Q6Q-79VY9':+>W
M:%H;N2Y4]IM,)2TA: \5*'3*DJ"@%;;@@^PUB.R^![-L>QF7;VI$6YW.1BMI
M9AS;A)2@6Z=&EQ9<F"H-)'48<7$1P>XJ6G;8[C=2IW-T$U'O^3RM2;KCV.S+
MV_D[=X. 2[H783L=JUF CG)+!07P274DMD)!]H)V2&B+GX@M,;&^TS=-0\4M
MKKK*)#;<N^16E.-JWXK2%. E) W"AV/NKHS-7<)M]OM\^5E]@BP+C)7#A2GK
MHRAN4\A90MMM15LM86DI*02000>XJD+?X=9DFX:*2KCB6(P!CCUP<OL"SQP(
M;;;T5]#3;27 5. ..(WW]X*@$^P5[;O"YJ!C]CCJ:QG%\MDS[1=L>?@7N?TV
MK7YFZS);<QL]!T+26Y" XA(2L]-O;?;L&NY>H^,6]=T1+R&TQ5VIQAFXH>GM
M(,);_'H)>!5\FISFCB%;%7).V^XKU9;FM@P*U>D\DO=MQ^V!8;,VZRVXK 4?
M8"M9"=S[AOWK$F1^"K/FIM\EV>Z19DI]W'+<^]-DGE=;?"CV_K+4._%Y,B E
M:2KOQ4Z-_7[Z=7I^;QI_G%EDX['B.7*;<W6(\JX*N"'UNE9:D$NCY'GR"ND/
M5;WV&X%!.\-SW&]0[8[<<7O]KR.WM/&.N5:9K<II+@ )05MJ("@%).V^^RA]
M-=ZL29IX8=1E:?::6?%C%MTNU8M'MLGR=W=MZ+;>1Y3_ +4/13_A)2EAU.QW
M)Y#V[G:S/$QH?G.HF2VN3A>1+L<:9;7X-V7S'R;C*TRK>ZV@[;GS""A>Q *'
M.^X!!"[Y&?8]$O"[2]>[8U=$.,LK@KF-A]+CP664%!/(%8;<*1MZP0K;?8U_
M+.H6-R++;+PU?[2Y:;FZVQ!GIG-EB6ZXKBVAIS?BXI2O52$DDGL-ZQK;_"GJ
M.K)K=D%^2QD$@Y!:,BG1G+L0.KQN2I[;78)2$+EQ@D  %#/8]N_@Q?P9YU:K
M/@]F? ]#Q6<?5>HR+V[LJ1%N;[LEQL\@4D1EMI24%.W'9.VU!ONH[\86-_!_
MT]Z?M7H+K>7]*>>;\MU.KT>'4WX\NK\GQWWY^K[>U8Z3X:=8F5X<VU<EGT:%
M,LS%9$^@V<IOCLI3W2 *9'5@EF/Q)]4(X[ 5R;QX2M4)%BL=NZ469#C]0IC>
MG7F&H#_PC<N"WN@D=)\NQE-)];NE36_M H-^US[Q?H%@;CN7&9'@M2'VXK2Y
M+J6TK><6$-M@GVJ6M24I'M)( W)K/6O6F>H>;:QX'><:X,8[8YD"9*>9N;C$
MAWA,"Y+):)X<%,=O5XE9W2M12E*321\+&K-YM6*1\D@1+JSC,:QM+B'(''!<
M5Q+C(>D. E(Z:ULO; J]R1N0?5 ;QL.0VW*+>)]HGQ;I 4M;:)4)]+S:E(6I
M"P%))&Z5I4DC?L4D'N*^V[W>'8;;*N-QE,0;?$:6_(E27 VTRVD;J6M1[)2
M"23V %8>A^%#4VR8Q<8=GEBWRI]FN;,QAJ^O,M29#E^;EMM)*2>EU(0=:YI
MXEY6_=2B>G;O#)J7*MMZ3<)#C#:L7R.+9+<F_/.BVS)4GE;V5.<DET,M%2>:
M@0D[; \4D!L6PY1:<H;DKM-RAW),9Q+3ZH<A#P:<*$N!"N)/%7!QM>Q[\5I/
ML(K[9U]@6ZX0H$B9'9G30XJ-%<>2EUX( *RA!.Z@D*!.P.VXW]M8/N&DF=Z&
M-72[62(DZA7?)TBS*;FR'F+DB;!1%>1(2D;(\N]_A)<64@AO8*]QMC5;PR9
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MF7'(;;:;A;H$N?%C3[DM;<**^^E#DE2$%:PVDG=92@%1"0=@"?8*Z-8IT/\
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MCK,H.E"2 5*<3N.8W;)Y$[@$:&KS3Y[-MB.R9+K;$=I"G''75A"$) W))/8
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MDA+8""I/S7"I+?;L5*"/G=J"N(_B4SDPO2#N/8^8'ED7,(;FO]8Q1-,12/\
M)[=17J+"O8CNDA>X57AG>+^^MY1FMMBXO!>:L[\^'#2[-4AQ3T66W&Y/]CLV
MYNM>Z4DH!;!"^1(L+"/$%I;F>G\3(O2-IMS"X$)Z5 ?""Y%$D@ML%(3Z^[I*
M $@[K2H#UA4ILV:Z>9/?VHMMF6BX7J]6YJY<&FD*>EQ.2D(<6>.Y2%,J3ZWS
M2C8[':@J#-O$=E%IQV;;7$8S9;XTW?4R+I.N3D:&?()8]5@J03UG/-(4GEN
M&'%;'V#@V3Q19^QIWZ=79+!,8CV3(+P%/S9"'WH]FDHCOE>S>P=>4XCB >(]
M8DGYE6]G>L^E]BM>7>;DVF]S<7CR[O,M++;;KQ=CH!<Z84.*G4E2$*V.Z%+
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MXA:C.KLD=,&2^6PZRVA$9V,A*WE E(""V@))5VV"1WV%!#M/M;;Y?\^7;+U
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M.Y+<E3!*MB!R2D]E5\6;PM8589;DB(;F"N4S*2T[-6MMLLSFIS2$)/9*4OM
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M1N^W^;Y?MQ]F_K>V@A4[Q?Z=0'[0A<Z46KG;XER:D"*L-H;E-E<9*R0-EN
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MB8PQRZWB&MR<RU9[<FZ3YRH3BH\9@Q1*"EJ2"4CHG?D1Q)!0%%?JU';YX?,
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M:8SC.K%IOC4O(<EN3%GLD3AYB;))#;7):4)W(!]JE)'^\BJL_#=T*_2;8O\
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M3W([585 I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
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M%SA=ECK](P<@MT]#Z(YM4RU.M2RI3"GP0A0V*>FG?EOMN0GYWJT%W4JM=/\
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M6-BI7+OXQX?,9QF[S[KU[G=[C/;F-RY%VF*DK?$IN$V]R*OI1;HP &P2 0
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MT$$$I((.U>RW>'?$K7%##")FW_994I<A2BI4">[/CGO[/\(><40-AL0D )
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M-2D\EN*4$I$]SL25'@C=>W(*M6E!"H&FXAW 7%4Y"IZ[F+H^M$4(0M9BF.I
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MI$-2N05R+(2$$\DI.^WM ->Z\X+8,BD+?NEEMUR>7$>@*=F0VWEF,Z '6-U
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MS6W634'1J[Z>V^ZQG9,&]>DVKE&0EM'-8EEI($7U=OGGYVX.VV]!;WQ7X?\
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MK-^#[HSD.?>A_3WHGR__ &?YKRW5ZLAIG_*<%\=NIR^:=]MNV^]!(_BOP_\
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M!_\ ]7C_ .:=>/\ [E0:FI2E!E^Y?_3(K7_\S)S_ .21K4%9?N7_ -,BM?\
M\S)S_P"21K4% K(/[(SB^H.1X?AZ\8@7:^X9%G..998[#)6S,GQ?D^* $ E2
M.(>!&R@"M"BD\=QKZJOUTE:JP8-FD:6P,:N;[4@JN4/(7G6E/,]@$,J1V"NZ
MB2H]N(V"M]B%%>#1OPZKR.\W/1V5+L]YDQA'F8M<ICX?CH2L*6X&'E*4H[\
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M@./65.0>$HY;E=O>+Z\@^,AJ%UEAY3C9\NATH3P24)V[A7#<^TU^D/Q=VO\
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M&):_R2]_4,_[B@E%*B_QB6O\DO?U#/\ N*?&):_R2]_4,_[B@E%*B_QB6O\
M)+W]0S_N*?&):_R2]_4,_P"XH)12HO\ &):_R2]_4,_[BGQB6O\ )+W]0S_N
M*"44J+_&):_R2]_4,_[BGQB6O\DO?U#/^XH)12HO\8EK_)+W]0S_ +BGQB6O
M\DO?U#/^XH)12HO\8EK_ "2]_4,_[BGQB6O\DO?U#/\ N*"44J+_ !B6O\DO
M?U#/^XI\8EK_ "2]_4,_[B@E%*B_QB6O\DO?U#/^XI\8EK_)+W]0S_N*"456
M$W\3&:_[K]_:952?XQ+7^27OZAG_ '%1>25JT3R]Q;#T?K,WI]")#*FE\%O2
M5H)0L!0W2H'8CWT%H4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@C&(_P#?V9_QJW_8(E?F-K-^QH:N9AJYF=_L
M[U@D6R[7B7<(RG9RVW.F\\MQ(4GIG8@*V/<]P:_3N3I]:9=PES5+N+#\I:7'
MO)W25&2M00E )2VXE._%"1OMOLD5_'Q=6K\JOGU_.^^HLN/SW\+/@VUU\,NI
M3F6L8[B.2%R$Y"5&D7=3*T!2DJYMN=%7!7J 'U3NDJ'OWJ":F?L<NN>I>H.0
MY4];L2M3MXFNS50X4]26FBM1/$?)]_\ ?[SN??7ZA_%U:ORJ^?7\[[ZGQ=6K
M\JOGU_.^^HNL4^ [P/:@^'C5NY99ES]I3#7:'8#3,"2IY:UK=:5N=TI  #9_
M^,5OZHO\75J_*KY]?SOOJ?%U:ORJ^?7\[[ZC*44J+_%U:ORJ^?7\[[ZGQ=6K
M\JOGU_.^^H)12HO\75J_*KY]?SOOJ?%U:ORJ^?7\[[Z@E%*B_P 75J_*KY]?
MSOOJ?%U:ORJ^?7\[[Z@E%*B_Q=6K\JOGU_.^^I\75J_*KY]?SOOJ"44J+_%U
M:ORJ^?7\[[ZGQ=6K\JOGU_.^^H)12HO\75J_*KY]?SOOJ?%U:ORJ^?7\[[Z@
ME%*B_P 75J_*KY]?SOOJ?%U:ORJ^?7\[[Z@E%*B_Q=6K\JOGU_.^^I\75J_*
MKY]?SOOJ"44J+_%U:ORJ^?7\[[ZGQ=6K\JOGU_.^^H)12HO\75J_*KY]?SOO
MJ?%U:ORJ^?7\[[Z@E%*B_P 75J_*KY]?SOOJ?%U:ORJ^?7\[[Z@E%*B_Q=6K
M\JOGU_.^^I\75J_*KY]?SOOJ"44J+_%U:ORJ^?7\[[ZGQ=6K\JOGU_.^^H)1
M2HO\75J_*KY]?SOOJ?%U:ORJ^?7\[[Z@E%*B_P 75J_*KY]?SOOJ?%U:ORJ^
M?7\[[Z@E%*B_Q=6K\JOGU_.^^I\75J_*KY]?SOOJ"44J+_%U:ORJ^?7\[[ZG
MQ=6K\JOGU_.^^H&EWXML4_BF)_4HJ45S[%9(N.6B%;(*5-PH;#<9AM2U+*6T
M)"4@J42I1V [DDGWDUT*",:B_P#<$3^-[9_;F*D]<O(L=AY1;O(S@Z8W4;>V
M8?6RL+;6EQ"@M"DJ20I"3V/NV/8D5R_BZM7Y5?/K^=]]02BE1?XNK5^57SZ_
MG??4^+JU?E5\^OYWWU!**5%_BZM7Y5?/K^=]]3XNK5^57SZ_G??4$HI47^+J
MU?E5\^OYWWU/BZM7Y5?/K^=]]02BE1?XNK5^57SZ_G??4^+JU?E5\^OYWWU!
M**5%_BZM7Y5?/K^=]]3XNK5^57SZ_G??4$HI47^+JU?E5\^OYWWU/BZM7Y5?
M/K^=]]02BE1?XNK5^57SZ_G??4^+JU?E5\^OYWWU!**5%_BZM7Y5?/K^=]]3
MXNK5^57SZ_G??4$HI47^+JU?E5\^OYWWU/BZM7Y5?/K^=]]02BE1?XNK5^57
MSZ_G??4^+JU?E5\^OYWWU!**5%_BZM7Y5?/K^=]]3XNK5^57SZ_G??4$HI47
M^+JU?E5\^OYWWU/BZM7Y5?/K^=]]02BE1?XNK5^57SZ_G??4^+JU?E5\^OYW
MWU!**5%_BZM7Y5?/K^=]]3XNK5^57SZ_G??4$HJ+ZH_BVRO^*9?]2NGQ=6K\
MJOGU_.^^KZ)NEMEN$5V,^]>'H[J"VXT[?)RT+21L4D%[8@CL1[Z"7TI2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@YU[R&VXW&;D72?%MT=:^FEV
M6^EI)402$@J(W.P)V^@'Z*\EKS>P7V2J/:[W;KE(2@N*:B3&W5!((&Y"23MN
M0-_X1]-9._92EV]K1C 7+J ;6G.(!E\DE2>CY>7SW &Y''?L.YJALR<T7S?4
MG3+\%^TSE9Y"R.(_,N-D@S&(T:!ZP=ZX="1MN4;GB4\0M*CL>)+)K])9VH&-
M6J8[$N%_M4"6UMS8DSFFW$[@$;I*MQV(/^XBNE9KY R")YJVS8T^-R*0]%>2
MZC<>T<DDC<5^;.I]WTILGCLUKE:KXQ)R6TMP+8N.(\!R4F,H08Y6XO@1P'$?
M.)VJQ?!+9H]QU\S[,=-L>N>+Z(7&V,L18T]*F6YEP2IH]5EI6YX)2'QN#L.>
MWOV2+,;<OF36K&FVG+K<HEM;=)2A<M]+041[@5$;FON<O,1F J:X^TB&ELO*
MD*< ;" -^7(]MMN^_L[?16&_"5I!C/B\LN3:R:K6I.4WZ]79^)!AS'EKBVN"
MV4]..TV"$]B5 J()( /8J652#P[V-K2;Q2ZF:"0D*G::O6-.06VUW)TRDP X
MIIM^.GGN5-N*D+)"B>R4[[J4M2B->Q\GMDNU*NC,Z*];0A;AF-R$*9XIWY'F
M#ML.)W._;8[^RO-#SFPW&3$CQ+S;I4B6@N1VF9;:E/)!4%% !W4 4+&X_P T
M_0:_,'-L?R;3K5RY>$S',R9M^!9E=XTR/)=>4M^UPGN3CL+ONK=92C9/+9S9
M.Y'7<K5?B/\ "T+/IOB&0:0P&;1G.FB$O6%##)4J9&3W>B+V[N%SUE#EN5+4
MH=NJI5%LQJ"[Y!;;#Y?TC/BP?,+Z;7F7TM]17T)W/<_[J_J\WR!C\3S5RFQH
M$;D$EZ4\EI&Y]@Y*(&YK$VC4F5XZM8[5JK?;4NW::X:TAFQV26>8E7524K??
M40 %AI92D'V$MHV ]>M.>)'3).L>B.8X?Q*Y%TMSB(J>0 ,E&SC&Y/N#K;9/
ML[;]Q[:(L:5*;ALJ==6EMM *E+6=@D#VDGZ*\4/(K?<;:+C%F1Y, A2A*9>2
MMK9)(4>0)'8@@_1M6#,FUWNV2_L;%B3$1U<OR$,X*&=^*W)!<5'6E0*ALM;#
M2U=R "ON![*Z&H&G+5_UHT4\,4UZ0-.;/BZ;S=XT:2IE5W<;ZK:$.*3LH)#K
M 7ZI&_47MQ4E!2&XK'DUJR5MURU7*)<FVB$K7$?2Z$D^XE).QKQSM0,;M4UV
M)/O]K@2VMN;$F<TVXG< C=)5N.Q!_P!Q%8M\6ND&,^$.RXSK)I3:DXM?K+=F
M(DZ'#>6B+=(+A5U([K9)3W(2 H $ D]RE!3(OV1O0_!6_#_J#J'\&H)S7_L_
M_MOBKS'_ *5&8]N__P K]3_=VH-7L:@8W+9D/1;_ &N4U&1U'W&9S2DM)_SE
M$*V _P!]>A[,+-'%NZMT@M^D=O)<Y*!YG?;;I]_7WY)VVWWY#;VBLC:IZ'8-
MIIX(\UO.+XW"LMRNF)L>=DQDD+D;I;6>6Y(^<2?954:T:9/:Q8EX-,1BS'+?
M<)V%W%R%*:<*"U*9L\-]A6X[@!UILDCN #19-?H[<;O#M/EO-R68WF7DQV>L
MZE'4=5\U"=SW4=CL!W.U?%VO$.Q0URY\EB%$1MS?DNI;;3N0!NI1 &Y('^\U
MAC--87=;-(?#G>[BV(N2P]6K):[]"X\%1KBP7T/)*?WO([.!/N2XD5U[5B%M
M\6?BXU1M^=-.WC#M.TPH-IQYV0XB-YE]#A<D.(0H!Q6[3FQ/;BI((]7L1LZS
M7R!D$3S5MFQI\;D4AZ*\EU&X]HY))&XK[;E<HUIB.2I;[,:,V.3CS[@;0@?2
M5'L!6$O#Q=/#ZSXG[=)T8U)D6UN\0'XK^"1[1/1$G/H0MTO]5Y(0WQ0@GCM^
M\V21R*3H;QN_N4-3?XH7_P R:"V'LPLT<6[JW2"WZ1V\ESDH'F=]MNGW]??D
MG;;??D-O:*]MQN\.T^6\W)9C>9>3'9ZSJ4=1U7S4)W/=1V.P'<[5^<6M&F3V
ML6)>#3$8LQRWW"=A=Q<A2FG"@M2F;/#?85N.X =:;)([@ U-<TUA=ULTA\.=
M[N+8BY+#U:LEKOT+CP5&N+!?0\DI_>\CLX$^Y+B11;,;@OF36K&FVG+K<H=M
M;=)2A<M]+041[@5$;FOB1D]LB6E-T>G16;:4(<$QR0A+/%6W$\R=MCR&QW[[
MC;VU^>NN%EMFF_B:SC+]<M-\@U(P6ZM1QC]WM[:I42TLH;^5;6US2EL^IN2I
M23LVM0"N:C5P^$O3C1K/]-<XLF'9$[FNFMUGL/KQ"[(4$V9T'J]/9?RI2I0;
M(4HE)+.Z2KUB19C2_P :&'?G78_K%G[5>F?G>/6AQMNX7VV6]QQL.MHDS&VU
M+0=]E $C<'8]Q]!K"6EOAHTPO?CAUIQ&;AEM?QNS6VV/6^VJ2KI1UN1V%+4@
M;[@E2E'V^TFO'XJV-/\ '_'%A<?.<;=R#$X^!H93:H<)<I0*9,L-<6T'?9.W
MM)[47'Z!V/)K5DK;KEJN4.Y-M$)6N)(2Z$D^XE).QK[;7?8%Y7*;A3(TIR*X
M6GT,/)<+2QN"E6Q]4C8]CW[5^?7AOAXSFOBTL67Z#8M<\;TUA6B1%R>8ZRJ/
M#G.*2YTFVTJ)YK2YT5$)V^821[U6SX$_QD^)C_YH4[^N>HEF-60+Y NDN9%B
MS8TB3#4$R&67DK6R3OL%I!W23L?;]!KRS<PLUMN4>WR[I!BSY''HQ7I*$.N<
MB4IXI)W.Y! V]I[>VL*XGG\O2S4+QOY9;TI5<;4N"_%ZB>2$O=.6EM2@>Q2%
M%)(]X!'OJ9Z->!K3+4S0"S7W+[>]D699E:6KS<,FF2'?.IDRFP]R00L <"X!
MMMLKCZP.Y%$:\O646?&^CZ6NT&U];ETO.24,\]MM^/(C?;<;[?2*\,343&+A
M+9BP\BM$N2\KBVRS/:6M9^@)"MR:J['?"9C$W3'$<5U,+&J<W&F76(EXN\8M
MN<'% D<0XK;9*6T=U$[-IW).Y.??V,W0[!;]HE9<ZG8U!DY=$N\KH79Q!+S?
M!0"=CO[@2!_OH-RVN^P+RN4W"FQI3D5PM/H8>2X6EC<%*MCZI&Q['OVKS/Y=
M9XMW;M;UT@M7)S;IPURD)>7O[-D$[G?W=N]?GKC>IMUT>TV\9^6V(I1=X6<R
MF8KJMOD7'YJHX=&X(*D=7F 1L2D ]JN;33P!Z39%HS:FLFL;MXR6\V]J=<\C
M>F.JG.S'D!:W4.%7J[+.X3L0=O6"MU<BV8U=>;Y Q^)YJXS8T"-R"2]*>2TC
M<^P<E$#<U\2+Y"BVY4]Z4PS"2CJ&2ZZ$MA'^=R/;;V=Z_-*XY?>M6? H+#F4
MMRZS;!J'&Q)^Y+<)>F,MNMD+4KV\@E_@#W)" 22HFII-RFXXYX/M<=%\FD*>
MR73V(J%&?>.RIMJ<4DPGD_3LCY/8?-"&P3NJA9C>TS(K?;K:;C*F1XT !*C*
M>>2AK91 2>1('<D ?3O7V6:^0,@B>:MLV-/C<BD/17DNHW'M'))(W%8$\1V)
M7(9#HUF.3X7>M2]'[7C3+,^P6<E9BRRC_P!)6SN.>Z5-@ D)^3()&^RI3X/I
M&B-_U=NM\T>O]QQ62];>%UT]FL+:"EA9_P (V<*AR0>*3TEJ"=N^P4 2-PTI
M2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I
M2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I
M2@4I2@4I2@4I2@4I2@SYXT-&\CUJPS"+;C+<9R3:LMA7B2)3X:2([3;R5D$^
MT[N)[?[ZT%M7S2@SI@6BN06+Q;ZN9_<HT56+Y1;X$6$ Z%N.%IAEMP+;V[#=
M"O\ >-OIKC:'Z$91X?-=LPC8W'C/:-Y,1<V8:)(0JS32GUTH9V *%<>("?8G
MH^W@36I*4&.L;T6U@\,V1Y3%TC@XUE&GM\G+N4:QWJ6Y%D6>0O;FAI2=TEG8
M #N5=D^S8J7(=(=#<ZT^FZA:JY.;/E&M&2QNDQ"ANN-6Z&R@#I16G'!S""I+
M963OV:2!N05*U)2@PE;_   2<ET5R>5F4Y#VMM\GJOHR%M06J!+0HEEAIT#D
M&C[%;;;<@1_DT;:OT-7FBM-;.WJ%#B1<N8:#$U4)\/-2"GL'@H>PK&Q(]Q)V
M[;5/J4&?/ SHWDFA&@\;%,J:C,W=J?(D*3%?#R."R"GUA[^U:#I2@P]C7@TR
M:U^*7TQ)<MITC@9#+S*WPD* =])/--I""UL0GIN(!3MMV1OOW"1:WB0\/>0Y
M9FF(:FZ;W"W6O4O& XRSZ52L0[E#7ORC/EL<]AR64[?_ "Q8.VX4G1=*#'62
M:+:P>)G(\6BZN0<:Q?3VQSD7*38[++<E2+Q(1OP0ZI6R0SL2#W"NZO;N%(MS
MQCZ7WW6CPYY9AF--L.WNY^4\NF2Z&F_DY;+JMU'V>JVK_CM5TTH*2U@TRON:
M^%6[X#;&F%9!)L#-N:2X[Q:+R4(!W7M[-TGO4,LVA&5P\H\*UP=8BB/IW89E
MOONT@$H==MC$9'3'[\=1M7?Z.]:@I08DU<\)F;S_ !)X_DV%^0.#3,ILV5WZ
M'(?Z:V9L-QQ*W64^P\VG5E6W=2]M_FC:=:C:$Z@8!K=<]6M('[1<)^0168>0
M8Q?G'&6)1;"4HD,N([)6$I V4  "X=R5\:U#2@R+@NB&L&=>)#%]6]3W<:QZ
M/C$>5&MM@L9=DN.)>9<:5U'5=AMU.04"K?;;BGVU=7B;P2ZZGZ#YGB=C0TY=
M[M 5&C)?<Z:"LD'UE>X=O;5H4H,OV;0C*X>4>%:X.L11'T[L,RWWW:0"4.NV
MQB,CIC]^.HVKO]'>H)JYX3,WG^)/'\FPOR!P:9E-FRN_0Y#_ $ULS8;CB5NL
MI]AYM.K*MNZE[;_-&VVZ4&5L@Q/Q$:=:J95?,*N-GU!P[('DR&[)DT]UEZTN
M '=#!'J):]GL]OO2""M72\,'AUR3!<_SK4K-G+)!RG+.BE5DQEHI@0FD)3[5
M* *G21ZVWJ[\CNKEVTO2@SQISH[DF,>+[5G46:S&&.9+ M\>WJ0^%.J6RPRA
M?) ^:-T*V/\ NKYONCV27#QMX[J>TS&^"L'$EV=YPOCK"0I]]8 1MW3LXGOO
M[:T-2@RU%T"R72?Q7.9YI]%B'!LMCI8RJS^82P&904>,MM'$!1[\MO;NI[O\
MH*XC.D&LFA.K.?Y%I?#QO*<6S2>;M(M-YE+BR84U1*G5A8!"D$J5L.7;D $)
M"=U; I09<T)\*MS;QO56;JM)M]RR/4]PKO,&SA0B0FN+H;::4KUN: ZH\^Y!
M"?644\U1&QZ>^)[2? %Z:XFYAE]M$9E4"RY;-D.QY<&,I12@NL[$*<;3W'$+
M2-D[]38@[1I05YH'I[==+-*['C5\R.;EEXAM'S=WGO..N/N*4I1 *R2$)W"$
MC?LE(]E5_P"!G1O)-"-!XV*94U&9N[4^1(4F*^'D<%D%/K#W]JT'2@R;IIX3
MIMQMGB(Q[.V8Z;%J#D<NX0U17DNN)9<<6MIW;;9+B%%"P#OZR17(QO$_%3@&
M"-Z>6AO!KU'A1S;K9F4J;(;=:C;<6UNL[$EU*>VX"@"$[\]B5;)I08^O/@ZF
M8AX8\=TZQ-QJZWAC)(5]NUQEN!HS'DO!;[I)W]B4I0D$D\4)!)()/]>-WPO9
M=JG+M^1Z;JB(R*5;G\=O3$MT--S;<YZZ>2O>IMU(4/X2GW)V.OZ4&6,VTSUP
MQ3(,+RK37(8%P;MUC8M-WPN_27$P7U)X!3S)3ZO4[=E'8IX'8J"RV>?I_H#J
M+FOB3L^LFID+&L8EV&$Y#MUJQPE]^2IQIQI3DM]2?6"4NKXA)[;C<#B>>MZ4
M"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4
M"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4%*P/&?HG=+A'A1-2K Y(
MD+"$!R5TT[D[#=2@ /\ B15IV[++5=<@NMCC36G;O:FV'9L-)]=A#W/I*4/H
M5TU[?^Z:PWI)$U6U1\&&/:>VS3S'$V"\V/T>SDEVR#J);;6HCKF(F.5!Q/=2
M %GBM*%=]MJZ6I>;WO0_/-6TXZ_)D7AZ+A-@8GH8;DR&NJJ8TIY#3JDMN.\0
MKBE:@CFH%1V!!#=-*R+I;F^?8W/S)F]*SFTX-"QF3=&LEU,ML1V1;9C1];_T
M-8Z[1;67"VKBH>7(!]?>HOI1J1FT37/3.$JZ:D7#&\K$QNX2\[AP(T2:M,)V
M2TY 89 =8!+95Q5[$K"2-P*#<5*PI=-5,ZP3+9%_SS)<YL4=N\N 7BSVB'=\
M)%N3*"$H<#0#[1*5!!6M0<2K<[G8IKFQ-;]6<T])YKC-NU%NETCWB3'M]D@6
MVW*QA<2/*4WY9U2UB2IQ24*Y/@!06O9*>*1N&[,AO\#%K)<+Q=)*(=L@1W)<
MJ2Z=D---I*EK/\ 2"3_ *^^V7)B[PF)<5Q+T9]M+S3J3NE:%#=*A_ 00:KWQ
M.?N;]5?U4NO]C=JEL#B9IIIJ!H:W(U!N636C-8$B'<;1<8C"(T535M,EE<0-
MI26@GI<"%%PJ"B5$J[T&M:5@*-K!FB,MP3)+-D^?9-:;WE<*W3+U<;5#M^+S
M(4B4E@B%&[R$]E@(4I1)X*62H'>K.N>HV20KI?\ 2L7UQ66S,WCP[=*\S_A#
M-ED)\^MQ/J\B&X[,Q@%7?DV#S[B@U?2L-Y]JOJ/F6I6H[6-C41E>*W VJS1L
M.MMMD6WK)CMK4Y/,A8=>*UK_ ,FD)2A"1Q*E%5:>",DSW1)HN\\1S*[6!*U)
M;6I)MD]R.#MOW)Z3I^@[\-B#N00L:E9(T\\0-[U-N.)W.*[(3$QG"Y5]RN&T
MH!$FYDJC(B.$#9O9R+-< ]I 0>(KEX[E^>8WA^CVJ4_4";?GL]O-JA73')#<
M9%L99N'9"(B4M!QMQCF@[EQ17TU\M]S0;+I6859]DBM(/%%<C>9/G\;N=[9L
M\C?UH26K5'>:"/\ W7%*4/X37FTM5ENI>M]U8F9Y>H%BQ^Q8U=?14(-!,V2^
MR^I?56I!4&E=)7-"=BLJ2>0X[$-0RI3<-E3KJTMMH!4I:SL$@>TD_17/Q?*;
M7FEDBWFR3F+G:I:.I'F1E\VG4[D;I/O&X/>N;J-IW:]4L;=Q^^*DJLTA0\Y$
MC/J9$MOWLN*00KIJ[<D@CD!L=TD@T]X4,9:S'P78!9I$N9!CS+(EEUZWOJ8?
M""I7((<3ZR"1N.22" 3L0=B O#&<OM&8QYDBS7"/<F(DIR$\Y&<"TH>;.SC9
M([<DGL1[J[-9K\)C%MTQTGU&CVZW2#9[!F&0MQK=;VE/O=!B4X$--(&ZG%<4
MA*4]U$[#N37DS[7JZZD7+!L1QAC*-.%9/>7K=,N]\LZH$QN,U$<D."*F0V4E
M:^F&PYLK@2=AN00%XWO5C%,<^$7I.]187P=CLR[MU5D>39=Y=):^W8*Z:]C_
M .R:EU8'R.1E6D2_%?(8S6=>;Y9L>Q]4"^24M(G-HXRR@.EM*4%:02.82.0(
M)&Y-3[)[GG&J$G6>_P!KU%GX2S@4QZVVFUVY$<QW5,PVGW7YI6V5N!PN<4A*
MDA 3VW.Y(:5N.HN.VB[W"V3KO#A3;?;?3$Q$ET-ICP^2T]=:CV2@%MP%1/;B
M=]MJ[=LN3%WA,2XKB7HS[:7FG4G=*T*&Z5#^ @@UA3*<MR?4#1_)+;<\GN:(
M[^@5OR-\L+0%/3%)D+>4K=)!#P:#;G;NA2@"D[$:CTN:<TU\/-GD.3[AD:K=
M8A.ZUS>27W1TB\&RM*   #P3ZO9*4[[G<D+2I65](&<VG8WIWJG?-7NJYE7E
M'9^/71+#-I4W+0DMQ(:4I"T2$**$H)6M2U)(.Y434+M&I6>(T7QG7UW.YDEV
M\72*F5AI$;T0(,B>F-Y9G9D.AYM*TJZQ63NVK<$$B@VY7)^%-K.0*L8G1U7A
M$435P$N@OH8*BA+I1[0@J!2%'L2E6V^QK+.76W.LZU$U\-OU1OV*P</\F[:(
M%L984TEU5K9D*+O40HK05;^HDH^<HDG<;1/"UWO+-85:CR,HNT6\3=&[;D;L
M*(MM$/K.MR4EH(X%0:2X"\D<N0<4HE1'J@-T5R,LRRU8/C\V^7R:U;;1";+L
MF8^=D,H'[Y1^CO61,:NF>-X!HK!>U+O3UZU7;C.W&]/IC@VR,W;EREM0FRT4
MH=='!LNKYDJ!6 "H<>?K#D%_MVC/B8TXO.0R,LC8M9[?*@7>Y!KSQ:EH62R^
M6D(2HH4P2%\=R'!O[*#<5*K[Q!W>=CNA.HMWMDIR%<[?C=RE1)+1V4R\B*XM
M"Q_"%)!'^ZJ/PQ.=8#J5HJ[<-1[MET'/8LIJ[VV[QV PRZBWJEH=B]-*2T I
MOB4J+FX4=SOL:#6-*R)C>IV62_"UH-D3U^E.7N]Y)88EQFJ/KR6GIP0ZA9]X
M4@[&HUGN3ZAP\1U[S^#J/=X'P$R=YJT61J/'5#4EMB(XM#_-"EK0H/$!*5(X
MG=7??8!M:YW)BT0GY<IQ+,9AM3SKJCLE"$C=2C_  ":^C'K_  ,ILEOO%KDH
MF6R?';EQ9+1W0ZTXD*0L?P%)!'\!K,,YG+L!U)R;"[KG=TS.V773RY7Y\W=A
MA'0FM/-M$QPTA/394E]6S1*N/%/K';O#=+I69:3:/>'_ "L9_-OD'('[#CTC
M')34=,!J'):2TT&.+?42\SNA145GGP4"-J#<-*P#IKK?JUGL/'-0+/;M1+M,
MN]P0J1:/1MN&+^CU2"AUEI:5>80MML$A\[J*V]E(XJ(%[8-"R7-/$YJB9F;W
MB/C>*7&W(@X[$#2(SI>MK+CG644%:D<EE00DI];<DJ[ !HBE9_U^3DV0ZVZ4
M8=9<SNN'6N\P;X]<GK0EHONA@0RV$%U*TH4"XH<BE6P4K8;D$4/==6-4LIO^
M>S\51J+,NF,7Z;9;+$LENMTFP/>47TN$XNK2^ZMXI4I:TE);ZH* > W#?%*R
M'K3F639'F2[/:+KJ*FZ1[/%E.8OI["AH]&2'@X4&=.D[A064E*4H">(;4H@G
MN.?I]J;FVOENT;Q>3ELK%';[B4C)+W>;(VPU.FN,O-,(::*VUH:W4LNK*4]P
M"D<$[@AK3'LLM64NW9NV36ICEJFJM\U+2M^A(2E*RVK^$)<0?_A"NQ6$\)OV
M4:681J9E;^2N71>+ZLJ=R":RTAKTC;C&A1Y'-M(#84E#B72!Q 4R=B/96C=!
M<GNVH%^U'RA^<Z[CCM\5:+%%WY,I8AIZ+S[:O8KJR.OW';9M(W.W8+?KD99E
MEJP?'YM\ODUJVVB$V79,Q\[(90/WRC]'>LD:B:CZ@M3=0M,L:OTOX=IR<S;3
M-6T5EJUN6]RXMH[)42CJQG8@]4=EH3N22:Y.LNH\G6G0W7W*K=<G7,+AX[;[
M;;HC:P6525L-S9#I[DJ4$RX[?+U1ZA&QVWH-R4K(N?Y%G?AISAN7*SRX:@PK
MIAU^O,FWWR,RTVU,MK+;X5'Z*4])MSJ\.GZVP'=2SL1P]$L]U3G9;@UU\OJ/
M?[9?> R!>3VRVLVAMIQ@J1*@JCJ+C(2X4[(5R"T+.Y24@T&UJ5A.V7K4BVZ%
MP-9%:H7J;/B90J%\'Y3#*K:]"5>EP"TXD)#BE[.%0<Y]@E"0!Q"ZU%XBG;_!
MT@R&ZXM)=BY!:61=(O17Q4]Y=:7G&.Z5 AU#:VME)(^4'LV! 652LH97XA;B
M[8-8-2\4FM7'&,4Q^+&L[75ZD:3<'F1*<>6$]CP1(AIX@[]G!NG>O=&:S#2W
M5+3G'9VI-VS*%G[-QBSU7 14+ARFH9DB5!Z3*."-T+3TU<D@+2>Y2*"]4:IX
MN[!M$QN]P7HEWN*K3 ?9>"VY,I)="F4*'8J!8>!'TMD5+*PGH6+WIWH]H\NW
MY7>I360ZFR[?+8FO-K0(Z7;J%-HXH20'%LH=7N3NLDC8; +9>M2+;H7 UD5J
MA>IL^)E"H7P?E,,JMKT)5Z7 +3B0D.*7LX5!SGV"4) '$+H-V4K(N3W/.-4)
M.L]_M>HL_"6<"F/6VTVNW(CF.ZIF&T^Z_-*VRMP.%SBD)4D(">VYW)OGP^7>
M=D6A.G5WN<IR;<[AC=ME2Y+IW4\\N*VM:S_"5*)/^^@E6)Y9:LXQ^%?+'-:N
M5HFMAV-,8.Z'D']\D_1VKKU^?6BLO,M)_"AIMJ9%U FW"*V]!@+Q-QN.FV.0
M'IR8RF4?)=4/I+G4ZW,[%)3Q*1M5CVS5#*Y-QM>D1O<HYI'SMZ!,N)4/,FQ,
M 7$/$^WUX[L:-R/?DX>ZCMS#4^699:L'Q^;?+Y-:MMHA-EV3,?.R&4#]\H_1
MWKKU1WC=_<H:F_Q0O_F342OF.9GJSX@=3L9@:G7_  NSV*TVB1"9LR&21*D(
ME#FI3B5'ICIDJ;3Q*R4GDG@-PT5<LEMEJNUMM4F=&:N=Q#JHD-QT!Y]+20IU
M2$>TI0%)Y'V#DG?YPWZE8:PN1>]9]2?"QFUZR:ZPKI<L;NDN4Q:U-,QW7(ZX
MJE[H*%;!_F$N@$;I0@)X;'?C::ZWZM9[#QS4"SV[42[3+O<$*D6CT;;AB_H]
M4@H=9:6E7F$+;;!(?.ZBMO92.*B &_J5CJ;<<TGV#Q(YDK4"]QVL,E7R)9+-
M%Z2(S2D6IMU+CBBDK7Q4XE2$\DA*DD^MRV'4PQ.=8#J5HJ[<-1[MET'/8LIJ
M[VV[QV PRZBWJEH=B]-*2T IOB4J+FX4=SOL:#6-<NV9-;+O=;G;(DZ/(N-L
M+:9T5ET+7%4XGFA+@'S5%.R@#WXJ2?803A7376_5K/8>.:@6>W:B7:9=[@A4
MBT>C;<,7]'JD%#K+2TJ\PA;;8)#YW45M[*1Q40+FT#PI^V^*+Q W)>27F<VF
MXP6_(2W6U1SUH,=\*XI0#NT/DF_6[-]CR/K4&F*5G3)5Y-JQKYE.$P,WNN#6
M7%+3;YR38A'\U.ERB]LMQ;S2_D6T,@=-(&ZE[E7S0FN;5J3G6L.,: 1D9A(Q
M>X9+=+U:[U<[$VV3*1":EH4XV%I*$*<\L5)/$AM2P0#P (:SSC.K%IOC4O(<
MEN3%GLD3AYB;))#;7):4)W(!]JE)'^\BJQB>-+1*X2V(L74:S29+[B6FFFW%
MDK6H@)2/5]I)JW;':C9+3#@F9(N!CL(9,J8H+?>XIVYN* ')1VW)V'<FJ=T6
M_="^(3^-K/\ _(B-07C7'M&6VF^WB\VJ#.:D7&SN--3XR#NJ,MQL.(2KZ"4*
M2K_<:PU$UOU9S3TGFN,V[46Z72/>),>WV2!;;<K&%Q(\I3?EG5+6)*G%)0KD
M^ %!:]DIXI&_5U6U-ONFVINKK>.F>W<,CSC';$7K1'9D3FFW+*AU9C-O$-J>
M4&2VGF=AU.7<I H-T4K&MGSC4NP:8:THEQ\XC6:UXE*NF/WW-X\1FZ1IB8[Y
M6URBDH>2%!MQ"E!*D^LDA0"2.OCURSK3ZZ:-9)/S^?F:<]EM6Z[664AA,-D/
M0G'VWH26VPM :Z0"BM3A6%;J()Y -.8GEEJSC'X5\L<UJY6B:V'8TQ@[H>0?
MWR3]':NO6 =$(V::<Z#Z 9E U!N4B)=+Q:[%(QE^*P+:(,N262E(2D.=5//G
MU5.*)4 -@GU:F>19?GF28?K#JE U FV%[ KS=85KQR.W&7;'F;?V6B6E31<<
M<?X+.X<24=1'';84&RZ5DZ)&S/7S5W.;? U(O^!6>#CUBN4*'9@RLMRI;$E6
MZEN()+:>!Y(3P*SQ/)/$;U^]XA\ZU!Q71NU*7E*9&18R_?KS(T_B0U724MMU
M#*$(\RH-LM[DK6I ))XI"4(*C0;QI5/^&&_YM?L%N2<ZMUVA3H5T>BP'[]%9
MC3IL()0IEY]MDEM+GKJ;)0=E=+EL"HBK@H%*4H%*4H%*4H%*4H%*4H%*4H%*
M4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H(UIQI]:=*\)M&*V)+J+1:V!'C)?7S6
M$ D]U>\]SWK@9!H)AV5S<QD7BWJN2<MBPH=T8>=4&UHBE:F"CB0I"TJ<*@M)
M"@0D@@@58E*"H\,\,&%X<Q?$N&[9,_>H*K5-EY-=)%Q>7"(V,8%Q9X-D$[A(
M&_;??8;<[$/"+@^%Y78<DB2LAG7FPK4+5(NU[D3?),%EQE49I+JE!+10X1Q
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M;I21<5*"):9:7V+27'/0M@:?3&4ZJ2^_,D.2)$E]7SW777%%2UJ.VY)[;
M  2VE*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2
ME*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2
ME*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2
ME*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2
ME*!2E*!2E*!2E*!2E*!2E*!2E*#$V4:!8)K[XY<_MV=V/TY$@8Q;7XS?G)$?
MIK*U G=EQ!/;W'<58?[7!X=_T?'ZZN/]XK^<$_=\ZG_JE:_ZQ5:8H,T_M<'A
MW_1\?KJX_P!XI^UP>'?]'Q^NKC_>*TM2@S3^UP>'?]'Q^NKC_>*?M<'AW_1\
M?KJX_P!XK2U*#-/[7!X=_P!'Q^NKC_>*?M<'AW_1\?KJX_WBM+4H,T_M<'AW
M_1\?KJX_WBG[7!X=_P!'Q^NKC_>*TM2@S3^UP>'?]'Q^NKC_ 'BG[7!X=_T?
M'ZZN/]XK2U*#-/[7!X=_T?'ZZN/]XI^UP>'?]'Q^NKC_ 'BM+4H,T_M<'AW_
M $?'ZZN/]XI^UP>'?]'Q^NKC_>*TM2@S3^UP>'?]'Q^NKC_>*?M<'AW_ $?'
MZZN/]XK2U*#-/[7!X=_T?'ZZN/\ >*?M<'AW_1\?KJX_WBM+4H,T_M<'AW_1
M\?KJX_WBG[7!X=_T?'ZZN/\ >*TM2@S3^UP>'?\ 1\?KJX_WBG[7!X=_T?'Z
MZN/]XK2U*#-/[7!X=_T?'ZZN/]XI^UP>'?\ 1\?KJX_WBM+4H,T_M<'AW_1\
M?KJX_P!XKA^!["[-ISG>O>,X]#]'V2V9.U'B1>JMWIH$<';DM2E'VGN236LJ
MS1X5/QS^)#];6_[.F@TO2E*!63?'#A=FU&SO03&<AA^D+)<\G=CRXO56UU$&
M.3MR0I*A[!W!!K659H\5?XY_#?\ K:Y_9U4'S^UP>'?]'Q^NKC_>*?M<'AW_
M $?'ZZN/]XK2U*#-/[7!X=_T?'ZZN/\ >*?M<'AW_1\?KJX_WBM+4H,T_M<'
MAW_1\?KJX_WBG[7!X=_T?'ZZN/\ >*TM2@S3^UP>'?\ 1\?KJX_WBG[7!X=_
MT?'ZZN/]XK2U*#-/[7!X=_T?'ZZN/]XI^UP>'?\ 1\?KJX_WBM+4H,T_M<'A
MW_1\?KJX_P!XI^UP>'?]'Q^NKC_>*TM2@S3^UP>'?]'Q^NKC_>*?M<'AW_1\
M?KJX_P!XK2U*#-/[7!X=_P!'Q^NKC_>*?M<'AW_1\?KJX_WBM+4H,T_M<'AW
M_1\?KJX_WBG[7!X=_P!'Q^NKC_>*TM2@S3^UP>'?]'Q^NKC_ 'BG[7!X=_T?
M'ZZN/]XK2U*#-/[7!X=_T?'ZZN/]XI^UP>'?]'Q^NKC_ 'BM+4H,T_M<'AW_
M $?'ZZN/]XI^UP>'?]'Q^NKC_>*TM2@S3^UP>'?]'Q^NKC_>*?M<'AW_ $?'
MZZN/]XK2U*#$V+Z!8)H%XY< MV"6/T'$GXQ<GY+?G)$CJ+"T@'=YQ9';W#85
MMFLSYW^[YTP_5*Z?UB:TQ0*4I04=XW?W*&IO\4+_ .9-1_3WP7Z)7/ \<F2]
M.;-(DR+;&>=<<;42M:FDE2CZWM)-2#QN_N4-3?XH7_S)JRM+OQ:XG_%,3^I1
M05K^!%H5^C*Q?^$K[5/P(M"OT96+_P )7VJO&E!1WX$6A7Z,K%_X2OM4_ BT
M*_1E8O\ PE?:J\:4%'?@1:%?HRL7_A*^U3\"+0K]&5B_\)7VJO&E!1WX$6A7
MZ,K%_P"$K[5/P(M"OT96+_PE?:J\:4%'?@1:%?HRL7_A*^U3\"+0K]&5B_\
M"5]JKQI04=^!%H5^C*Q?^$K[5/P(M"OT96+_ ,)7VJO&E!1WX$6A7Z,K%_X2
MOM4_ BT*_1E8O_"5]JKQI04=^!%H5^C*Q?\ A*^U3\"+0K]&5B_\)7VJN:XW
M6):6@[,DLQ&O_EC[@0G_ .,_[ZX;>IF+NNAL7N(%'MZSFPW^C<]J"M?P(M"O
MT96+_P )7VJ?@1:%?HRL7_A*^U5T0;C&N3/5BOMR&O<MI84D_P#$5Z:"COP(
MM"OT96+_ ,)7VJ?@1:%?HRL7_A*^U5XTH*._ BT*_1E8O_"5]JGX$6A7Z,K%
M_P"$K[57C2@H[\"+0K]&5B_\)7VJ?@1:%?HRL7_A*^U5XTH*._ BT*_1E8O_
M  E?:JC?&!X:-+]+-.;!?<4PJUV*[IRBU,)EQ&U!80J0GDG<D]CM6XZS1X__
M ,3%A_6VS_V@4&EZ4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I09GP3]WSJ?
M^J5K_K%5IBLSX)^[YU/_ %2M?]8JM,4"E*4"E*4"E*4"E*4'(RS++5@^/S;Y
M?)K5MM$)LNR9CYV0R@?OE'Z.]5,CQM:&NNH;1J98BI9X@EY20#_"2G8#^$U(
M_$U:%7[P]:E0&XJ9K[V-7(,L*0%<W1&<+>P/O"@DCZ" :Q6NUV;"O![H5?<?
MTJTXR;-LLNEMQ[K9-CK#J75/(>2A:UH"%%94TV"M2CN"HJW-%D;5_";T?_2K
MA/\ *.'][78M.M6 7Z()5NSC&Y\4DI#T6[QW4$CVC=*R-Q6,7/#GJ)=8T<WC
MPS:,/36PH*=M<DP&U GM\FC?OML-RH^_V;[5$\B\-^;RA+M_X'V%36"V0B7:
M\I3%]?CNA05YA#FR5[<D^KR 4G<!7*A)K66O'C6TTT$L*)=PN[-]NDD$0[19
MGD/O/$;=U*!XMI'($E1&X!XA9&U8:R']EYU"?GE>/X7C5MA'?Y&YJD3'/;V]
M=#C(_P#V:A5J\,/BSTQQ86ZVXC)B6@/%XQ83]LDE3RAMU"E*U+4K8;<COL !
MOL *[#E@\8;T%<-W!/,1EMEE;<C#[*Z%H(V*5<HYY;CL=]]_?O1J2)MIM^RZ
MW]F[M-Y[A=MDVQQ9#DC'%N,O,H.VQ#;SBTK(];L5H'K#N-O6_0_2#6G$==<2
M;R/#KLW=+>2&W4@%+L=SB%%MU![I4 H?P'?<$C8U^16C6=R\Z;U+Q7+,.PEU
MR%B-_FHDLXE;HDR+)8AN%'!QAE 2I"QON.X/O]@JK_#?XB<B\-VHL/(;*^MV
MVNK0W=K45[-SXP.ZD?P. $E"]MTD^])4"+/X_?ZE<+!\TM.HF)VG)+%)3,M%
MTBMRXKZ=QR;6D$;@]TJ'L*3W!!!V(KNT8*4I0*4I0*4I0*S1X5/QS^)#];6_
M[.FM+UFCPJ?CG\2'ZVM_V=-!I>E*4"LT>*O\<_AO_6US^SJK2]9H\5?XY_#?
M^MKG]G50:7I2E I2E I2E I2E I2OC>@^:5\;US[WD-LQR.W(NEPBVZ.M?32
M[+?2TDJ()"05$;G8$[?0#]%!T:574_Q&:5VF8[$GZE8?!EM;<V)%_B-K3N 1
MNE3@([$'_C7T?A.:/_I5PG^4</[V@LRE1JT:D8Q?WF&;9D%IN+T@%3+<2>TZ
MIP $DI"5$GL">WN%23>@^:4I0*4I0*4I0*4I0*4I09GSO]WSIA^J5T_K$UIB
MLSYW^[YTP_5*Z?UB:TQ0*4I04=XW?W*&IO\ %"_^9-65I=^+7$_XIB?U**K7
MQN_N4-3?XH7_ ,R:LK2[\6N)_P 4Q/ZE%!)Z4I0*4I0*4I0*JS4CQ.Z9Z09+
M"L&999#L%WF1C,9C24.'=GD4<RI*"E.ZDJ "B">*MM]C5IU^?>+X58_%;X]=
M59N4VQB_8GA=O:L#,.0.;?7#FW<]]@'&Y9V3Q[GVD\N0;?Q;4C%\Y9#V.9%:
M<@9V*NI:YS4E.P)23N@D; @C_@??VJ2UD3*_V,'1Z[OF9CJK]@]R02XQ(LMQ
M40TYLH;[.\SMNH$A)3\T $"HLKPC^(G38N#3?Q#RYT=*4H9A98TIY+21LG@"
ML2$@!(W!2A/T  =P&Y*5AU.LWB^TQ:ZN5Z0V;.K8RG=3^-R0B4YW4HC@A;BB
M0!Q]5G;V=RHBO?;_ -E"Q*R34V[4;3[,-/;J4!18F0PZ@*V]9/K=-P]^P^3[
M^_;V4&TZKO4[5-C#FDQ(7"3=U@$-G<I92?WRMO?]"?\ B>U0VT>,7374&SRE
M8+DT;(KJADN(A-M.MO-IY!!<6VXA*@A)([D=]T_YPJI)<MV?+>DR'"Z^ZHK6
MM7M))W-634MQZ+M>9U]EJDW"4Y+?5^^<43M_ ![A_ .U>+:E*Z.;HV/(+CC<
MP2K;+=BN]N00?57W]BD^Q0_@-:)TTU*C9G"++H3'NK*?E6?8' /WZ?X/X/=_
MNV-9EKHX]>Y&-WJ)<8IV=8<"^.^P6/>D_P !&XJ6:LN-BTKP6.\L7^UQ9\;_
M "$AI+J=_: 1OL?X17OKFZ%*4H%*4H%9H\?_ .)BP_K;9_[0*TO6:/'_ /B8
ML/ZVV?\ M H-+TI2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@S/@G[OG4_\
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MI2@4I2@K+Q*W_),4T*S:]8@\J/D=NM;TR(ZAI#BD%L<U*"%@I40D*/$@[^P
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MEN70L@L-GA96VC"I\)#4W'X\Y =5,:<4[S?9!"R@H7'*2=T\D;[).Q/V>";
MC@?AZ=O[S:D7/-YW42=O_P @B%3:.W_M.EU7<#<(2>^P-93\2!L&JOB=O;NG
M%UN&4Q\FNH\NY+84A2I3SI3TV]R5*;Y%(02$^J0D#U03^C]RLD'$F;;B]J*5
M6O'8+%GCK2WPZ@90$J61N>ZE\E$CVE6YW))-DVL^KDQ8/A\__'27_P#T*_ZQ
MNM#U07AXC<K[=9/ DMQDM\_<.2M]O^/'_P"<:OVKZ^T*4I60I2E K-'C_P#Q
M,6'];;/_ &@5I>LT>/\ _$Q8?UML_P#:!0:7I2E I2E I2E I2E I2E I2E
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M!DD=UN2S=[:CR[H>;4%)6XE)"'O9L0XE6X[>X;792@_/O5;PP:4YW<;DQ?\
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M1Y*%J+>X'/8'?;<@;^SN/IJ+WW7/$\<U-L6 S9P1DEX9<D,,;@)0A.VW-1(
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M+MJY+:);,=Q+*(BB#S>3Q0D<25C?;]\=^6O3R;:Y.!7C4_2[(]2L95IG;[-
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MV82I*E#J): 2E2B -MJ-8V/@/B-QO,H>8S+@MG%X>-Y9*Q%<B[S&FFY,EDH
M4A1('KEP!*?G$BK8K(VF&&W;",8U8.1Z9OY<F[:KW"ZP+4^PR[SC.K9Z4Y(<
MW'%'$J"NRAMV[UKFC)6:/'_^)BP_K;9_[0*TO6:/'_\ B8L/ZVV?^T"@TO2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*#,^"?N^=3_U2M?]8JM,5F?!/W?.
MI_ZI6O\ K%5IB@4I2@5\;5\TH/C:OFE*!2E*"'93JK8L0S_#<-GK?%[RWSGH
MQ#;14VKRK277N:OWNR5#;Z:F&]9RUSMLN1XOO#3-9BONQ(GPE\P^VTI3;/*
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M,6'];;/_ &@5I>LT>/\ _$Q8?UML_P#:!0:7I2E I2E I2E I2E I2E I2E
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MJ(X[=JU)2@R_EW@'Q:^.2H=CRS),/Q>Z1HD2]8]:)"!%N*(S:&FB>226U<$
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ME#B$+VW[\=JIW#?#GFERUCQC4#/K[B<RYXTRZU'E8]CYBS;F7(ZV"J6^MU1
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MKQC.;!.N=NCVJZ6J^:<7-^$ZVP7/+O-=,H+:VTN*1Q^84[=@0>7FC76%(O\
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M?^T"M'0(#-MB-1HS3;$=I"6VVFD!"$) V  '8 #W#V5G'Q__ (F+#^MMG_M
MH-+TI2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@S/@G[OG4_]4K7_6*K3%9G
MP3]WSJ?^J5K_ *Q5:8H,J8KJ=DS'A\G,(TZR^YA$"X)3?6IEJ#*@%/@.)ZDY
M+P">WM;"O5[ ]J\.7Z_Y=IUAGG;2Y!ND>Q8_&G2+:C'KC<7WDIAID.B3.;6B
M/!)1OQY]4[*0HI._&M'VK3BTV?"G,5C];T2MAZ.4J7NO@Z5%?K>W?USL?=4)
MOGA<Q#((]QAR)=]9M%TBMQ;E:H=V?8BSN$9,9*W4(4-U=)#2200#TD<@=NX<
MW*-;;M8+KE^+MQ(KN8,RX#./,J;5TY;$[=#+ZT%8*@RXS,+J4J3NW%*@4\MA
M%G?$9DDG*)[ELM,R;9H=^>LIL\;#[Q)??0Q+,9^0FYMI,1)!2ZL-\2-DA*W4
M**@B[[AIE8[OEUARB='\U?K(T\U#F+)"D]1'!2BD;)*N)6$DCU0ZYQVYJWX2
MM!,=3E#]Y8F7J&W)FBY2[1&NCR+?*D^]UQCEQ))V*DC9*RD%25'?<.EG6:2<
M0RW#F7Q'38+P_)M\F0X"%L2>B7HZBO?BELAE]!"AW6XULH'LJM[!JIFVH#]@
M@6/T-8WKO;I61(N%S@/2D-6Y4D(@(,=#[2B\XRH..$K2&R./%7NEWB+T^D:K
M:>IQ)J"F7&NEQAHF/JE*CJB1D/H<=>04;*4L)04A((W*]B>/*NQE6C]DRB3:
M9:'IUCN-J87$ASK)(5$=:CK*"MCU?5+9+39XJ! * 1L>]!$-)M7KOJ!E+-KN
M%OAV]35OF^=;:*ED38ER=@O<%%6W2*F%*2"GEL1N?:*XNEVJ><ZFYK&B)<QZ
MVV2)9HEUN ,%]R2^MZ;<(X;:5UPEL<82%<E!>Q)]4@^K-G/#YBK%MLL2T+NF
M.>BHZX;,BSW%YA]QA:PXXVZYR*G>2QSYK)6%%1"@5JY=?3S2+'],7'%V-M]K
MG;XULXNNE8###TEUL=^^X5,>W/O&WT4$:S/),VD:JQ<1Q658+6PJT&Z/7"[V
M]^:I*@^6PVEIM]D*"M]]RL;;>Q6^PA-DUOS+)KQ%X,66RV^TVZX3,@;<B.S9
M#KL"X.0Y#44A]I*$N>7=4EQ?(I]7="MSQF>9:3R,SU;CY"N?<;1%CV,P6Y=I
MG*CR Z9'-2"!\Y!3L?6!&X!VW -2RQZ4X_CDV-)MT7R_E[8+0VR5%;?0Y\SR
M"MRI1422I1)5N2222:"K8>HNIB8>&O3%8PA[.&'&K8RW!D<;/.,!Z:TB0OS'
M^%-E+#J%*0ED@A.P/+MS[1XEKSEV-WK,+5;;=$Q;')$6%?&Y3BW9+;X6RJX%
M"P4I2U&8=4L.$*#O'<!" %JG4#PT8K;(R(\:9>T,1(;MOM;2[FZXFT,.-AM:
M8H63P/3 0%'DI*=PDI!(/WWS2*S8S8[X[C..1WW)=B39?0#*TQ(<IEL*2RA>
MP]4I2XM'(=^*MCOLD@.[@66S,LR'+^#; L%KFIMD-Y*"'7WVT?X4HGD04)6H
M- ; A3+N^X*34)L^=9QDMQ-^MZ<?;PUG(9-B=MDQ+K<]26)KD)R2F3U.GRZ[
M:BECI$J1L.J%JXB::+:?M:6Z88YBS:D..6Z$VW)?2HJ\Q)(Y/O$J[E3CJEN$
MGN2LUX5Z$XXK*47H.W)"$S_2OHD3G3;U3?;Y@L%13SW]?;YO,!SCSW40JW#M
M><LNFH^)VN:JWW6Q9!,?AF3;<=N$2-&6F))E-*9N$E8:F@IBJ2>DRD>L%<@$
M[+_O =4M3LVQW3EE<O%(M_S6Q+R5$IFU251;9$:;BE;:FC+"Y#BUS6 "%MA
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MK@P8T1;J&VW%,,I;*DMCBVD[#N$I[ >X>RONCVB'&N4BXMQ6$W"2TVP]*2V
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ME(4.&RMFPG<I*@=28+9(.*V?T)#D(>,5:W'$)"$<%.N+<("$;!"=U*XIV[
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MZCAY-A6Q5L-P.6P^@ #W5*+C8X%UD1WY<*-)?CA:677F4K4V%IXK"21N H;
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MA6X)!*5#B%[I]A3.\,T6PK3RY/S\<QV#9Y+S?0*HK7$(:Y%?3;3OLVCD=^"
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M@1V_@J09-H7@68^2],8K;)GDHOD&/D WPB_D_J[;L]O\D=T?P4'9T[N]QO\
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M4TI'N4V4G^&N GPU8"F#)C&URU.2)C-P<GKNLQ4[S32%-MR!++W62Z&UJ1U
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M3[2?DP=C]-?=COAWLV.7"R\+S>)EAL,A4JRXY*4P8-M<*%H26^+275A"75A
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MUK;_ "P_Z-:6I09I_ D_V]:V_P L/^C3\"3_ &]:V_RP_P"C6EJ4&:?P)/\
M;UK;_+#_ *-/P)/]O6MO\L/^C6EJ4&:?P)/]O6MO\L/^C3\"3_;UK;_+#_HU
MI:E!FG\"3_;UK;_+#_HT_ D_V]:V_P L/^C6EJ4&:?P)/]O6MO\ +#_HU8.@
M_AXM&@+.1^C<AR+)I=_EHFSI^2S$2I*W4HX;]1+:">WO5N?X:M6E I2E JJM
M>/#Q:-?F<<])9#D6,R[!+7-@S\:F(BR4.J1PWZBFUD=O>G8_PU:M*#-/X$G^
MWK6W^6'_ $:?@2?[>M;?Y8?]&M+4H,T_@2?[>M;?Y8?]&GX$G^WK6W^6'_1K
M2U*#-/X$G^WK6W^6'_1I^!)_MZUM_EA_T:TM2@S3^!)_MZUM_EA_T:?@2?[>
MM;?Y8?\ 1K2U*#-/X$G^WK6W^6'_ $:?@2?[>M;?Y8?]&M+4H,T_@2?[>M;?
MY8?]&GX$G^WK6W^6'_1K2U*#-/X$G^WK6W^6'_1I^!)_MZUM_EA_T:TM2@S3
M^!)_MZUM_EA_T:?@2?[>M;?Y8?\ 1K2U*#-/X$G^WK6W^6'_ $:?@2?[>M;?
MY8?]&M+4H,T_@2?[>M;?Y8?]&GX$G^WK6W^6'_1K2U*#-/X$G^WK6W^6'_1I
M^!)_MZUM_EA_T:TM2@S3^!)_MZUM_EA_T:?@2?[>M;?Y8?\ 1K2U*#-/X$G^
MWK6W^6'_ $:?@2?[>M;?Y8?]&M+4H*"TT\'MGTYU+@YR]J!GV97J%$>A,#++
MRB<VAMS;EM\DE0[@'8* W[[5?M*4"E*4$:U'T^M.JF$W?%;ZEU=HNC!CR4L+
MX+*"0>RO<>P[U1;/['WIQ'90TW>LU;;0.*4-Y)(2E(]P W]E:9I09I_ !T[_
M -/9S_*:1_YT_ !T[_T]G/\ *:1_YUI:E!FG\ '3O_3V<_RFD?\ G3\ '3O_
M $]G/\II'_G6EJ4&:?P =._]/9S_ "FD?^=/P =._P#3V<_RFD?^=:6I09I_
M !T[_P!/9S_*:1_YT_ !T[_T]G/\II'_ )UI:E!FG\ '3O\ T]G/\II'_G3\
M '3O_3V<_P II'_G6EJ4&:?P =._]/9S_*:1_P"=/P =._\ 3V<_RFD?^=:6
MI09I_ !T[_T]G/\ *:1_YT_ !T[_ -/9S_*:1_YUI:E!FG\ '3O_ $]G/\II
M'_G3\ '3O_3V<_RFD?\ G6EJ4&:?P =._P#3V<_RFD?^=/P =._]/9S_ "FD
M?^=:6I09I_ !T[_T]G/\II'_ )T_ !T[_P!/9S_*:1_YUI:E!FG\ '3O_3V<
M_P II'_G3\ '3O\ T]G/\II'_G6EJ4&:?P =._\ 3V<_RFD?^=/P =._]/9S
M_*:1_P"=:6I09I_ !T[_ -/9S_*:1_YU_(_8_-,S,A2'[CED\Q)#<IMJ??7G
MVN:%!224*W![@5IBE I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2
ME I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2
ME I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2
ME I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2
ME I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2
ME I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2
ME I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2
ME I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2
ME I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2
ME I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2
ME I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2
6E I2E I2E I2E I2E I2E I2E!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2212755d1_pre14asp1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2212755d1_pre14asp1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !! ,,# 2(  A$! Q$!_\0
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M12'&"N??'ZCTH [^LK5O$>EZ*,7EW$LO7RO,4/CUP2*R_&6LW=K':Z/I)/\
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MJT>ZOKF."%!RSG^0[GV%<79_:/''BBUU8++'H&GMNMQ(-IGE'\0'H#_+'<T
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-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2212755d1_pre14asp1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2212755d1_pre14asp1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L '\# 2(  A$! Q$!_\0
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M579DGKUQCCZ9\VUK7M.\4_$_3/'%UI=RGA"PGCLVOC'Q*Z[V1V4_P[B,\=
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M)==*'!.FZ*9%'KRP KT33O WA72CNL_#^G1O_P ]# KO_P!]-D_K6^ %
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%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2212755d1_pre14asp1img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2212755d1_pre14asp1img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L '\# 2(  A$! Q$!_\0
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M579DGKUQCCZ9\VUK7M.\4_$_3/'%UI=RGA"PGCLVOC'Q*Z[V1V4_P[B,\=
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M)==*'!.FZ*9%'KRP KT33O WA72CNL_#^G1O_P ]# KO_P!]-D_K6^ %
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%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2212755d1_pre14asp4img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2212755d1_pre14asp4img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  K 'X# 2(  A$! Q$!_\0
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MI'XUT/\ 8F^#V@_\%$?^"=OQ NM \?>+/"7C[XQ?#;X ?M'_  I^.L^B^'O
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MYA#_ ,$2_P#@XC_:JU6"]_;8_P""U.I?##P[JMQC6_#/[.GB?XDB+[ #@*/
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$@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
